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Structure-based drug design (SBDD) is an essential component of many drug discovery 
programs. In SBDD, a large number of potential molecules are virtually screened against 
the known three-dimensional protein structure. Proper creation of ligand libraries and 
selection of target binding sites are critical for SBDD. This thesis focuses on knowledge-
based approaches to improve SBDD in two aspects, the construction of the ligand 
libraries and analysis of the target binding sites used. 
First, this thesis presents ChemTreeMap, a visualization tool to explore structurally 
diverse molecules and mine for correlation between chemical structure and biological 
data. The visualization tool is applicable to a wide range of questions involving small 
molecule/drug binding and exploration and construction of ligand libraries. 
Experimental data and molecular properties can be interactively visualized with graph 
properties. With the help of this powerful tool, this thesis reports the findings on 
discriminating physicochemical properties between allosteric and orthosteric 
competitive molecules. It is observed that allosteric ligands are more hydrophobic, 
aromatic, and rigid. The result is useful to guide building new chemical libraries biased 
towards allosteric regulators. Thirdly, the selection of target binding sites of drug 
candidates needs to take account for possible interruption due to mutations which 
xx 
 
occur from non-synonymous single nucleotide polymorphisms (nsSNPs). Disease nsSNPs 
occur more frequently in a protein core or binding site, rather than the rest of the 
protein surface. The result can be used to imply the probability and consequence of 




Chapter 1. Introduction 
1.1 Overview: 
Proteins are composed of one or multiple chains of amino acids, performing various 
biochemical functions in a living organism. Proteins perform a wide variety of functions 
including DNA replication, responding to stimuli, transporting small molecules, and 
catalyzing biochemical reactions [1]. Functions are accomplished by interacting with 
other components in the cellular environment, including other proteins, DNA, RNA, or 
smaller molecules like metabolites, substrates, nucleotides among others. Proteins are 
common biological targets for drugs [2]–[4], which are typically small molecules that can 
be used to diagnose, prevent, treat, or cure a disease or enhance well-being[5]. 
Understanding protein small molecule interactions is essential to comprehend the 
biological process and facilitate the design of a small molecule or potential drug to 
modulate protein function by mimicking these interactions.  
The most widely-adopted method for drug discovery is known as forward 
pharmacology, which only relies on testing of known chemical substances with drug-like 
characteristics on biological assays (i.e. proteins or cultured cells) [6] and does not 
necessarily utilize protein target information. In contrast, rational drug design takes the 
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reverse approach by modulating a specific biological target with a small molecule to 
achieve a desired physiological response[7]. In early stages of rational drug design, the 
discovery of novel leads that have potential interactions with specific protein targets is 
of central importance [8]. This requires a large diverse library of potential substances to 
be tested against targets in a relatively short amount of time. One typical searching 
strategy for identifying novel leads is through high throughput screening (HTS), which 
can quickly assay the biological or biochemical activities of a large number of 
compounds. However, the application of HTS is limited because of its high cost and low 
hit rate. In order to overcome this disadvantage, the earliest efforts were made in the 
early 1990s to successfully design a set of molecules targeting HIV, by investigating the 
interaction between inhibitors and enzyme to occur and symmetry characteristics of the 
enzyme active site[9]–[11]. This approach, termed structure-based drug design (SBDD), 
is guided by knowledge of target three-dimensional structures obtained by x-ray 
crystallography or NMR spectroscopy[12]. SBDD has become a starting point and 
integral part of many drug discovery programs[13]. In SBDD, a large number of potential 
molecules are virtually screened against the known three dimensional protein structure 
computationally [8]. It can accelerate the screening process for large molecule sets. 
Chapter 2 and 3 for this thesis are about finding properties or developing visualization 
tools to help focus and explore the chemical space to potentially optimize libraries of 
molecules used in SBDD. 
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A typical flow chart (Figure 1-1) of SBDD begins with a target structure and a compound 
library. The target structure is either experimentally solved (using x-ray crystallography 
(preferred) or NMR) or computationally modeled. A compound library of drug-like 
molecules, for example, a database of commercially-available compounds is described 
computationally. Then, molecules in the library are tested against the target protein by 
virtually docking into a target binding site. The docking program serves to position a 
complete small molecule in the protein’s binding site. Alternatively, one could integrate 
with linking and molecule building methods to generate plausible modulators by 
incorporating multiple functional groups. The methods of linking/building may produce 
compounds that are not synthesized or cannot be synthesized, but may be able to 
provide a framework to search for a small molecule that may have the desired affinity. 
The combined molecule generated by linking and building may have higher target 
affinity than components separately[14]. The positioned ligands are sorted by scoring 
functions that approximate the free energy change upon protein-ligand binding. 
Promising compounds with high scores are synthesized and tested in a biological array 
for specificity, pharmacodynamics, and toxicity. The results from testing can initiate a 
new round of structure-based drug design until the desired compounds are discovered 










Much efforts in SBDD involved in characterizing and testing molecules in the compound 
libraries, which provides potential candidates in the early-stage of SBDD. The success of 
SBDD will be dependent on the coverage of the desired “chemical space” in the 
compound library. “Chemical space” is defined as “the total descriptor space covered by 
all the known and possible small organic compounds”[15]. However, the total number 
of possible molecules could be too large to proceed following analysis for a selected 
chemical space. For example, the total number of molecules for complete coverage is 
theoretically more than 10^60, for considering molecules composed by only carbon, 
nitrogen, oxygen, or sulfur atoms, with up to 30 atoms, 4 rings, and 10 branch points 
[16]. In practice, initial libraries usually are extracted from existing sources, such as 
corporate screening collections, purchasable compound libraries (e.g. ZINC), public 
chemical databases (e.g. ChEMBL), or combinatorial libraries [17]. Some widely used 
chemical compound repositories are shown in Table I, which covers libraries with 
varying numbers of protein targets. There are roughly three types of libraries based on 
the number of protein targets: 1) large general libraries which can be used against many 
targets (e.g. PubChem, ZINC, CoCoCo, eMolecules, ChEMBL); 2) focused libraries which 
targets a protein family or a small group of related targets (BindingDB, DrugBank); and 
3) an enriched specific library on a single target (ChemDiv) [18]. After the libraries are 
selected, careful preparation of molecular structures has pivotal effects on the success 
of the docking process. It is important to ensure proper chirality, stereo chemical 
specifications, tautomeric state, and protonation states [17]. 
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There are multiple ways to build an enriched library, including using fast 
physicochemical filters or drug likeness [19], ligand structure similarity searching to 
known drugs [20], empirical high-throughput docking and scoring [21], genetic 
algorithm for focused descriptor active space (GAPDAS) [22], or geometric constraints 
(i.e. the location of hydrogen bonds) [23]. The most common strategy is to take 
advantage of the computational speed and intuitive understanding of filtering for drug-
likeness based on the physicochemical properties [8]. Drug likeness is widely quantified 
by Lipinski rule of 5, which requires that an orally active drug should have no more than 
one violation of the following criteria: 1) maximum of five hydrogen bond donors, 2) less 
than or equal than 10 hydrogen bond acceptors, 3) molecular weight of less than 500 
Da, and 4) an octanol-water partition coefficient of not greater than five [19]. If a ligand 
violates two or more conditions, they are expected to have poor absorption, 
distribution, metabolism, and excretion (ADME) properties and would not be considered 
suitable drugs. Some studies also show that applying physicochemical filters in enriching 
the compound library can improve both computational efficiency and hit rate of the 
docking process, including but not limit to virtual screening for G-protein coupled 
receptors[22], non-peptide malignant brain tumor (MBT) repeat antagonists[24], and 
non-nucleoside HIV-1 reverse transcriptase inhibitors[25]. 
An example of the use of structure-based drug design is in the design of allosteric 
ligands. Allosteric ligands bind at a binding site that is spatially distinct from the native 
ligand’s binding site. Over the past 20 years, designing and synthesizing allosteric 
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molecules has experienced considerable growth in the pharmaceutical industry and 
medicine as a whole [26]. Allosteric drugs offer several advantages over the 
corresponding orthosteric ligands targeting the same protein, including better 
selectivity, favorable physicochemical properties, and improved chemical tractability for 
synthesis[27]. However, the general physicochemical properties for allosteric 
compounds are not well understood. The third chapter of this thesis focuses on 
elucidating the physicochemical properties which can differentiate compounds targeting 
allosteric sites from competitive compounds.  
Due to the iterative process of SBDD, acquisition of compound collections may be 
needed for a new iteration. These new compounds preferably should cover new 
chemical space. Depending on the stage or purpose of the project, new compounds with 
wide chemical diversity may be desirable to enhance breadth of the library. 
Alternatively, compounds in nearby chemical space may be needed to increase the 
depth of coverage. The precise method used to quantify molecular similarity or diversity 
depends upon the context of the question. Examples where a new set of compounds 
which covered a wider range of chemical space is required is described by Eckert et 
al[28]. For example, finding bioactive peptide-like molecules requires exploration of 
highly structural diverse data set[29]. Adding new set of compounds covering a deeper 
depth of chemical space is necessary to extract of structure-activity relationship (SAR) 
information[30]. The characterization the association between structure and activity is 
usually non trivial and require many structure similar compounds [31]. Especially for 
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activity cliff that is structurally similar compounds having large potency difference, many 
similar compounds are needed to better characterize the activity landscape around 
activity cliff [32]. To both increase breadth and depth of chemical space in molecular 
dataset, visualization of chemical similarity with associated bioactivity becomes vital to 
examine the relevance between compound structures and particular biological values. 
This is especially true now with continual expansion of biological data sets. In the second 
Chapter of this thesis, we developed a new ready-to-use visualization tool, 
ChemTreeMap to handle data mining for multidimensional, heterogeneous, biological 
chemical data sets. 
The above discussion has focused on developing datasets of ligands for SBDD, however, 
the target proteins and binding sites are also of importance.  The target binding sites 
must be annotated and have high-quality three-dimensional coordinates available. 
Target binding sites, the other input of SBDD, are required to have 3D structures of 
desired protein targets and annotations of binding site locations. In recent years, 
structural genomics of protein families have provided a major boost to SBDD. These 
projects have identified and solved new structures of known and potential drug targets 
[33]. To annotate the binding site location, a protein target in complex with a compound 
can be used to determine the possible drug interaction by molecular basis of existing 
protein ligand interactions. Alternatively, binding site prediction or protein structure 
prediction methods are necessary if there isn’t a solved complex.  
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Target binding sites might be altered by permanent gene mutations, which vary across 
individuals[34]. Most variants take the form of single nucleotide polymorphisms (SNPs). 
Non-synonymous SNPs (nsSNPs) cause changes to a protein through mutation of an 
amino acid or the introduction of a premature stop codon which affects the stability 
and/or function of the protein. These structural changes may have detrimental effects 
on drug binding, thereby inducing drug resistance which has become one of the biggest 
challenges in drug development in recent years [35]. The binding sites, which are easily 
mutated by nsSNP, are at high risk to confer drug resistance. Chapter 4 of this thesis 
focuses on finding the role that structure and nsSNPs play in understanding the general 
molecular basis of disease. Additionally, these factors may be of use to account for the 
possibility of drug resistance when choosing drug targets.  
All of the above-mentioned challenges in structure-based drug design are related to 
determining the chemical space of potential drug candidates that target at protein 
binding sites. Solving those issues requires solid statistical analysis for assessing the 
similarities or differences between chemicals, exploration of the relation between 
biological data and chemical compounds, and understanding the impact of nsSNPs on 
protein structures. 
This dissertation focuses on knowledge-based approaches to improve SBDD based on 
both the construction of the ligand libraries and analysis of the target binding sites used. 
First, we propose a visualization tool (ChemTreeMap) to mine for correlation between 
chemical structure and biological data. The performance of the visualization tool does 
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not depend upon assumptions of activity and chemical structure and thus may be 
applicable to a wide range of question involving small molecule/drug binding. The tool 
can be used to construct and explore ligand libraries. With the help of this generic tool, 
this thesis reports the findings on discriminating properties between allosteric and 
competitive molecules. To remove ligand redundancy in the data set, clustering is 
conducted at two levels, protein level and ligand level. The significance of properties is 
assessed by Wilcoxon test and bootstrapping to obtain confidence interval. The result 
can be used to build chemical libraries biased towards allosteric regulators. Thirdly, the 
target binding sites of compounds may be vulnerable to nsSNPs. The location of nsSNP 
on protein structures are accessed by taking account the heterogeneous distributions of 
nsSNPs across protein families. The result can be used to imply the probability and 
consequence of nsSNP on new target binding sites. Extension and future direction for 





Table 1-1. Some commonly used free chemical databases for screening. 





PubChem contains biological activities of small 
molecules. 
commercial, bioactive, 
research 3/29/2016 88 million https://pubchem.ncbi.nlm.nih.gov  
ChemSpider 
ChemSpider integrates and links compounds 
from ~500 data sources to present a 
comprehensive view of freely available 
chemical data. 
commercial, bioactive, 
research 3/29/2016 45 million http://www.chemspider.com  
ZINC 
ZINC contains commercially-available 
compounds in ready-to-dock, 3D formats. 
commercial, bioactive, 
research 2/4/2015 35 million http://zinc.docking.org/ 
CoCoCo 
CoCoCo collects commercial compounds  from 
eight chemical vendors and standardizes their 
structural information commercial 9/7/2012 7 million http://cococo.isof.cnr.it/ 
eMolecules   
eMolecules provides an online molecule search 
engine for public domain structures from 
vendors worldwide. commercial 3/1/2016 5.0M https://www.emolecules.com/ 
ChEMBL 
ChEMBL is a manually curated chemical 
database of drug-like bioactive molecules with 
binding, functional and ADMET information. bioactive 2/1/2016 2 million https://www.ebi.ac.uk/chembl/ 
ChemDiv 
ChemDiv provides a diverse and highly 
specialized compound selections, which have 
been extensively validated in biological assays. bioactive, commercial 7/16/2013 1.5 M http://www.chemdiv.com/ 
BindingDB 
BindingDB provides binding affinities between 
small, drug-like molecules and drug-targets, 
with crystal structures. bioactive, research 9/1/2015 0.5 million https://www.bindingdb.org 
DrugBank 
Drugbank contains extensive drug information, 
including chemical, pharmacological and 
physiological data, with detailed targets 
information, including sequence, function, and 




1.2 Visualization for aiding structure-based drug design 
Many steps of SBDD, including construction and exploration of compound collections , 
involves visualization of compound structures and biological attributes, like data mining, 
chemical library design, acquisition of compound collections [36], prioritization of 
molecules in a compound library for biological evaluation [37], ADME profiling [38], 
multi-objective optimization (specificity, pharmacodynamics, toxicity, etc.) [39]. 
The visualization is based on a key concept in medicinal chemistry, that molecules with 
similar structures will usually have similar physicochemical properties, including 
biological activity [40]. Visualization is represented by a graph, including but not limited 
to networks, trees, scatterplots, and bars. Therefore, similar molecules are grouped 
closely in the graph and biological properties are mapped to graph attributes. 
Informative visualization of structurally heterogeneous compounds with activity data 
has steadily gained more interest as the size of biological datasets and the amount of 
data has dramatically increased[41]. The visualization of heterogeneous chemical space 
is not limited to SBDD, but some can be applied to understand the relation between 
chemical structures and their general biological actions, like off-target effects [42], 
synergy effects [43], or drug repositioning [44], [45]. The second chapter of the thesis 
describes the development of a tool to present heterogeneous chemical space with 
multivariate properties in a tree structure. Two fundamental questions need to be 
answered for the graph representation: 1) how to quantify the similarity between 
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molecules; 2) how to represent the similarity in a graph. This section discusses methods 
that are commonly used to address these questions.  It details other available tools and 
their advantages and disadvantages that have inspired the development of 
ChemTreeMap described in the second chapter of this thesis. 
1.2.1 Molecular similarity 
Any visualization starts with the calculation of molecular similarity, which is a subjective 
concept which varies with the context and details of the molecules in the chemical 
database [46]. Chemoinformaticians, chemists, and medicinal chemists each may have a 
different perspective on what molecules are similar [47]. If the similarity method is 
chosen properly according to the cheminformatics problems, a more accurate model(s) 
of the chemical activity of the compounds would be built[47]. The visualization tool 
must be able to handle variety of similarity metrics. It is especially difficult to quantify 
and assess the similarity. In order to provide an objective measurement, computational 
methods are necessary to generate a consistent value for molecular similarity. The 
similarity calculation usually involves three steps: 1) representing a molecule structure 
by chemical and/or structural features; 2) weighting each feature by their contribution; 
and 3) quantifying the similarity between two representations. A similarity value 
between 0 and 1 is obtained. A value of 1 where 1 represents complete identity of two 
representations of the structure and may not require two structures to be identical, 
while a value of 0 indicates no overlap in the representation[47]. 
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There are various ways to represent a molecule. Two common methods of representing 
the molecule are with a chemical representation or a structural representation. 
Chemical representation uses physicochemical properties, like solubility, boiling point, 
log P, molecular weight, electron density, or even reaction information to describe the 
molecule[47]. On the other hand, structural representation utilizes structural features, 
like shared substructures, ring systems, topologies, chemical environment of atoms, etc. 
Sometimes, new descriptors are created from combining multiple chemical or structural 
features using mathematical functions. Structural representation is more popular, 
because the experimental data for physicochemical properties is far from complete and 
many of them are only predictions based on the structural features [48]. The 
representation of the molecule is expressed as a vector of numbers, which indicate the 
presence of most relevant chemical or structural features. 
Molecular representations have two categories: two dimensional (2D) and three 
dimensional (3D). 2D structure can be captured by molecular graphs, whose vertices 
correspond to the atoms and edges correspond to chemical bonds. Compounds are 
inherently three-dimensional and their molecular conformations can provide more 
information than 2D. 3D structure can be determined either by experiment (X-ray 
crystallography) or by calculation from molecular graphs and optionally followed by 
optimization. The 3D features include surface area, 3D shapes[49], [50], 3D distance 
between atoms[51], energy, dipole moment, and so on. 2D features that are directly 
calculated from molecular graph can be physicochemical properties (like atom counts, 
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ring counts, formal charges, etc.) or graph properties (like fragment and topological 
atom environment). Many studies try to directly compare two molecular graphs, but the 
computational complexity of these algorithms make them infeasible to large scale 
molecular similarity analysis [52], [53]. 2D features are more widely applied in 
comparison with 3D, including extracted from molecular graphs. Two-dimensional 
features are preferred, because 1). 2D Molecular graphs can contain annotation for 
conformational and stereo chemical information; 2) chemists are more comfortable 
with molecular graphs than 3D conformation. 3) The determination of biologically active 
conformations in vast ensembles of test compounds is uncertain [47]. In contrast, 2D 
features are much more robust and often have good prediction power for bioactivity 
[54], [55]. 
The thesis adopts a 2D representation, extended connectivity fingerprint (ECFP), which 
is currently one of the most popular fingerprints for similarity searching[56]. ECFP can 
capture many different atom environment features by recording local bond topology, 
which provides more details than other fingerprints with predefined fragment libraries 
[47]. The ECFP generation process is as follows. ECFP begins with assigning atom 
identifiers to each heavy atom of the molecule by a hash function, which captures atom 
local information (e.g. atomic number, connection count, type of bond, etc.) (Figure 
1-2). After that, the algorithm combines the current atom identifier with the identifiers 
of neighboring atoms within a certain diameter to generate new identifiers for each 
fragment. The iteration will continue until a specified diameter is reached. The larger 
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the diameter can capture greater structural details. The produced identifier list will be 
mapped to a fixed-length binary representation by another hash function[47]. 
The similarity of two representations (i.e. ECFP) can be quantified by Tanimoto 
Coefficient (Tc) [57], [58], Dice [59], or Tversky [60] similarity coefficient. Tc is generally 
defined as the number of features shared by A and B divided by the total number of 










Tversky coefficient is an asymmetric similarity measure defined as: 
𝑆(𝐴, 𝐵) =
|𝐴 ∩ 𝐵|
|𝐴 ∩ 𝐵| + 𝛼|𝐴 − 𝐵| + 𝛽|𝐵 − 𝐴|
 
Here, |𝐴 − 𝐵| denotes the number of features existing in A but not in B. 𝛼, 𝛽 ≥ 0 are 
parameters. The Tversky coefficient can be viewed as a generalized form of Tanimoto 
Coefficient and Dice coefficient. Setting 𝛼 =  𝛽 = 1produces the Tanimoto Coefficient. 
Dice coefficient can be produced by setting 𝛼 =  𝛽 = 0.5. The second Chapter uses Tc, 
because Tc is by far the most widely used method in chemical informatics and 
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1.2.2 Graph representations of molecular data sets 
Graphical representations of structure-based drug design data are increasingly required 
in order to comprehend and manage the large amounts of data and capture complex 
relationships involved in drug discovery processes[61]. The representation of large 
compound libraries is made possible through the use of numerical similarity methods. 
To generate a graphical summary [62], [63] on the compound sets, many methods are 
developed to visually capture patterns among molecular structures with other 
properties (e.g. biological activity). These methods be roughly grouped into three 
categories: Network-like, Tree-like and Scatterplot-like, each having been optimized for 
specific purposes. For example, various graph layouts have been designed for 
Structure−Activity Relationships [64]–[66], representing large chemical databases [67], 
analyzing complex multidimensional data [7], exploring sub- and superstructure 





Table 1-2. Example chemical space visualization methods developed in recent years. 























SCONP[59], The Scaffold 
Tree[60] The Molecule Cloud[75] 
*MCS: maximum common structure 





Network-like graphs can represent relationships between many different elements in 
coordinate-free spaces, which can capture complex interaction relations by explicitly 
accounting for all pairwise relationships [41]. Each node can either represent a single 
molecule in the data set (i.e. CSNs [76]), or a substructure shared by a set of molecules, 
(e.g. HierS[69] and Hasse-based graph[68]). Many network principles (like homophily) 
and analysis gained from the study of social networks can be applied to compound 
network and used to recognize community structures [80]. One challenge for network-
like graphs is that each node in the network does not have any hierarchical order, which 
hides the relationship between molecule groups. Both HierS [69] and Hasse-based 
graphs [68] try to represent the hierarchical order of each node in subnetworks by 
assigning a number to each node. But, if one node shares a common scaffold with other 
nodes in terms of different substructures, those methods will assign the node multiple 
values for the hierarchical order. The hierarchical order assignment becomes harder 
with larger networks [61]. Another challenge is that optimization of the network 
topology, which is essential for detecting community structures, is computationally 
intensive [80]. Thus, a number of heuristic optimization methods have been introduced 
with varying levels of effectiveness [81]–[84].  
Tree-like graphs satisfy the demand of hierarchical organization. The hierarchical order 
of nodes can easily be defined. The root is the top node representing level 0. The child 
node (level N) is directly connected to another existing node (level N - 1) when moving 
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away from the root node. Each child has only one parent, which may have many 
children (siblings). Each non-leaf node can represent the most common structure of all 
its end leafs.  
Existing tree-like methods all generate a collection of trees, with each tree representing 
molecules in a nearby neighborhood. Some methods focus on interpretation of 
structure-activity relationships [65], [66], while others concentrate on the relations 
among ring structures [70], [73], [74] and consensus fragments [71], [72]. Comparing 
with all those methods, inSARa is feasible for a large set of molecules [61]. inSARa 
constructs similarity networks first, and then simplifies networks to trees by calculating 
the minimum spanning tree (MST) [79]. The final output are trees with hierarchical 
organization, which is easier to interpret than the complex network. However, MST 
won’t guarantee the edges between every two nodes can still represent their similarity. 
As much edge information is not encoded in trees, molecules with multiple parents may 
not be well positioned. Since the tree layout could become hard to read with more than 
thousands of nodes, many layout algorithms are developed to optimize the layout, like 
force-directed layout[85], spectral layout[86], hierarchical graph drawing[87] and so on. 
ChemTreeMap, presented in the second Chapter, organizes molecules in a single tree 
structure, for viewing large scale heterogeneous compounds in a single connected graph 
and positioning molecules based on their hierarchical relations. 
Scatterplot-like graphs are coordinate based space representation in which each data 
point designates a compound on the basis of physicochemical properties or shared 
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structure. It can reveal the coverage of the molecule set on selected descriptors. The 
most common way for generating coordinates is a dimension reduction method, which 
could be principal component analysis (PCA) by MQN-Mapplet and CheS-Mapper, 
multidimensional scaling (MDS) by CheS-Mapper, t-Distributed Stochastic Neighbor 
Embedding (t-SNE) by Synergy Map, or neural network based methods [88]. Another 
way to use the plotting space is tiling common structural features by structural images, 
like the Molecular Cloud, which indicates frequency of substructures by image size and 
biological activity by image color. 
1.3 Ligand chemical space for allosteric compounds 
Structure-based drug design strategies frequently focus on the targeting of a protein’s 
active site, but this can be difficult if the physicochemical properties of this site are such 
that it cannot be targeted with typical drug-like molecules[89]–[93]. One strategy to 
avoid this issue is to design allosteric modulators targeting other sites, which may have 
improved physicochemical properties. The third chapter discusses most distinguishable 
physicochemical properties to differentiate allosteric compounds from orthosteric 
competitive compounds. The usage of physicochemical properties analysis is discussed 




1.3.1 Rules derived from physicochemical properties analysis 
Screening large compound libraries demands a large amount of computational 
resources and time. Researchers become more interested in focused libraries that are 
generated using target relevant information and its known active compounds [94]–[98]. 
The most widely used methods for building an enriched library are physicochemical 
rules and undesirable functional group searches [99]. The underlying assumption of 
using physicochemical-based descriptors to design focused libraries is that compounds 
with similar structures are more likely to have similar interactions with the same targets 
[100]–[103]. Similar chemical structures also lead to similar physicochemical property 
ranges [100]–[103]. 
The most popular physicochemical-based filters are drug likeness rules, such as Lipinski’s 
rule of 5[19], Oprea lead like [104]–[106], and Veber rules [107]. These rules are based 
on simple physicochemical properties, like the number of hydrogen bond donors and 
acceptors, the number of rotatable bonds, molecular weight, logP, polar surface area 
[19]. They have been extensively adopted to reduce the size of the screening library and 
bias towards drugs or lead-like compounds. More specific rules has been developed for 
a few target classes like GPCRs [108] and kinases [109]. The desired rules should cover 
the biologically relevant chemical space for a particular class of targets and minimize the 
size of screening libraries [109]. 
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There are other approaches to design a target-focused library: 1) scaffold-based design 
[109]–[112], and 2) two-dimensional and three-dimensional pharmacophore similarity-
based design [113], [114]. Those approaches try to find molecules with structures 
similar to existing active compounds. Physicochemical property filters outperform these 
approaches in designing target-focused library on selecting compounds with novel 
structural scaffolds, because highly diverse scaffolds can share similar physicochemical 
properties. 
1.3.2 Distinguishing allosteric modulators by physical chemical properties 
Ligands exerting their effects via protein binding sites may be grouped into two classes, 
those that target the active site binding natural ligands, termed orthosteric modulators, 
and those that target distal sites, termed allosteric modulators. This thesis work aims to 
find general trends for physicochemical descriptors to differentiate allosteric 
modulators from orthosteric competitive modulators. The ability to differentiate these 
classes would provide deep insight into chemical properties underlying allosteric 
mechanisms and facilitate the building of a molecule libraries biased for the discovery of 
allosteric modulators. 
Despite much efforts, scientists frequently encounter difficulty finding orthosteric 
competitive compounds with high selectivity, drug-like physicochemical properties, and 
that are non-toxic [27]. For example, it is difficult to achieve selectivity among 
compounds targeting class C GPCR’s orthosteric site is difficult as these compounds tend 
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to be small in size, which limits the addition of specificity-improving R-groups [115]. The 
chemical property of natural ligands of class B GPCRs is outside of classic oral drug-like 
space [116]. As allosteric ligands bind at a site with less evolutionary pressure for 
conservation across a protein family, it is likely that inhibitor of these sites can be 
engineered to have high levels of selectivity. The drawback to reduced evolutionary-
conservation is that these sites may be more likely to develop resistance mutations. 
Allosteric sites, being a secondary binding pocket, are not necessarily as conserved as 
orthosteric sites across paralogs and orthologs [117]. Especially for viral inhibitors where 
the genetic mutation and selection is rapid, the use of allosteric modulators might 
induce higher mutation rate. For example, the non-nucleoside reverse transcriptase 
inhibitors (NNRTI) is well known for a quick onset of drug resistance [118]. For systems 
with rapid genetic mutation and selection, non-allosteric inhibitors may be more 
effective due to their similarity to the natural substrate [119]. Nevertheless, allosteric 
modulators are still effective for targets with less evolutionary pressure. 
The interests of allosteric drug development steadily increase after the clinical success 
of benzodiazepines. In 1955, benzodiazepines are discovered as an allosteric drug, 
which potentiate the effect of neurotransmitter γ-aminobutyric acid (GABA) by targeting 
the ionotropic GABAA receptor [120]. After benzodiazepines, more protein targets are 
investigated to develop allosteric ligands, including GPCRs, ion channels, kinases, 
caspases, phospholipase, and so on [27].  
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1.4 The impact of mutations on protein-ligand binding sites 
As mutations conferring resistance are frequently encountered after drugs enter the 
clinic, it is wise to consider mutations at the early stages of structure-based drug design. 
This can lead to the discovery and development of candidate drugs which are less likely 
to select for mutations, or which may bypass known mutations [121]. Moreover, the 
structure and interaction information gleaned from these analyses may provide insights 
into the molecular basis of disease-associated or neutral mutations. 
Variation is the spice of life[122]. For two individuals, the genomes could be roughly 
99.9% identical, but these 0.1% differences account for phenotypic variation among 
individuals, including susceptibility to disease[122]. While the sequencing of human 
genome was a great milestone, how to interpret the downstream impact of variation is 
still ongoing. The variation of genotype can impact phenotype by many molecular 
mechanisms. This thesis focuses on the impact of SNP on protein-ligand binding sites. 
1.4.1 The impact of SNP and possible association with diseases 
Small scale mutations occur in one of three ways: single nucleotide polymorphisms 
(SNPs), insertions, or deletions[123]. SNPs are the most frequently encountered variant, 
which may occur in both coding and noncoding region of the genome. While some SNPs 
are known to be associated with a number of Mendelian diseases and complex genetic 
disorders[124], it is difficult to determine the biological impact of previously undefined 
SNPs. For example, SNPs in noncoding regions may affect protein transcription rates and 
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expression levels. SNPs in coding regions can be either synonymous or nonsynonymous 
substitutions, depending on whether the mutation triggers a change in the amino acid 
sequence. Even for synonymous SNPs in coding regions, there may be phenotypic 
effects through altering the rate of translation of a protein[125]. Non-synonymous SNPs 
(nsSNPs) clearly result in changes to a protein through mutation or the introduction of a 
premature stop codon, which should affect the stability and function of protein, but this 
information is impossible to determine from the sequence-level changes alone. 
1.4.2 nsSNP and the possible impact on protein structures 
A protein exists as a delicate balance of structure and function, and dramatic changes 
may occur when this balance is offset. For example, local conformational changes 
induced by nsSNP mutations could introduce hydrophilic residues into protein core 
[126], disrupt of hydrogen bonding patterns, or alter protein secondary structural 
elements like beta-sheets, resulting in a change to the biological function of the protein. 
These changes often have phenotypic implication and increase the possibility of disease 
[127]–[129]. 
Except for nsSNPs that introduce dramatic change in size or physicochemical properties, 
the impact of most nsSNP is hard to interpret. A number of prediction methods to 
predict SNP effects have been developed [130]–[132], which analyze sequence 
conservation and provide a score postulating the risk of an individual SNP. Several 
possible improvements to prediction methods has been proposed, including 
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incorporating information like protein stability and Gene Ontology [133]–[135]. On the 
other hand, measuring the distribution of nsSNPs on a global scale across many protein 
structures is also important to understand the molecular mechanism of nsSNPs. The 
distribution can provide insight for general understanding of disease mechanism and 
potential impact on drug binding. Yet, a number of questions still remain. For example, 
are nsSNPs concentrated on a specific location on proteins, such as binding sites? Are 
disease-associated nsSNPs statistically significantly in their difference from other benign 
nsSNPs? 
1.4.3 Existing databases of protein-ligand interactions 
Accurate annotation of protein ligand interaction sites is critical to understand the 
impact of SNPs on the binding site. Existing databases with protein-ligand complexes 
can be used to characterize the interaction between molecular complexes with the goal 
of interpreting the mechanism of various enzymatic processes. The worldwide Protein 
Data Bank (PDB) contains the largest collection for experimentally determined 
biomolecular structures [124]. As of March 2016, more than 117,000 structures have 
been deposited into PDB.  
A number of secondary, derivative databases have been developed from the PDB to 
summarize some specialized information For example, PDBsum was developed as a 
pictorial summary of the key information on each macromolecular structure [136], 
Relibase+ to provide an easy accessible web-browser interface for searching  protein–
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ligand interactions [137], Het-PDB Navi for navigating heterogens (compounds or 
ligands) in PDB and provide statistics for interactive residues when enough data are 
available [138], scPDB for pictorial analysis of binding sites of PDB [139]. Collectively, 
these databases allow visual exploration of protein-ligand complexes on a large scale. 
In SBDD, the high quality protein-ligand complexes with energetic properties (like 
binding affinity) is more desirable especially for developing scoring function for docking 
of small molecules. In recent years, many sets of protein-ligand complexes have been 
collected and have online web server for searching and downloading. Binding MOAD 
[140], [141], PDBbind [142], and BioLiP [143] are three most outstanding databases 
curated for high-quality, protein-ligand complexes, augmented with the inclusion of 
binding affinity data. Other similar databases, including LPDB [144], PLD [145] and 
AffiDB [146] are much smaller in size and haven’t updated since their original release. 
Binding MOAD, PDBbind, and BioLiP were all developed independently at the University 
of Michigan, Ann Arbor. Binding MOAD, developed in the Carlson lab, has 25,771 
protein-ligand structures and 12,440 unique ligands for version 2014 [147]. The aim of 
Binding MOAD is to build and maintain the largest-possible collection of high-quality, 
protein-ligand complexes available from the PDB. PDBbind, originally developed under 
Shaomeng Wang, currently has 29,008 protein-ligand complexes and 11,376 small-
molecule ligands for version 2015 [148]. The original focus is on developing scoring 
function and searching ligand substructure [142]. The project is currently maintained by 
Renxiao Wang at the Shanghai Institute of Organic Chemistry [149]. In general, Binding 
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MOAD and PDBbind share similar semi-manually curated procedure. The key difference 
is that: 1) PDBbind has various types of molecular complexes, including protein-ligand, 
nucleic acid-ligand, protein-protein, and protein-nucleic acid complexes; Binding MOAD 
doesn’t have any nucleic acid structure; 2) PDBbind does not have strict control about 
the protein structure resolution; Binding MOAD only takes structures with resolution 2.5 
A or better; 3) PDBbind limits the entries with only one ligand in the crystal structure 
and excludes complex with only cofactors bound [142], [150]. BioLiP is developed in 
Yang Zhang’s lab in 2013 as a resource for protein-ligand binding site prediction [143]. 
Most of BioLiP binding affinity data are extracted from Binding MOAD and PDBbind 
[143]. 
1.4.4 Determining residue locations on protein’s structure 
Depending on the specific location of mutations (surface, binding site, or protein core), 
nsSNPs may have distinctive biological consequences. These locations can be 
discriminated based on the degree of solvent exposure or even accessible surface area 
(ASA) can be used to quantify the interacting surface area between individual residue 
and solvent molecules and locate the residue on protein structures.  
Many methods have been developed to calculate the ASA, such as ACCESS [151], DSSP 
[152], ASC [153], NACCESS [154], and GETAREA [155]. ASA was first described by Lee & 
Richards in 1971[156]. Accessible surface of an atom is the sphere surface of a solvent 
molecule, on which the points are required not penetrating any other atoms of the 
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same molecule. The radius of the sphere surface is the sum of the Van der Waals (VDW) 
radius of the atom and of the solvent molecule. In 1973, Shrake and Rupley proposed a 
more efficient “rolling ball” algorithm to calculate ASA [157]. The algorithm is a numeric 
method that draws a mesh of points with equal distance from each atom of the protein 
and counts the number of points that can be accessible by solvent. The points are 
checked against the VDW surface of neighboring atoms to determine whether they are 
on the surface of the protein. Those points on the protein surface may still not be 
solvent accessible. Another check against the vdW radius plus a probe distance (the 
radius of the solvent, 1.4 A for a water molecule) determines whether the point is 
solvent accessible. ASA is calculated by the number of accessible points multiplied by 
the portion of surface area each point represents, which is determined by the van der 
Waals surface of that atom divided by the number of points created on the mesh. The 
result of the algorithm depends on the choice of the 'probe radius' (could be the radius 
of a water molecule) and the definition of vdW radius of each atom. For example, 
hydrogen atoms may be implicitly included in the atomic radii because some structures 
may not have hydrogen atoms.  
This thesis uses DSSP by Kabsch and Sander in 1983, which implement an algorithm 
similar to Shrake-Rupley algorithm with triangle area instead of equal distance grid 
[152]. DSSP is commonly used to generate training data for predicting solvent 
accessibility [158]–[161], secondary structure [162]–[164] and aromatic-backbone NH 
interactions[165] from protein sequences. DSSP has also been applied to generate 
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structural features for mutation impact studies [134], [166]. Another widely used 
implementation is NACCESS by Hubbard and Thornton [154]. This thesis is interested in 
two categories of residues “surface” or “non-surface”. The result is quite consistent 
between NACCESS and DSSP in terms of determine surface residues (> 5 Å SASA). Many 
other algorithms have attempted to improve the speed of surface area calculation and 
provide other structural metrics, but they mostly follow the same definition of ASA 




Chapter 2. ChemTreeMap: An Interactive Map of Biochemical 
Similarity in Molecular Datasets 
2.1 Abstract 
Motivation: What if you could explain complex chemistry in a simple tree and share that 
data online with your collaborators? Computational biology often incorporates diverse 
chemical data to probe a biological question, but the existing tools for chemical data are 
ill-suited for the very large datasets inherent to bioinformatics. Furthermore, existing 
visualization methods often require an expert chemist to interpret the patterns. 
Biologists need an interactive tool for visualizing chemical information in an intuitive, 
accessible way that facilitates its integration into today’s team-based biological 
research. 
Results: ChemTreeMap is an interactive, bioinformatics tool designed to explore 
chemical space and mine the relationships between chemical structure, molecular 
properties, and biological activity. ChemTreeMap synergistically combines extended 
connectivity fingerprints and a neighbour-joining algorithm to produce a hierarchical 
tree with branch lengths proportional to molecular similarity. Compound properties are 
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shown by leaf color, size, and outline to yield a user-defined visualization of the tree. 
Two representative analyses are included to demonstrate ChemTreeMap's capabilities 
and utility: assessing dataset overlap and mining structure-activity relationships (SAR).  
Availability: Examples of ChemTreeMap may be accessed at 
http://ajing.github.io/ChemTreeMap/chemtreemap.html and 
http://ajing.github.io/ChemTreeMap/example. ChemTreeMap may be accessed at 
http://ajing.github.io/ChemTreeMap/. Code for the server and client are also available 
in the Appendix B (pg #162) and Appendix C (pg #215) and 
https://github.com/ajing/ChemTreeMap. 
2.2 Introduction 
Researchers in the field of bioinformatics are frequently tasked with exploring the 
relationship between chemical structures and their potential biological actions. For 
example, one can predict the interaction between a small molecule and a corresponding 
protein target, given the chemical structure [169]. The degree of similarity between 
chemical structures can also indicate a potential for drug repositioning [44], [45] or off-
target effects [170]. A molecules’ ability to inhibit protein-protein interactions may also 
be predicted [171]. In order to discover such interactions, researchers must harness 
large databases, including PubChem [172] and ChEMBL [173], which contain vast 
amounts of heterogeneous biological and chemical data. The size and complexity of 
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these datasets necessitate automated tools to explore available chemical space in order 
to determine chemical relationships and predict potential interactions. 
Exploring chemical space frequently requires a comparison of the number of shared 
chemicals among multiple databases [45], an understanding of the similarity within a 
compound series [44], [45], [170]series, and an analysis of how compound structures 
give rise to a specific biological action [171]. Such analysis begins with the visualization 
of molecular datasets. There are general visualization strategies such as Venn diagrams 
[45], networks [45], heat maps [170], and clusters [44]. However, those strategies have 
limited utility, depending on the biological question and how detailed the analysis must 
be.  
Graphical tools have been developed for cheminformatics that group structurally similar 
molecules together and display information about molecular structure and bioactivity 
[61], [65], [66], [70], [74]. The previous methods usually require users to choose 
selection rules [65] and tune parameters [61]. This can limit the utility of these tools for 
large, diverse sets of data that are the hallmark of bioinformatics. Those tools can also 
require domain experts to effectively use them, which limits their extension to a larger 
user base.  
To overcome these limitations, we have developed ChemTreeMap, an open-source tool 
for visualizing compound similarity coupled with associated biochemical information. 
We have carefully selected techniques for calculating molecular similarity and 
36 
 
representing chemical space to satisfy the needs of bioinformaticians. The tool uses 
standard procedures, requires no tuning parameters, and allows users to interactively 
explore a molecular dataset. ChemTreeMap organizes molecules into a hierarchical tree 
based on chemical similarity, much like phylogenetic trees that are commonly used in 
biology. This provides a familiar framework for scientists to view and access desired 
information.  
Users can map any property of interest to the graph’s leaf attributes (i.e. color, size, and 
border color). This facilitates an on-the-fly, customized exploration of the relationships 
between molecular structure and other properties. ChemTreeMap’s organization 
reflects the similarities of molecules at various levels and in different chemical series. It 
does not rely on any assumption about the similarity cutoff. Users can explore the 
branches to understand the similarity across the nearby molecules. The branch lengths 
quantify the difference in features, which is particularly useful for structurally diverse 
datasets. Longer distances between chemical families highlight more diverse regions of 
chemical space. 
To illustrate ChemTreeMap’s utility, we describe two practical applications: the 
visualization of chemical overlap between molecular datasets and the extraction of 
structure-activity relationships (SAR).  
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2.3 Methods  
Organization and visualization of a molecular library requires three considerations: first, 
how to represent a molecule, second, how to quantify the similarities between different 
molecules, and lastly, how to represent these similarities graphically. Each 
ChemTreeMap is then completed by coloring the resulting tree to convey biochemical 
information.  
2.3.1 Representation of the molecules 
Our primary molecular descriptors are stereochemistry-aware, extended connectivity 
fingerprints (ECFP6#S). These are topological descriptions that capture large, recursive, 
circular neighborhoods around each atom. This method identifies the functional groups 
in each molecule, and it is quick to calculate, which makes it well suited for large 
molecular datasets [56]. ChemTreeMap also calculates atom-pairs fingerprints [174] as 
an alternative metric. Others can be added easily, such as MACCS keys [175], topological 
torsion fingerprints [176], and 2D-pharmacophore fingerprints [177]. 
A potential concern about fingerprints is that their pair-wise comparisons may not be 
optimal for a global description of the data [61]. Fortunately, ChemTreeMap’s display 
uses a global, hierarchical organization to convey information at the local level and in 
the overall patterns across the data.  
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2.3.2 Construction of the chemical similarity tree  
The similarity of two molecules is calculated by a Tanimoto coefficient (Tc) [178], which 
refers to the number of chemical features they share in common divided by the union of 
all features (a % similarity that ranges in values from 0 to 1). Tc was chosen because of it 
is fast, easy to implement, and widely used in chem-informatics and drug-discovery 
software. Branch lengths in ChemTreeMap are inversely proportional to the Tc between 
the molecules, where shorter branches show high similarity and longer indicate greater 
diversity. 
To build the hierarchical tree, we chose the Neighbor-Joining algorithm (NJ, see 
Appendix A (pg #148)) [179]. The NJ algorithm is widely used in building phylogenetic 
trees for large and diverse sequences [180], [181]. It has been mathematically proven 
that given a correct input distance matrix, the output tree and branch lengths from NJ 
will also be correct [182]. Furthermore, NJ does not rely on any parameter tuning, 
making the tree construction more robust. RapidNJ has a best-case running time of 
𝑶(𝑵𝟐) and at worst 𝑶(𝑵𝟑) [183]. It is an agglomerative joining method that follows:  
1. 𝑫 is an 𝑵 ×  𝑵 distance matrix, where each element 𝑫𝒊𝒋 = Tc(i,j) (i, j represent two 
molecules from the set of 𝑵 molecules) 
2. The average distance from molecule i to all other molecules k is: 
𝒖𝒊 = ∑
𝑫𝒊𝒌
𝑵 − 𝟐 ⁄
𝒌
 
3. With 𝑵 average distances, we create the Q matrix, with elements:  
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𝑸𝒊𝒋 = 𝑫𝒊𝒋 −  𝒖𝒊 − 𝒖𝒋. 
4. Find the i, j with the smallest value 𝑸𝒊𝒋.  
5. For that i, j pair, an imaginary ancestor node 𝑎 is created to replace i and j. The 
distance between 𝑎 and i, j is: 
𝒗𝒊 = 𝟎. 𝟓 × 𝑫𝒊𝒋 +  𝟎. 𝟓 × (𝒖𝒊 −  𝒖𝒋) 
𝒗𝒋 = 𝟎. 𝟓 × 𝑫𝒊𝒋 +  𝟎. 𝟓 × (𝒖𝒋 −  𝒖𝒊) 
6. D is then updated by replacing i and j with an ancestral node 𝑎 . The distances 
between 𝑎 and all the other nodes k are: 
𝑫𝒂𝒌 =  (𝑫𝒊𝒌 + 𝑫𝒋𝒌 − 𝑫𝒊𝒋)/2 
7. Keep updating until the last two nodes are joined. 
 
 
2.3.3 Clustering of Molecules for Very Large Datasets 
For huge datasets, such as ChEMBL [173], BindingDB [184], and ChemBank [185], the 
molecules need to be clustered by similarity to reduce the size of the task. An 
interactive display of millions of leafs is not possible with current technology. For 
tractability, ChEMBL and ChemBank were each independently sorted into their own 
4000 clusters. Because BindingDB is smaller, its molecules were clustered into 2000 sets. 
All clusters were represented by the molecule with the highest sum of Tc across the 
subset, the molecule most similar to all the others in the group. The size of the leaf for 
that center is proportional to the number of molecules in the group. It would be 
possible to produce a ChemTreeMap for each cluster, but wading through thousands of 
smaller trees is not practical. 
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MiniBatch-KMeans was chosen for clustering, which has low runtime complexity 𝑶(𝑵), 
memory usage 𝑶(𝑵), and relatively low error [186]. The RDKit (http://www.rdkit.org, 
accessed 28 October 2015) fingerprint was selected for this initial clustering, which is an 
implementation of a Daylight-like fingerprint. The task of finding nearest neighbors is 
relatively easy, and this alternate fingerprint is fast and saves memory. With MiniBatch-
Kmeans and RDKit fingerprint, the clustering step for ChEMBL – the largest dataset – 
took less than 5 hours to run on a machine with 16G memory (i3-2100 CPU @ 3.10GHz). 
In comparison, the maximum dissimilarity method [187] implemented in PipelinePilot 
[188] takes more than a week to cluster ChEMBL, and an algorithm with average 





Figure 2-1. ChemTreeMap work flow. Each compound (encoded as a standard SMILE 
string) and its biological data are processed in steps to yield a JSON file, which is then 
used by a JavaScript App to create the graphic tree map (clearly three independent 
chemical series in this sample). Specifically, ECFP6#S and Atom-Pair fingerprints are 
calculated as two options for the Tc used in building a tree structure. By default, LE 
and SlogP are calculated for each molecule and its activity data. Tree structures and 





The application has a client-server paradigm [189], in Figure 2-1, which allows online 
access to the results and facilitates sharing data with colleagues. The server performs 
tree construction, including fingerprint calculations, similarity calculations, neighbor 
joining, layout optimization, pIC50, ligand efficiency (LE = 1.37×pIC50/heavy-atoms, for 
rough conversion to ΔGbind/HA), and SlogP calculations [190]. The code for the server is 
provided in Appendix C (pg #215). All output from the server processes are packaged 
into a JavaScript Object Notation (JSON) file[191][190][31] for client input. The client 
process displays the tree structures and supports functions, such as searching by ID and 
changing leaf attributes: circle size, colored border, and biochemical metric mapped to 
the circle. Layout optimization uses a multi-scale version of dynamic, spring-model 
layouts implemented in GraphViz [192]. This allows users to actively pull and reorient 
nodes/branches to improve the visual layout in a local area. The code for the client 
process is provided in Appendix B. 
ChemTreeMap is a web-based tool, which is easy to set up on any computer with 
Python 2.7. GraphViz and RapidNJ are freely available online for major operating 
systems [183], [192]. The graphics can be viewed on any computer with an HTML5 
capable browser (tested on Google Chrome Version 46, Internet Explorer 11, and Safari 
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9.0). We recommend Google Chrome for displaying ChemTreeMaps of thousands of 
molecules because of the computational intensity of its force-directed graph. Speed is 
also dependent on the client hardware.  
2.4.1 ChemTreeMap can be easily extended with more features 
A straightforward option to add functionality is to input additional data for each 
molecule, as columns in a tab-delineated input file (e.g. SMILE string, data 1, data 2, 
etc.). The program will present the additional data as options in drop-down menus for 
the user to map that information onto the ChemTreeMap leafs through display options 
(color, border, circle size).  
A more powerful alternative is to extend the functionality in ChemTreeMap’s 
TreeBuild.py file. Currently, the chemical properties of LE and SlogP are calculated using 
RDKit in TreeBuild.py, and developers can very easily add 55 additional descriptors from 
RDKit. For more descriptors, we recommend adding data from MOE [193] or PaDEL 
[194] with the simple tab-delimited option. Any in-house, custom analysis is best added 
directly in the python code if it will be used frequently. 
2.4.2 Comparing ChemTreeMap to other SAR methods 
We compared ChemTreeMap with four freely available programs: Similarity-Potency 
Tree (SPT, [65], Data Warrior [66], Scaffold Hunter [70], and CheS-Mapper [77], [78]. SPT 
is the method most similar to ChemTreeMap. It also uses Tc and ECFP6#S fingerprints to 
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calculate chemical similarity, but it uses a different type of tree display and network 
analysis. SPT has a compound-centric view, focusing on potency and a limited set of 
nearest neighbors in chemical space. Their tree structures rely on a chosen reference 
compound. Similar molecules are not necessarily grouped together in some cases.  
Data Warrior is an open-source program with highly interactive graphical views and 
interesting statistical analysis. It focuses on similar neighborhood relations only and 
ignores similarity relations below a certain threshold. Such methods may not capture 
enough structural breadth for a diversified dataset.  
Scaffold Hunter identifies chemical cores for each molecule and associates them in a 
hierarchy based on medicinal chemistry rules. A tree-like output is used, but the local 
SAR of individual molecules sharing the same scaffold is not displayed.  
CheS-Mapper organizes compounds in three dimensional (3D) space, where the 
compounds similarity is encoded in the spatial distance between them. This software 
employ multidimensional scaling methods to generate the 3D coordinates for each 
molecule. These methods usually do a decent job of grouping similar molecules closely 
together. However, the available space is not used efficiently and it only accept 
numerical descriptors. In the visualization, similar molecules tend to be overcrowded, 




We did not have access to a maximum common substructure (MCS) method for 
comparison. MCS are another way to organize molecules into groups, based on pre-
defined chemical functionalities and novel pattern matching [195]. Like Scaffold Hunter, 
MCS techniques identify common core patterns across a dataset. inSARa is a recently 
introduced MCS method [61] that uses reduced graphs to create tree-based output like 
ChemTreeMap, SPT, and Scaffold Hunter. Its final representative substructures are 
sensitive to many parameter choices [61], which is where ChemTreeMap and inSARa 
differ. Our generalized Tc-based distances have no tunable parameters, other than the 
choice of fingerprints. A tunable method has its own benefits, and we see inSARa as a 
complementary method to ChemTreeMap, SPT, and Scaffold Hunter. 
2.5 Datasets 
ChemTreeMap is applicable to a wide range of datasets with various levels of complexity 
and sizes. To demonstrate ChemTreeMap, we have chosen diverse biomolecular 
datasets ranging from thousands to millions of molecules. To show chem-data overlap, 
we use some of the largest datasets with bioactivity data: ChEMBL v. 20 [173], 
BindingDB [184], and ChemBank [185].  
For SAR examples, we assembled chemical datasets for the four protein targets shown 
in Table 1. Clotting factor Xa (FXa), cyclin-dependent kinase 2 (CDK2), p38α MAP kinase 
(p38α), and cytochrome P450 3A4 (CYP3A4) were chosen because their SAR are well 
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characterized [196], [197], and they have been used in previous studies for visualizing 
chemical data [61], [65]. The data for FXa, CDK2, and p38α are from BindingDB. CYP3A4 
data (bioassay AID:884) was pulled from high-throughput screening (HTS) data in 
PubChem [172]. All four systems have a large range of inhibition data. The average Tc for 
each set is under 0.2, which indicates high chemical diversity. 
Each of the SAR datasets was prepared using the following protocol:  
1. For inclusion, a molecule must have an IC50 or pIC50 for bioactivity. For PubChem 
data, only molecules in the “Active” category was kept for analysis.  
2. If there were multiple activity data for a molecule, the average of the IC50 was used 
(i.e. no repeat chemical structures). 
3. The ionization state and tautomer for each chemical structure were determined 
using the “wash” utility in MOE 2014 [193]. 
Table 2-1 Datasets used for SAR analysis. 
Protein 







FXa protease 2161 10.7 3.0 0.172 
CDK2 kinase 1923 9.5 2.9 0.141 
p38α kinase 5139 10.4 2.9 0.167 





2.6 Results and Discussion 
2.6.1  Comparing chemical diversity of large datasets 
When more data is needed for a project, information that covers new chemical space is 
typically preferred. Depending on the project, very wide diversity may be desirable to 
enhance breadth, or new compounds in nearby chemical space may be needed to 
increase the depth of coverage. ChemTreeMap can identify both types of chemical 
similarity/diversity. 
Existing methods count the number of duplicate molecules between the sets [45], or 
they map chemical features to a 2D scatter plot with overlapping regions, based on 
principal component analysis or multidimensional scaling [43], [67]. These methods can 
fail to convey enough information on the structural similarity within/between the 







Figure 2-2. The addition of ChEMBL (blue) and ChemBank (red) adds breadth of chemical 
space. ChemTreeMap details the regions of chemical similarity and diversity for both 
sets. Shared molecules are in black clusters. Regions A and B contain molecules only 
from ChemBank. Region C contains molecules only from ChEMBL.  Representative 
molecules are shown. Leaf size (circles) is proportional to the number of molecules in 
each cluster from the initial processing step for large databases. The view is scaled out 
to show the entire data space. Full details can be seen with ChemTreeMap by zooming 






Figure 2-3 The addition of ChEMBL (blue) and BindingDB (red) adds depth to chemical 
space: Shared molecules are in black. Representative molecules are shown. The view is 
zoomed out to show all data. 
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Our examples for comparing large sets revolve around ChEMBL [173]. It is a dataset with 
~1.3 million chemicals with significant biochemical annotation from the literature (~50 
journals). We compared ChEMBL to ChemBank and BindingDB to show datasets that 
represent collections with more breadth vs more depth, respectively. ChemBank [185] is 
a set of ~1.15 million molecules constructed from chemical HTS studies. Many 
compounds in ChEMBL are not from HTS studies and will not appear in ChemBank. 
Though many HTS studies eventually appear in the literature, the full data for every 
compound rarely appears in a final publication. Therefore, we knew that many 
molecules would appear in one but not the other. We did not know how 
similar/different the chemical sets were from one another, but we expected significant 
populations of ChEMBL-only and ChemBank-only compounds with many in similar 
chemical space. 
The traditional Venn diagram in Fig. 2 shows that the overlap is relatively small as 
expected; 11.3% of ChEMBL molecules are the same as 12.8% of ChemBank’s 
compounds. To show the chemical similarity and diversity, a more detailed display is 
needed. ChemTreeMap highlights regions where the chemical space is unique to 
ChemBank (red branches A and B) and to ChEMBL (blue branch C). Though some 
branches contain red and blue leafs in similar chemical space, combining the two sets 
primarily increases the breath of chemistry structures overall.  
ChEMBL [173] and BindingDB [184] both curate molecules from the biochemical 
literature. BindingDB focuses on protein targets with crystal structures in the Protein 
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Data Bank. It enhances the structures with experimental binding data for many ligands. 
ChEMBL is a major source of data for BindingDB’s molecules, but BindingDB includes 
data from 12 biochemical journals not covered by ChEMBL. Together, ChEMBL and 
BindingDB’s shared efforts provide ~60 journals-worth of data to the scientific 
community. 
Based on their construction, a large overlap is expected for ChEMBL +BindingDB (Fig. 3). 
About 82% of the molecules in BindingDB are also in ChEMBL (black nodes). No large 
branches are dominated by BindingDB. Instead, many of ChEMBL’s branches contain 
new molecules from BindingDB. Fig. 3 shows that this augmentation to ChEMBL from 
BindingDB adds depth of coverage, specific to drug-like space. (Note: The ChEMBL-only 
branches are for targets that do not have a protein-ligand crystal structure, a 
requirement for BindingDB). 
 
2.6.2 Options for displaying more information 
A distinct advantage for ChemTreeMap is the ability to display multiple layers of 
information simultaneously through leaf color, outline, and size. For example, molecules 
with good solubility and high LE are desirable for drug leads. Fig. 4 shows how 
ChemTreeMap adds more data through outlines. Molecules with good solubility (low 
number, red) or good LE (higher number, red) can be easily recognized in the graph. 
Users could extend ChemTreeMap with more SAR metrics, like SALI scores (Structure-
52 
 
Activity Landscape Index, Guha and Van Drie, 2008) or PAINS alerts (Pan Assay 
Interference compounds, Baell and Holloway, 2010). 
ChemTreeMap uses a broad color scheme purple-blue-cyan-green-yellow-red. Previous 
studies have scaled the colors green-yellow-red to fit the max/min range in each dataset 
[61], [65]. Having twice the number of colors allows us to show a larger span of 
properties with better clarity. It also allows users to easily compare different datasets 
because the static colors always indicate the same IC50 in any ChemTreeMap. The 
spectrum basically covers the full range of affinities obtained in biological assays, where 
inhibitors vary in IC50 from ~100 μM (purple: pIC50 ≥ 4) to ~1 nM (red: pIC50 ≤ 9). For LE, 
the range is 0 (purple) to 0.5 (red) kcal/mol-HeavyAtom, which covers 90% enzyme 
activity data from our previous study [198]. For SlogP, the range is set from -5 (red) to 5 
(purple). Users can switch between attributes while inspecting the branches, and the 
features are interactive, e.g. navigating, dragging, or zooming to see details. 
2.6.3 ChemTreeMap can be used to extract SAR information  
For the rest of our examples, the molecules were not clustered, and all leafs represent a 
single compound. Traditionally, SAR information is deduced by analyzing molecules from 
several chemical series, often incorporating predictive statistical models 
[65].Interpretation can be strongly dependent on the experience of the chemists, and 
these paradigms are limited in the number of compounds one can analyze. 
ChemTreeMap provides an intuitive, robust, and effective way to extract SAR 
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information from a chemical library. ChemTreeMap does not rely on any assumption 
about the similarity cutoff. Its hierarchical organization of molecules, based on 
structural similarity, facilitates the identification of SAR hotspots and activity cliffs. The 
distance between leafs highlights the (dis)similarity between any pair of molecules. 





Figure 2-4  Multi-layer information: (a) pIC50 color inside the circles and 
SlogP mapped to the outline color. The left branch shows a common pitfall 
of good affinity but poor solubility of the molecules. (b) Gray background 
added to make outlines more visible. pIC50 color inside the circles and LE 
mapped to outline color. Most leafs have high potency, but those with 
green outlines are larger molecules with lower LE. These molecules are less 
“efficient” because they have the same binding affinity but need more 




Figure 2-5 The ChemTreeMap for CYP3A4 (6837 molecules) shows a few compact 
regions of chemical space with moderate activity (green leafs, highlighted by black 
ovals). Compounds in these groups have a higher potential for drug development. 
There are also a small number of one-off, strong inhibitors that are likely HTS error 
(rare orange and red leafs). The top bar contains drop down menus for ECFP or 
Atom-Pair fingerprints and the leafs (circle size, circle border, activity metric, 
settings, and info). The tree is dynamic using a force-directed graph with control of 
the “Radius of Display” (see Supplementary Information). The color bar shows the 
activity metric. Each color represents one level of potency (pIC50): which is 4 
(purple, IC50 = 100 μM, indigo), 5 (blue), 6 (cyan, IC50 = 1 μM,), 7 (green), 8 (yellow), 




HTS is a screening technology that tests thousands of molecules in a biochemical assay. 
Hits are typically inhibitors of an enzymatic assay, but many different assays exist that 
test a variety of effects. ChemTreeMap displays can help with interpreting the data. 
ChemTreeMap has an advantage when exploring large, heterogeneous datasets from 
HTS because of its speed, hierarchical structure, and broad color range.  
Most of the compounds used in HTS are inactive, which can be seen by the 
predominance of blue and purple in the CYP3A4 ChemTreeMap, Fig. 5. HTS data is 
notorious for many false positives and false negatives. One of the hallmarks of true 
positives is finding many similar molecules displaying moderate activity like those 
marked in Fig. 5. These regions indicate chemical space with potential for further 
development. Groupings of hits can be a small, 5-molecule sub-tree or a large branch of 
30+ compounds. Of course, proper statistics are critical to assessing signal-to-noise in 
HTS data. One way that ChemTreeMap could be easily extended for a custom HTS 
application is to map statistical significance of each compound’s signal onto their leaf 






Figure 2-6. ChemTreeMap for 2161 FXa inhibitors: Sub-tree I contains high potency 
molecules; the dashed region highlights many modifications in the nearby chemical 
space cause a drop in potency. Inspection of those compounds shows that the most 
detrimental changes involve removing a positive charge from an essential functional 
group. The color bar follows the same activity pattern as in Figure. 2-5. The upper-





2.6.3.2 SAR of FXa 
Fig. 6 is the ChemTreeMap of our SAR set for FXa. A typical SAR set explores a more 
focused area of chemical space (inhibitors in this example). The molecules have a range 
of activities that change with the structural features. Branches dominated by strong 
inhibitors in red clearly denote specific chemistry linked to high potency.  
Sub-tree I is the largest region of the ChemTreeMap with high activity. The neighboring, 
dashed region shows how potency starts to decrease as larger chemical modifications 
are made. Fig. 7(a) shows a magnified view of sub-tree I from Fig. 6, with LE data shown 
on the outlines of the leafs. By inspecting the neighboring molecules, we can identify 
shared chemical features that are correlated with high activity. Fig. 7(b) shows that all 
molecules A-L in sub-tree I share a 2-(4-(N,N-dimethyl carbamimidoyl)benzamido)-N-
(pyridin-2-yl)benzamide core, marked in gray. ChemTreeMap makes a rather complex 
chemical analysis and description straightforward for informaticians because the pattern 
is clear from the visual display. An “activity cliff” is easy to identify for compounds J and 
K. Activity cliffs occur when a small chemical modification leads to a large change in 
activity [199]. ChemTreeMap makes it easy to find molecules in very close proximity 
with large color changes. Several other structural features are also seen in the full 
dataset, such as activity switches and SAR hotspots also identified using inSARa [61], but 




Figure 2-7 (a) Sub-tree I from Fig. 6 with activities as fill color and LE as outline color. 
Inhibitors with larger functional groups have less favorable LE values (compounds D-F). 
(b) The chemical structures of representative molecules A-L are shown. The common 
core is marked in gray, and the differences in the functional groups are noted with red 
circles. The functional group circled in purple is an essential feature for these FXa 




Molecules A-H/J/K differ by small chemical changes on the central ring. Molecule I 
differs from H by a methyl group in place of a chlorine at the bottom of the molecule. I is 
a “descendent” of H because they are most similar, but I is one step away from the 
common structure of the other compounds. The addition of a four-membered ring in L 
is a large chemical change that places it in a nearby sub-tree separate from A-K. 
Fig. 8 provides the analyses of the FXa dataset with SPT, Data Warrior, and Scaffold 
Hunter. Here, we focus the discussion on compounds from sub-tree I. SPT is a state-of-
the-art method for cheminformatics. An accurate method should show agreement with 
SPT and improvement where possible. Fig. 8(a) shows that the same molecules from 
sub-tree I were a large structural feature in the highest-ranked tree found with SPT, 
which is in good agreement with our finding that sub-tree I is the largest contiguous 
region of high activity. The majority of compounds in Fig. 8(a) are from the two marked 
regions in Fig. 6. SPT constructs a different visual tree that uses the compounds as 
nodes. All molecules with Tc >0.4 of the root compound are organized into levels. Each 
level shows all molecules with Tc >0.55 to the root-molecule above it. SPT organizes 
each level by increasing activity from left to right, but removes the structural 
relationships between molecules in the same level. The ordering directs the user toward 
the most active compounds, but it may obscure structural features of the SAR. For 
instance, H/J/K only differ by the location of one chlorine atom, yet they appear 




Figure 2-8. Sub-tree I of the FXa dataset visualized using three other tools: (a) SPT, 
(b) Data Warrior, (c) Scaffold Hunter, and (d) CheS-Mapper. 
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In Fig. 8(b), Data Warrior spreads A-L across its entire network, with few connections 
between them. Several of the molecules are shown as lone data points. In Fig. 8(c), 
Scaffold Hunter correctly identifies the common substructure of A-K, but molecule L is 
placed in another tree with cyclobutane as a root. The relationship between the A-K 
scaffold and the L scaffold is lost. The impact of small modifications on activity is not 
presented, but the information is necessary for SAR studies. In Fig. 8(d), CheS-Mapper 
groups A-L together, but as many molecules shared similar compound features with A-L, 
this region becomes too crowded to reveal the relationship between structure changes 
and activity. 
Clearly, future enhancements for ChemTreeMap should include scaffold information. 
The ancestor nodes that serve as branch points are prime locations for showing the 
shared common substructure of the descendent molecules. It would also be an 
appropriate point in the graph to display SAR alerts based on the patterns of activity in 
the descendent branches. 
2.6.3.3 SAR hotspot in CDK2 data 
An SAR hotspot is a collection of similar molecules displaying a wide range of potency. 
Finding these series are important for SAR, but they can also facilitate “patent busting.” 
ChemTreeMap makes finding SAR hotspots easier by having 1) a wide color range for 
activity and 2) branch lengths between nodes that are proportional to chemical 
similarity. Short branches with many colors are candidates for SAR hotspots.  
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In Fig. 9(a), the ChemTreeMap for CDK2 contains sub-tree II, an SAR hotspot. In Fig. 9(b), 
two sets of molecules can be seen in different branches because of their chemical 
similarity: A/B (ether substitutions) and C-E (alkane substitutions). These are separate 
from F-H which have larger chemical differences between each other and the rest of 
sub-tree II. If these molecules were ordered by potency, these groupings would be more 
difficult to identify. However, the preference for a branched, 4-atom substituent would 





Figure 2-9 (a) ChemTreeMap for the CDK2 dataset. Sub-tree II contains molecules with large variance in bioactivity. 




Figure 2-10 The visualization of CDK2 compounds using three other tools: (a) SPT, (b) Data Warrior, 




In Fig 10(a), SPT identifies sub-tree II compounds in its second-ranked tree. The ranking 
of the tree is fitting because some of the compounds have low activity. The chemical 
similarity is clear from the SPT tree, but SPT’s color scheme is a limitation. The colors are 
scaled to span the minimum to maximum values across the whole dataset. 
ChemTreeMap’s color scale makes it easier to identify the drop in activity for 
compounds B and F. Data warrior in Fig 10(b) captures the similarity of the ethers in A 
and B, but they are far separated from the rest of the compounds. Also, C-E are not 
necessarily distinct from F-H. Scaffold Hunter in Fig 10(c) shows that all molecules of 
sub-tree II share the same scaffold, but the chemical differences between them are not 
revealed. CheS-Mapper in Fig 10(d) identifies the similarity among A-H, but overlapping 
nodes make distinguishing the activity difference difficult. 
Results for p38α can be found in the Appendix A (pg #148). It should be noted that our 
analysis is based on global exploration of each dataset, but the discussions have focused 
on local sub-trees. The Appendix A (pg #148) contains resulting diagrams for each 
method, using solely the sub-tree compounds. Occasionally, there are slight 




ChemTreeMap is innovative for quantifying chemical similarity in the branch lengths as 
done for phylogenetic trees, organizing molecules in an alternative hierarchy, and 
mapping multiple properties to graphical attributes. It uses robust, widely accepted 
methods. 
ChemTreeMap is designed as a general purpose chemical visualization and data mining 
tool with many interactive features to ease the navigation in large datasets, like 
dragging, zooming, and searching. Single clicks on a leaf yields detailed molecular 
information. Its dynamic layout allows users to modify the tree, using a click-and-drag 
feature on the nodes that can reposition branches to improve the view.  
ChemTreeMap is applicable to a wide range of problems. Any data can be mapped onto 
the similarity tree. The approach does not make any assumptions about the relationship 
between activity and structure, thus enabling a data-driven interpretation of 
biochemical information. It is also implemented in a client-server format that allows 





Chapter 3. Physicochemical differences between allosteric and 
competitive ligands 
3.1 Abstract 
In many drug design projects, the target is the protein’s active site, but in some cases, 
allosteric sites are more amenable to drug development.  Here, we utilize the Allosteric 
Database (ASD) and ChEMBL to systematically obtain large datasets of both allosteric 
and competitive ligands.  Our original set was created in 2012 and was composed of 
8827 unique allosteric ligands and 3194 unique competitive compounds.  This was 
updated in 2015 to contain 70,488 and 11,874 unique ligands for the allosteric and 
competitive sets, respectively.  Physically relevant compound descriptors were 
computed to examine the differences in chemical properties of these extensive 
datasets.  Particular attention was given to removing redundancy in the data and 
normalizing across ligand diversity and protein targets.  The resulting individual and 
pair-wise distributions show that allosteric ligands are more hydrophobic, aromatic, and 
rigid.  These results are robust across different normalization schemes, and they are 
found in both the 2012 and 2015 data.  Furthermore, the ligands that are highly similar 
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between the two sets (compounds with the potential to have both allosteric and 
competitive mechanisms in different targets) fall squarely in allosteric chemical space.  
These insights may aid future molecule design to create compound libraries with 
specific biases for allosteric or competitive modes of action.  
3.2 Introduction 
The major goal in drug discovery is to design a small molecule that binds specifically to a 
particular protein target and achieves a desired physiological effect. Typically, the 
binding site for these small molecules is the protein’s functional active site. However, a 
large number of active sites have physicochemical properties which are hard to target 
with a drug-like small molecule[200]–[203]. However, these proteins may also have 
secondary, allosteric sites that have the ability to modulate function by inducing 
conformational or dynamic changes.  Typically, allosteric sites have no steric overlap 
with the active site.  It is hypothesized that these binding sites have different physical 
and chemical properties which may be amenable to small molecule design when the 
active site has been found to be difficult to target and potentially “undruggable”.[204]  
Many examples of allosterically modulated proteins have been annotated and 
thoroughly studied in the literature since the formalization of the theory by Monod, 
Wyman, and Changeux in 1965[204], [205].  Until recently, most studies have focused 
on characterization of allosteric ligands to a single protein[206]–[209].  Studies of 
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allosteric ligands have ranged from the control of metabolic mechanisms to signal-
transduction pathways[210].  Large databases such as PubChem[211], DrugBank[212], 
and ChEMBL[213] have allowed researchers to mine interesting patterns to help predict 
protein-ligand interactions.  In particular, ChEMBL is annotated with descriptions of the 
included assays, which often includes the type of interaction, including allostery[213].  
An additional allosteric-specific database, Allosteric Database (ASD) has been created 
with >100,000 allosteric ligands for mining[214], [215].  This study utilizes both ChEMBL 
and ASD to mine patterns that discriminate allosteric from competitive ligands. Many 
studies have explored allosteric mechanisms, but they tend to focus on a single protein’s 
mechanism[216]–[219] or investigate the issue from the perspective of the 
protein[220]–[223]. 
The goal of this study is to understand the ligand’s role in allostery and what makes 
them unique. Two other studies have mined for generic properties of allosteric ligands.  
Wang et al. compared the properties of the ligands contained in ASD to several 
databases of known biological active compounds[224]. They showed that ligands in ASD 
contain more hydrophobic scaffolds and have a higher structural rigidity than the 
molecules in other databases, including Accelrys Available Chemicals Directory (ACD) 
[225], Accelrys Comprehensive Medicinal Chemistry (CMC) [226], Chinese Natural 
Product Database (CNPD) [227], DrugBank [2]–[4], MDDR [228], and NCI Open Database 
[229]. In this study, although ASD contains only allosteric compounds, there was no 
guarantee that the other databases do not contain allosteric ligands.  In the second 
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study, Van Westen et al. compared allosteric versus non-allosteric compounds in 
ChEMBL[230]. Their main focus was on a few classes of protein targets and the 
development of predictive models for: Class B GPCRs, HIV reverse transcriptase, 
Adenosine receptors, and Kinase modulators.  In their analysis of allosteric versus non-
allosteric compounds, two important observations were made: firstly, allosteric ligands 
are not distinct from and tend to be a subset of non-allosteric ligands; and secondly, 
allosteric ligands are more drug-like than non-allosteric ligands.[230]  
In this study, we focus on specifically differentiating allosteric and competitive ligands, 
and their impact upon protein-substrate binding or protein activity by binding to 
allosteric or active sites, respectively. This answers a different question than that 
answered by Wang et al. or van Westen et al described above.  In those studies, they 
compared allosteric ligands to all other biologically active ligands or non-allosteric 
ligands. These definitions can avoid any falsely identified non-allosteric complexes. This 
study uses both ASD[214], [215] and ChEMBL[213] to have better coverage of possible 
allosteric compounds than any previous study. An issue that has not been addressed 
before is normalizing the data to correct for biases that come from some systems having 
much more data than others. To address this, clustering was performed on two levels to 
reduce the redundancy of protein-ligand complexes and yet maintain the diversity 
across the sets. First, targets are grouped by sequence similarity, and then ligands are 
clustered within each protein family. Since each of these databases is also annotated 
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with the protein target, we examined the distributions of protein targets from each 
dataset. 
3.3 Methods: 
3.3.1 Data Collection 
The study utilizes three datasets: a 2012 dataset, a 2013-2015 dataset, and a full dataset 
(2015). Previous studies only used one dataset, a single snapshot of the compound 
databases before a certain date. However, with exponentially growing data, the results 
could be biased by newly studied compounds. Multiple datasets from multiple time 
points should reduce this potential problem, when they are normalized for redundancy. 
The approach in this study is relatively conservative. Significant descriptors are found 
with 2012 dataset and confirmed in the full dataset. Seeing consistent patterns across 
the different datasets and different normalization schemes show that our results are 
robust. 
The information on molecular structures and target proteins in the 2012 dataset were 
collected for allosteric and competitive binding from ASD version 1.0 and ChEMBL 
version 11. ASD is a database with a detailed description of allostery, biological 
processes, related diseases, and binding affinities. ChEMBL is a large library of drug-like 
bioactive compounds, containing binding, functional, and ADMET (Absorption, 
Distribution, Metabolism, Excretion, and Toxicity) information. It covers >500,000 assays 
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mapped to 8200 targets, including 2388 human proteins (Release 11). The full dataset 
was collected from ASD version 3.0 and ChEMBL version 20. The 2013-2015 dataset was 
the resulting data after taking 2012 dataset out of the full dataset obtained in 2015. 
Filtering was done on all datasets as described below. 
The allosteric data was extracted from both ChEMBL and ASD. ASD data is imported 
without filtering since it focuses exclusively on allosteric mechanisms. Data from 
ChEMBL was filtered in order to select appropriate allosteric ligands to augment the ASD 
dataset. The entire set of ChEMBL assay descriptions was filtered for those which 
contain the term “alloster*”. All ligands which were characterized by high throughput 
screening (HTS) assays were then removed because of the high error rate in HTS 
approaches. Allosteric-relevant assays from the remaining set were then selected by 
manually reading the descriptions. Of those selected, only active molecules were kept. 
The dataset for competitive compounds, which is based only on ChEMBL, was obtained 
by searching for the term “compet*”. Then, the dataset is filtered by the same 
procedure as the allosteric set, including by-hand verification of assay descriptions. 
The 2012 allosteric set produced by this process has 7873 unique ligands from ASD and 
954 from ChEMBL, that together make 8827 unique allosteric ligands that target 314 
unique proteins. The 2012 competitive set contains 3194 unique ligands from ChEMBL 
that target 338 unique proteins. For the full 2015 dataset, the allosteric set is composed 
of 68,612 unique ligands from ASD and 3,390 from ChEMBL, totaling 70,488 unique 
ligands targeting 1,048 unique proteins. The full competitive set has 11,874 unique 
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ligands from ChEMBL, targeting 1,004 unique proteins. All these datasets (Table 1) are 




Table 3-1 The number of protein families and their subsequent protein-ligand clusters at varying cutoffs for sequence (% Identity) and 
chemical (Tc) similarity. 
 # Unique Ligands #Protein Families (Providing #Protein-Ligand Clusters) 
 100%/1 90%/0.9 75%/0.75 60%/0.6 
Original Set (2012)     
8827 Allosteric Ligands 314 (9917) 294 (9353) 283 (6357) 269 (3114) 
3194 Competitive Ligands 338 (5649) 287 (5104) 258 (3473) 220 (1809) 
Full Set (2015)     
70,488 Allosteric Ligands 
1048 
(145,056) 924 (96,318) 859 (55,007) 760 (24,939) 
11,874 Competitive 
Ligands 1004 (17,551) 896 (16,491) 784 (11,387) 679 (6474) 
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3.3.2 Calculation of Compound Descriptors 
Molecular Operating Environment (MOE) 2014[193] was used to calculate the 
compound descriptors. The SMILES were converted to molecular structures in MOE and 
ligands were properly protonated using the default options of the “Wash” procedure in 
MOE. While we expect some small error rate, there is no reason for the rate to differ 
across the various subsets of molecules. 
Descriptors were calculated to characterize molecules in various aspects, including atom 
counts, bond counts, physical properties (SlogP, FCharge), and drug/lead-like 
characterizations. Some descriptors are highly correlated with ligand size (i.e. the 
number of carbons is highly correlated to the number of heavy atoms), so the 
normalizations of these descriptors by size were also calculated (e.g. chiral/a_heavy, 
a_nC/a_heavy). All descriptors available in MOE were computed, but emphasis is placed 
only on the descriptors that are experimentally measurable and can be predictively 




Table 3-2 The list of physicochemical properties that were compared. 




a_heavy Number of heavy atoms.  
a_acc Number of hydrogen bond acceptor atoms.  a_acc/HA 
a_acid Number of acidic atoms. a_acid/HA 
a_aro Number of aromatic atoms. a_aro/HA 
a_base Number of basic atoms. a_base/HA 
a_don Number of hydrogen bond donor atoms. a_don/HA 
a_nC Number of carbon atoms. a_nC/HA 
chiral The number of chiral centers. chiral/HA 
rings The number of rings.   
Physical 
Properties 
FCharge Total charge of the molecule. FCharge/HA 
SlogP Log of the octanol/water partition coefficient. 
logS Log of the aqueous solubility (mol/L).   
Drug/Lead-
like 
lip_druglike One if and only if lip_violation < 2 otherwise zero. 
lip_violation The number of violations of Lipinski's Rule of Five. 
opr_leadlike One if and only if opr_violation < 2 otherwise zero. 
opr_violation The number of violations of Oprea's lead-like test. 
Bond 
b_1rotN Number of rotatable single bonds. b_1rotN/HA 
b_ar Number of aromatic bonds. b_ar/HA 
b_count Number of bonds. b_count/HA 
b_rotN Number of rotatable bonds. b_rotN/HA 
b_single Number of single bonds. b_single/HA 
b_single/b_count (Number of single bonds) / (Number of bonds). 
b_1rotN/b_count (Number of rotatable single bonds) / (Number of bonds). 
b_ar/b_count (Number of aromatic bonds) / (Number of bonds). 
* Descriptors corrected by heavy atom, which corrects for the correlation between 




3.3.3 Removing Redundancy 
Redundancy has not been appropriately addressed in previous studies and may 
potentially lead to bias from overrepresented data. Previous studies have only clustered 
molecules[231] or limited their analysis to one protein family[232]. Properties of 
allosteric compounds are highly dependent on the function of the protein and the 
effects that compounds have. Different protein functions are involved with distinctive 
biological process, which may require allosteric molecules to have specific 
physicochemical properties to perform the interaction. Therefore, clustering for both 
proteins and ligands is necessary to have a dataset that evenly represents the various 
interactions. 
This study adopted a two-level clustering method. The target proteins were clustered by 
sequence identity, which was calculated by BLAST[233] (formatdb and blastp) (x-axis of 
Figure 3-1), by running formatdb and blastp on the target protein sequence fasta file 
with default parameters. Four different thresholds for BLAST identity were used (60%, 
75%, 90%, and 100%) to cluster sequences into protein families. Then, for each protein 
family, ligands are clustered by Pipeline Pilot 9.2[234] (y-axis in Figure 3-1), with the 
Cluster Molecules component at the maximum dissimilarity[187] setting. The ligand 
similarity is quantified by the Tanimoto coefficient (Tc) of the ECFP6 fingerprint[56]. Four 
different thresholds for similarity were used to cluster the ligands (Tc = 0.6 for protein 
families at 60% sequence identity, 0.75 for 75% sequence identity, 0.9 for 90% sequence 
identity, and 1 for 100% sequence identity). This process allowed us to examine the data 
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in fine detail and across broad levels. At this point, the most common procedure is to 
choose the “center” of each protein-ligand cluster to represent those molecules in the 
data analysis. The center is defined as the molecule with smallest sum of Tc distance to 
other molecules in the cluster.  This is the top scheme shown in Figure 3-1, and that 
analysis is provided in Appendix D as Table D-2 and Table D-3. 
3.3.4 The Weighting Procedure, a Better Method for Removing Redundancy while 
Maintaining Diversity 
The traditional clustering chooses only one ligand (the center) for each cluster.  
However, this loses the information from the other ligands in the cluster. We used a 
weighted procedure where every molecule is included, but its contribution to the 
analysis is down-weighted by the number of molecules in its cluster (also shown in 
Figure 3-1). In this approach, summing the weighted data in the cluster results in the full 
distribution of the properties of the cluster weighted as “one molecule.” Clustering in 
this fashion also facilitates bootstrap sampling to determine the errors and variability in 
the calculated physical properties. Here, 100,000 samples (on the order of the number 
of ligand clusters in each set) were generated by selecting from each bin with 
probabilities based on the weighted distributions. The bin widths for the weighted 
histograms are 1 for descriptors with discrete values and 0.02 for continuous variables.  
The distributions of the mean and median from each sample are computed, and the 
95% confidence interval (95%ci) of the mean and median are then defined as the range 
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of 2.5% to 97.5% of those distributions. Statistically significant differences required no 



























Centers of Clusters 
Weighting the 
Clusters 
Figure 3-1 Clustering the data in two levels that includes both protein and ligand 
diversity. Horizontal axis represents clustering in protein space, which is done first. 
Vertical axis represents clustering the ligands found in all members of the protein 
cluster.  The top scheme shows one approach for normalization where each protein-
ligand cluster is represented by the ligand in the “center” as described in the text.  
The lower scheme shows our preferred approach where we maintain the full details 
of all molecules in the protein-ligand cluster, but we scale them by the number of 
ligands so that each protein-ligand cluster has the same contribution (i.e. counts as 
one molecule just like the top example). 
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3.3.5 Overlap between allosteric and competitive dataset 
ChemTreeMap[235] is used to view the chemical space of the structures and determine 
differences in the two sets. ChemTreeMap can organize molecules in a hierarchical tree 
structure to convey molecular similarity information by combining extended 
connectivity fingerprint and a neighbor-joining algorithm. With hierarchical organization 
and color coding, ChemTreeMap is able to highlight the regions where chemical space is 
unique to one group of compounds. ECFP6 is used to characterize the molecules, and 
the hierarchical structure is determined from the Tc between molecules. 
3.3.6 Chemical composition of datasets 
Ring structures and chain assemblies are essential to the molecule scaffold and can 
significantly contribute to the physicochemical properties of the molecule. To 
investigate the difference between the allosteric and competitive sets, the count of the 
most frequent ring and chain assemblies are analyzed using Pipeline Pilot. All 
substructures and their frequency were obtained using the Most Frequent Fragments 
component in Pipeline Pilot, by setting the NumberToKeep variable to an extremely high 
value (the number of returned fragments is less than that value). The default maximum 
fragment size was kept at 25.  
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3.3.7 Data Analysis 
3.3.7.1 Removing seven overrepresented molecules.  
There are seven compounds in the competitive set that are overrepresented because of 
a study, where each compound was tested against a panel of >200 kinases. ChEMBL has 
all included data and marked them as active[236]. Figure 3-2 shows the influence that 
these seven “standards” molecules have on the set of thousands of competitive ligands; 





Figure 3-2 When the seven kinase standards are included in the full 2015 dataset of 
11,874 competitive ligands, there are obvious artifacts in the distributions of 
physicochemical properties.  As an example, the distribution of heavy atoms is shown 
with (dark, dashed line) and without (red, solid line) the seven compounds included.  We 





3.3.7.2 Identifying physicochemical properties that discriminate between allosteric and 
competitive ligands.  
In addition to requiring no overlap in the 95%ci of the physicochemical properties, the 
differences between the allosteric and competitive distributions were assessed by two 
methods: the Wilcoxon test[237] for data from the centers of the clusters and the 
weighted Wilcoxon test for our weighted distributions. Many descriptors have non-
Gaussian distributions; therefore, the non-parametric Wilcoxon test was the 
appropriate choice. The weighted Wilcoxon test is calculated with all compounds in the 
cluster based on the weights determined in the weighting procedure described above. 
We used a strict threshold of p-value < 0.0001 to define a statistically significant 
difference between allosteric and competitive distributions; this was to reduce the 
likelihood that the differences were a coincidental artifact of having two extremely large 
datasets and 37 comparisons of physical properties. These tests were implemented 
through R-Statistics (version 3.2.2), the Wilcoxon Test in stats package[238] is used for 
Wilcoxon test. Functions svydesign and svyranktest in survey package are used for the 
weighted Wilcoxon test.  
3.3.7.3 Analysis of pair-wise distributions.  
Pairs of descriptors were mined to find simple and intuitive rules to differentiate them. 
For example, the SlogP may be higher because there is A) a decrease in the number of 
hydrogen-bond donors/acceptors or B) the addition of hydrophobic groups, and the two 
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cases could be differentiated using two-dimensional histograms of A) SlogP and 
a_acc+a_don vs B) SlogP and a_nC. The significance of a descriptor pair is then 
quantified by 2D Kolmogorov–Smirnov (K-S) test. The 2D K-S test is a nonparametric test 
of significance with no assumption about the descriptor distribution. The results 
generated by this method are sensitive to differences in both location and shape of the 
empirical cumulative distribution of the two samples; therefore, the distance can 
capture multiple aspects of the distributional differences. 
3.4 Result and Discussion: 
We clustered the data at several levels to ensure that we identified robust trends that 
were valid for the data in fine detail and over broad categories. The clustering was done 
at four levels of BLAST and chemical similarity: sequence identity/Tc = 100%/≥1.0, 
90%/≥0.9, 75%/≥0.75, or 60%/≥0.6. Trends in the physical properties had to be 
statistically significant at all four levels of clustering, and those that were observed in 
both the full dataset and the original 2012 dataset were considered more universal. 
Below, we show that allosteric ligands are more hydrophobic, aromatic, and rigid.  This 
is in agreement with previous studies.[224],[230] 
Furthermore, we examined the compounds with the highest similarity between the 
allosteric and competitive sets.  These ligands should have the most potential to exhibit 
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both allosteric and competitive mechanisms of action in different protein assays.  We 
show that this “overlap chemistry” falls squarely in allosteric chemical space.  
3.4.1 Distributions of Protein targets 
Due to the different modes of action, one might expect to see a difference in the types 
of proteins targeted by allosteric vs competitive ligands as this depends upon protein 





Figure 3-3 The distribution of protein targets in the protein-ligand clusters of allosteric 
and competitive compounds. The first row (A, B) is for the full 2015 dataset, second row 
(C, D) is for the original 2012 dataset, and the third row (E, F) is for 2013-2015 dataset. 
The protein categories are taken from Enzyme Classification numbers and keywords in 




When clustering the 2015 dataset at 60%, the number of unique proteins in the full 
allosteric dataset is 760, while there are 679 different proteins in the competitive 
dataset (2012 dataset has 269 allosteric and 220 competitive protein targets).  ASD 3.0 
has increased by >400% since the initial ASD 1.0, due to the significant expansion of 
allosteric drug discovery[26], [239], [240]. Three categories of allosteric proteins are 
dramatically augmented from ASD 1.0 to ASD 3.0: kinases (from 46 to 207), GPCRs (from 
48 to 118), and ion channels (from 21 to 134)[26], which are highly associated with the 
therapeutic targets in recent drug discovery studies[3], [241]. As one would expect, 
there are differences in the protein targets of allosteric and competitive ligands. A large 
portion (46.3%) of allosteric ligands target GPCR proteins, while 29.1% of competitive 
compounds bind to these proteins. A larger percentage of allosteric compounds (14.4%) 
target neuronal proteins (for example, the GABA receptor, glutamate receptor, and 
acetylcholine receptor) compared to competitive compounds (8.1%). Li et al. found that 
the majority of allosteric proteins obtained from ASD were transferases (44.8%) instead 
of GPCR; however, they did not have a designation for non-enzymatic proteins, so this 
percentage is artificially high.[242] In our full dataset, 21.9% of allosteric ligands and 
13.2% of competitive ligands target transferases. For enzymes in the datasets, 53.3% of 
the targets in the allosteric set and 26.7% of the targets of the competitive set are 




A large number of GPCR-based allosteric compounds were developed[26] over 2013-
2015. GPCRs play a critical role in multiple diseases, which provides an attraction for 
large efforts in developing new GPCR-based drugs[243]. Moreover, many subtype GPCRs 
have high sequence similarity in the orthosteric site. Targeting those sites has been 
difficult to obtain high selectivity. In recent years, targeting allosteric sites is a major 
thrust for developing GPCR drugs[244], [245]. 
Van Westen et al. built a dataset from ChEMBL (417 targets for allosteric ligands and 
1,869 for non-allosteric ligands) and examined the distribution of targets and found a 
bias to transmembrane proteins (~50%). That study did not remove redundancy on the 
protein level or the ligand level. Our study reduced this bias caused by overrepresented 
proteins and ligands utilizing two-level clustering for both protein and ligands to remove 
redundancy.  
3.4.2 Protein-Ligand Clusters 
It is worth noting that the full dataset in 2015 is >500% larger than the 2012 dataset.  
The number of protein-ligand clusters is different for each protein and is dictated by the 
chemical diversity of its ligands. In our full dataset, there are 70,488 allosteric ligands 
and 11,874 competitive ligands. These are spread across 1048 and 1004 protein targets, 
respectively. Some compounds can interact with more than one target, and the number 
of protein-ligand clusters ranges from 679 clusters for the competitive compounds at 
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60/0.6 clustering up to 145,056 for allosteric ligands clustered at 100/1.0 (Table 3-1).  
The clusters are used to reduce the bias from heavily studied proteins vs newer targets.   
The sizes of the ligand datasets derived from ChEMBL are smaller than those used by 
van Westen et al. because the datasets were designed with compounds that are 
expressly either allosteric or competitive. Therefore, concrete evidence must exist based 
on restrictive search terms on the assay descriptions as opposed to parsing the language 
of the ChEMBL documents. The allosteric set from ChEMBL is smaller (3,553 vs. 17,829) 
due to the fact only “alloster*” was used in the keyword search of the assay description 
and a manual curation was performed to remove HTS data. However, van Westen used 
several additional terms, which may imply allostery, when searching the whole 
document from ChEMBL. Discarding the HTS data also limits the size of the dataset used 
in this study. Using the assay description and the more restrictive search term helps to 
ensure that each ligand obtained from ChEMBL is indeed an allosteric modulator. The 
“competitive” dataset obtained from ChEMBL is also smaller than the “non-allosteric” 
set, since the focus is on competitive inhibitors annotated in the assay descriptions, and 
thus natural ligands for the protein active site are not included in this set. Any bias the 
natural ligand has on the properties of the competitive dataset is removed by searching 
for only “competitive” ligands in ChEMBL. The growth of allosteric ligands from the 




3.4.3 Chemical Space of Allosteric and Competitive Ligands 
The allosteric and competitive ligands both span similar chemical space (see Figure 3-4). 
Van Westen et al. suggested that allosteric modulators form a subset of non-allosteric 
modulators, based on the observation that their allosteric ligands had a narrower range 
of molecular weight and covered a smaller area in a scatter plot of logP vs molecular 
weight. However, when we compare our allosteric and competitive sets based on ligand 
similarity (Tc), the compounds of both categories appear to cover similar chemical space. 
We were particularly interested in the ligands that were the most similar (Tc≥0.9) 
between the allosteric and competitive sets.  These molecules should exhibit both 
allosteric and competitive mechanisms of action depending on different protein targets.  
It turns out that the “overlap chemical space” is significant.  For the full dataset, 2589 
allosteric ligands (3.7%) are within Tc ≥ 0.9 of a competitive ligand, and 2494 
competitive ligands (21.0%) are within Tc ≥ 0.9 of an allosteric compound.  Combined 
together, there are 2631 “overlap” molecules.  In the last section, we compare these 





Figure 3-4 This ChemTreeMap[235] is a hierarchical tree based on grouping ligands by 
Tc. There is good overlap in chemical space for allosteric (blue) and competitive (red) 
ligands in the 2015 set. The size of each circle represents the number of ligands in a 
cluster of Tc ≥ 0.6. Though a few small regions of chemical space are dominated by one 
set or the other, the large number of branches with interdigitated red and blue circles 
shows that there is a great deal of chemical similarity between the allosteric and 
competitive ligands.  To quantify the overlap, we should note that 5226 out of 70,488 
allosteric ligands (7.4%) are within Tc ≥ 0.6 of a competitive ligand, and 3113 of the 






3.4.4 Physicochemical Differences between Allosteric and Competitive Ligands 
The medians of each physicochemical property (and their 95%ci) are given in Table 3-3 
and Table 3-4. The values that are listed with bold font have statistically significant 
differences between the allosteric and competitive sets. This is determined by both the 
weighted Wilcoxon test (p-value <0.0001) and no overlap in the 95%ci. The physical 
property label is in bold font when the same statistically significant trend is seen for all 
levels of protein-ligand clustering.  Properties listed in red font are only significant for 
the 2012 or 2015 dataset, but not both.  For instance, the original dataset showed that 
competitive ligands had more chiral centers, but that was no longer observed when the 




Table 3-3 Medians (95%ci) of the 37 physicochemical properties for the original 2012 dataset. Numbers in bold are statistically significant 
differences between allosteric and competitive compounds. The list is ordered by largest differences. Red properties do not repeat in 2015 data. 
 Clustering level 60%/0.6 75%/0.75 90%/0.9 100%/1.0 
Descriptors Allosteric Competitive  Allosteric Competitive  Allosteric Competitive  Allosteric Competitive 
chiral 0(±0) 1(±0)  0(±0) 1(±0)  0(±0) 1(±0)  0(±0) 1(±0) 
chiral/HA 0(±0) 0.049(±0.001)  0(±0) 0.04(±0.00)  0(±0) 0.04(±0)  0(±0) 0.043(±0.007) 
SlogP 3.3(±0.2) 1.9(±0.2)  3.58(±0.06) 2.1(±0.2)  3.70(±0.06) 2.2(±0.1)  3.69(±0.06) 2.1(±0.2) 
b_single/HA 1.18(±0.01) 1.52(±0.02)  1.17(±0.01) 1.50(±0.02)  1.17(±0.01) 1.53(±0.02)  1.18(±0.01) 1.53(±0.01) 
b_ar/b_count 0.29(±0.01) 0.21(±0.01)  0.309(±0.001) 0.222(±0.002)  0.309(±0.001) 0.214(±0.006)  0.309(±0.001) 0.214(±0.006) 
b_single 29(±1) 36(±2)  30(±1) 38(±1)  32(±0) 41(±1)  32(±1) 41(±1) 
b_ar/HA 0.52(±0.02) 0.43(±0.02)  0.545(±0.005) 0.44(±0.01)  0.545(±0.005) 0.429(±0.001)  0.548(±0.002) 0.429(±0.001) 
a_aro/HA 0.50(±0.02) 0.41(±0.02)  0.54(±0.01) 0.43(±0.01)  0.55(±0.02) 0.43(±0.01)  0.55(±0.01) 0.42(±0.01) 
b_1rotN/HA 0.17(±0.01) 0.20(±0.01)  0.172(±0.002) 0.194(±0.006)  0.172(±0.002) 0.20(±0.01)  0.172(±0.002) 0.211(±0.001) 
b_single/b_count 0.667(±0.003) 0.763(±0.007)  0.66(±0.01) 0.76(±0.01)  0.655(±0.005) 0.763(±0.003)  0.66(±0.01) 0.76(±0.01) 
logS  -4.7(±0.1) -4.2(±0.1)  -5.01(±0.07) -4.42(±0.05)  -5.26(±0.08) -4.61(±0.06)  -5.32(±0.06) -4.7(±0.1) 
a_acc/HA 0.107(±0.003) 0.097(±0.003)  0.107(±0.003) 0.091(±0.009)  0.107(±0.003) 0.095(±0.005)  0.107(±0.003) 0.097(±0.003) 
b_count/HA 1.80(±0.02) 1.97(±0.03)  1.80(±0.01) 1.97(±0.03)  1.81(±0.01) 2.00(±0.03)  1.81(±0.01) 1.98(±0.02) 
b_count 44(±1) 48(±1)  46(±1) 50(±1)  49(±1) 54(±1)  49(±0) 55(±1) 
a_nC/HA 0.74(±0.01) 0.76(±0.01)  0.74(±0.01) 0.77(±0.01)  0.75(±0.00) 0.767(±0.007)  0.75(±0.00) 0.756(±0.006) 
a_base 0(±0) 1(±1)  0(±0) 1(±0)  0(±0) 1(±0)  0(±0) 1(±0) 
a_base/HA 0(±0) 0.02(±0.02)  0(±0) 0.024(±0.006)  0(±0) 0.02(±0.01)  0(±0) 0.025(±0.005) 
a_acc 3(±1) 2(±0)  3(±0) 2(±0)  3(±0) 3(±0)  3(±0) 3(±0) 
a_don/HA 0.037(±0.003) 0.041(±0.001)  0.03(±0.01) 0.03(±0.01)  0.034(±0.004) 0.034(±0.006)  0.03(±0.01) 0.03(±0.01) 
a_aro 12(±0) 11(±1)  12(±0) 12(±0)  14(±1) 12(±0)  15(±1) 12(±0) 
b_ar 12(±0) 11(±1)  12(±0) 12(±0)  15(±1) 12(±0)  16(±1) 12(±0) 
a_nC 18(±0) 19(±1)  19(±0) 20(±1)  20(±0) 21(±0)  20(±0) 21(±0) 
b_rotN/HA 0.21(±0.01) 0.21(±0.01)  0.2(±0.0) 0.209(±0.009)  0.2(±0.0) 0.217(±0.007)  0.2(±0.0) 0.226(±0.006) 
b_1rotN/b_count 0.1(±0.0) 0.103(±0.007)  0.098(±0.002) 0.1(±0.0)  0.098(±0.002) 0.103(±0.003)  0.097(±0.003) 0.106(±0.004) 
b_1rotN 4(±0) 5(±0)  4(±1) 5(±0)  5(±0) 5(±0)  5(±0) 5(±0) 
a_acid 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
a_acid/HA 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
a_don 1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
a_heavy 24(±0) 24(±1)  26(±0) 26(±0)  27(±0) 27(±1)  27(±0) 28(±1) 
b_rotN 5(±0) 5(±0)  5(±0) 5(±0)  6(±1) 5(±1)  6(±1) 6(±1) 
FCharge 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
FCharge/HA 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
lip_druglike 1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
lip_violation 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
opr_leadlike 1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
opr_violation 0(±0) 0(±1)  0(±0) 0(±0)  0(±0) 1(±0)  0(±0) 1(±0) 
rings 3(±0) 3(±0)  3(±0) 3(±0)  3(±0) 3(±0)  3(±0) 3(±0) 
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Table 3-4 Medians (95%ci) of the 37 physicochemical properties for the full 2015 dataset. Numbers in bold are statistically significant differences between 
allosteric and competitive compounds. The list is ordered by largest differences. Red properties are not found in 2012 data. 
 Clustering level 60%/0.6 75%/0.75 90%/0.9 100%/1.0 
Descriptors Allosteric Competitive  Allosteric Competitive  Allosteric Competitive  Allosteric Competitive 
a_don/HA 0.036(±0.004) 0.048(±0.002)  0.034(±0.004) 0.043(±0.003)  0.032(±0.002) 0.042(±0.002)  0.031(±0.001) 0.042(±0.002) 
SlogP 3.20(±0.06) 2.67(±0.07)  3.40(±0.04) 2.88(±0.06)  3.535(±0.004) 2.946(±0.007)  3.56(±0.02) 2.90(±0.06) 
b_single 30(±1) 34(±1)  31(±1) 36(±1)  34(±0) 39(±1)  34(±1) 39(±0) 
b_single/HA 1.22(±0.01) 1.38(±0.02)  1.20(±0.01) 1.38(±0.01)  1.20(±0.01) 1.40(±0.01)  1.212(±0.002) 1.42(±0.01) 
b_ar/b_count 0.28(±0.01) 0.25(±0.01)  0.293(±0.003) 0.254(±0.006)  0.29(±0.01) 0.24(±0.01)  0.293(±0.003) 0.239(±0.001) 
b_count 44(±0) 48(±1)  47(±0) 50(±1)  50(±1) 53(±1)  51(±0) 54(±0) 
a_acc/HA 0.12(±0.00) 0.111(±0.001)  0.121(±0.001) 0.107(±0.003)  0.12(±0.00) 0.107(±0.003)  0.12(±0) 0.107(±0.003) 
b_1rotN/HA 0.167(±0.003) 0.179(±0.001)  0.167(±0.003) 0.179(±0.001)  0.172(±0.002) 0.188(±0.003)  0.174(±0.004) 0.189(±0.001) 
b_count/HA 1.8095(±0.0005) 1.92(±0.01)  1.8(±0.0) 1.926(±0.006)  1.806(±0.004) 1.933(±0.007)  1.81(±0.01) 1.94(±0.01) 
b_single/b_count 0.682(±0.002) 0.721(±0.001)  0.672(±0.002) 0.72(±0.00)  0.672(±0.002) 0.727(±0.003)  0.673(±0.003) 0.732(±0.002) 
a_aro/HA 0.5(±0.0) 0.47(±0.01)  0.522(±0.002) 0.48(±0.01)  0.522(±0.002) 0.462(±0.008)  0.522(±0.002) 0.458(±0.008) 
b_rotN/HA 0.192(±0.002) 0.200(±0.005)  0.1905(±0.0005) 0.2(±0.0)  0.2(±0.0) 0.2105(±0.0005)  0.2(±0) 0.214(±0.004) 
b_ar/HA 0.50(±0.01) 0.48(±0.01)  0.52(±0.01) 0.48(±0.02)  0.53(±0.01) 0.47(±0.01)  0.522(±0.002) 0.462(±0.002) 
a_nC/HA 0.7308(±0.0008) 0.75(±0.00)  0.731(±0.001) 0.75(±0.01)  0.7308(±0.0008) 0.75(±0.00)  0.7308(±0.0008) 0.75(±0.00) 
a_nC 18(±0) 19(±0)  19(±0) 20(±0)  20(±0) 21(±0)  20(±1) 21(±0) 
b_1rotN/b_count 0.093(±0.003) 0.097(±0.003)  0.094(±0.004) 0.096(±0.004)  0.098(±0.002) 0.1(±0.0)  0.098(±0.002) 0.1(±0) 
logS -4.50(±0.01) -4.63(±0.08)  -4.806(±0.002) -4.86(±0.05)  -5.16(±0.05) -5.12(±0.01)  -5.17(±0.06) -5.14(±0.07) 
b_1rotN 4(±0) 5(±1)  4(±0) 5(±0)  5(±0) 5(±0)  5(±0) 5(±0) 
a_acc 3(±0) 3(±0)  3(±0) 3(±0)  3(±0) 3(±0)  3(±0) 3(±0) 
a_acid 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
a_acid/HA 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
a_aro 12(±0) 12(±0)  12(±0) 12(±0)  15(±0) 12(±0)  15(±0) 12(±0) 
a_base 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
a_base/HA 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
a_don 1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
a_heavy 25(±1) 25(±0)  26(±0) 26(±0)  28(±0) 28(±0)  28(±0) 28(±0) 
b_ar 12(±0) 12(±0)  12(±0) 12(±0)  16(±0) 12(±0)  16(±0) 12(±0) 
b_rotN 5(±0) 5(±0)  5(±0) 5(±0)  5(±0) 6(±0)  6(±0) 6(±0) 
chiral 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 1(±0)  0(±0) 1(±0) 
chiral/HA 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0.026(±0.006)  0(±0) 0.028(±0.002) 
FCharge 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
FCharge/HA 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
lip_druglike 1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
lip_violation 0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0)  0(±0) 0(±0) 
opr_leadlike 1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
opr_violation 0(±0) 0(±0)  0(±0) 1(±0)  1(±0) 1(±0)  1(±0) 1(±0) 
rings 3(±0) 3(±0)  3(±0) 3(±0)  4(±0) 4(±1)  4(±0) 4(±0) 
97 
 
3.4.4.1 Allosteric ligands are more hydrophobic.  
Allosteric ligands have more positive SlogP than do competitive ligands (see Table 3-3, 
Table 3-4, and Figure 3-5). In keeping with the increased hydrophobicity, the types of 
atoms found in allosteric molecules are different compared to competitive compounds. 
Allosteric ligands have a lower number of hydrogen-bond acceptors per heavy atom. 
Allosteric ligands also have fewer hydroxyl groups (Table 3-5). Furthermore, competitive 
ligands may be more hydrophilic because they have more pyrrolidine, piperazine and 
piperidine rings (see Table 3-6). 
This is consistent with the study by Li et al.[246] where they found allosteric binding 
sites contain more hydrophobic surface area, hence would bind more hydrophobic 
ligands. Hydrophobicity is also used as an important characteristic for the prediction of 
allosteric sites by Huang et al.[247] and by Demberdash et al. [220]. It is also important 
in the prediction of ligand-protein interactions using models developed by Li et al.[248] 
The MWC model also states that protein-protein or subunit interfaces are frequent 
allosteric binding sites[204], and protein-protein interfaces have generally been shown 
to be more hydrophobic in nature[249]–[251]. A large portion of allosteric compounds 
were found to contain hydrophobic scaffolds by Wang et al., and that contributed to the 
overall hydrophobic nature of their allosteric set[224]. 
The structure properties of allosteric binding sites likely constrain the chemical 
characteristic of allosteric ligands. Studies for identifying allosteric binding sites show 
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that the solvent-accessible surface area (SASA)[220], the number of hydrogen 
bonds[220], interaction between residues, local hydrophobic density[246], [252], pocket 
size[220], [247], and correlated features are important for describing an allosteric 
binding site. Van Westen et al observed that allosteric compounds for GPCRs  tend to be 
more lipophilic, more rigid (higher sp2 C and lower sp3 C), and relatively smaller than 
non-allosteric ligands from ChEMBL data[230]. Wang et al. compared allosteric ligands 
from ASD with compounds from databases like DrugBank, MDDR, ACD, etc[224]. 
However, the compounds in these databases can have many mechanisms to bind target 
proteins, which are not necessarily binding at the active site.  Even so, they also showed 





Figure 3-5 The histograms of SlogP and the number of hydrogen-bond acceptors per 
heavy atom for the full dataset. The median (dashed line) is labeled on the graph with 





Table 3-5 Chemical analysis with Pipeline Pilot showed that these 10 functional groups 
have the greatest population differences between allosteric and competitive ligands of 
the full dataset.  The list is organized by the highest absolute difference between 
normalized frequencies. Bold indicates which set of ligands have more such functional 
groups. For brevity, only data clustered at the 60/0.6 level is shown. 
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Table 3-6 Analysis with Pipeline Pilot showed that these 10 rings have the greatest population differences 
between allosteric and competitive ligands in the full dataset.  The list is organized by the highest absolute 
difference between normalized frequencies. Bold indicates which set of ligands have more such rings. 
SlogP < 0 are noted in italics. For brevity, only data clustered at the 60/0.6 level is shown. 
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102 
 
3.4.4.2 Allosteric ligands are more aromatic and constrained.  
In keeping with those same previous studies, we too find that there are multiple 
descriptors that indicate the allosteric ligands are more rigid. For both the original and 
the full datasets, the distributions indicate that allosteric ligands have more aromatic 
atoms and fewer bonds per heavy atom (meaning fewer saturated bonds). There are 
also fewer rotatable single bonds. The distributions are shown in Figure 3-6. The relation 
between SlogP and aromaticity can be shown in pair-wise tests and 2D plots (Figure 
3-7). The population with ~3 rings in allosteric compounds have clearly higher SlogP, 
which is shown in both b_ar and a_aro. The increase in density of structures with three 
rings coincides with a shift in the SlogP, as the black circle in Figure 3-7 A and B shows 
that the density is shifted to the upper right as is appropriate for the higher populations 
in the allosteric ligands. The distribution of the number of aromatic atoms (not shown) 
shows that although allosteric and competitive ligands have the same median (12 
atoms, or ~2 ring systems); the allosteric ligands have a much larger peak around 18 





Figure 3-6 The histograms of the number of aromatic atoms corrected by size, the 
number of bonds per heavy atom, and the number of rotatable single bonds per heavy 
atom for the full dataset. The median (dashed line) is labeled on the graph with the 






Figure 3-7 For the full dataset clustered at the 60%/0.6 level, 2D density plots showing 
the distributions of each molecule’s SlogP and A) their number of aromatic bonds or B) 
their number of aromatic atoms. The black circle highlights the populations that 
contribute most significantly to the greater aromaticity and hydrophobicity of allosteric 
ligands over competitive ligands. White regions have no density, and the bins are colored 
from red (low population) to green (middle) to blue/purple (high populations). 
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The combination of the increase in aromatic atoms and the decrease in the number of 
rotatable single bonds in the allosteric ligands suggests that these molecules tend to be 
more rigid. This rigidity is somewhat surprising since allosteric binding sites must 
undergo a change in conformation upon ligand binding. However, a recent study by Li et 
al. suggested that the pocket flexibility (normalized B-factor) and pocket depth are not 
significantly different for allosteric binding sites.[246] 
The change of protein flexibility upon ligand binding has been indicated by Demerdash 
et al.[220]. That study used a Support Vector Machine (SVM) and indicated that the 
deformation energy and change in SASA of the protein residues are important features 
in predicting an allosteric hotspot. The SVM models indicated that allosteric hotspots 
would form dense networks within the protein. They did not look specifically at the 
residues in contact with allosteric ligands, and they make no comment on their 
flexibility[220]. Panjkovich and Daura also noted that a large change in B-factors can be 
used to indicate the location of allosteric binding sites[253]. The decrease in flexibility of 
allosteric compounds is consistent with two other studies on large datasets of allosteric 
compounds[224], [230]. In Wang et al.’s work, allosteric ligands have significantly less 
rotatable bond fraction than drug molecules from DrugBank (their criteria was p-value 
<0.01, two sample t-test). Van Westen et al. describes that allosteric ligands have a 
higher sp2 hybridized carbon fraction, lower sp3 hybridized carbon fraction, and higher 
aromatic bonds fraction[230] compared to non-allosteric compounds targeting 
transmembrane proteins. Taken together, it appears that relatively rigid ligands bind to 
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allosteric sites, inducing a change in flexibility of the protein as it adapts to the presence 
of the allosteric ligand.  
3.4.4.3 “Overlap” molecules are more like allosteric ligands than competitive ligands.   
As noted above, we are interested in the molecules with the highest similarity (Tc ≥ 0.9) 
between the allosteric and competitive sets.  Basically, do the sets overlap where 
allosteric ligands look like competitive ligands or vice versa?  The full dataset has 2631 
unique molecules that comprise its overlap set, and the same analysis of physical 
properties is given in Table 3-7.  Across all levels of clustering, the physicochemical 
properties of the overlap compounds are nearly identical to the allosteric set in Table 
3-4.  These overlap molecules should exhibit both allosteric and competitive 
mechanisms of action depending on different protein targets.  Compound libraries that 
represent this overlap space may be particularly fruitful for finding leads for protein 
targets where competitive inhibition is possible, but has proved difficult. It is possible 





Table 3-7 For the combined set of highly similar allosteric and competitive ligands (the 
2015 “overlap” set), the medians of the significant properties (see Table 3-4) show that 
the compounds are allosteric in nature. 
 Clustering level 60%/0.6 75%/0.75 90%/0.9 100%/1.0 
 Allo+Comp (Tc ≥ 0.9) Allo+Comp (Tc ≥ 0.9) Allo+Comp (Tc ≥ 0.9) Allo+Comp (Tc ≥ 0.9) 
a_don/HA 0.04(±0.00) 0.037(±0.003) 0.034(±0.004) 0.03(±0.01) 
SlogP 2.98(±0.08) 3.14(±0.06) 3.40(±0.1) 3.50(±0.1) 
b_single 31(±0) 31(±0) 32(±0) 32(±0) 
b_single/HA 1.23(±0.03) 1.20(±0.01) 1.19(±0.02) 1.20(±0.01) 
b_ar/b_count 0.29(±0.01) 0.30(±0.01) 0.30(±0.00) 0.30(±0.00) 
b_count 45(±0) 46(±1) 47(±0) 47(±0) 
a_acc/HA 0.11(±0.01) 0.10(±0.01) 0.103(±0.003) 0.1000(±0) 
b_1rotN/HA 0.16(±0.01) 0.15(±0.01) 0.15(±0.01) 0.15(±0.01) 
b_count/HA 1.83(±0.02) 1.82(±0.01) 1.82(±0.01) 1.83(±0.01) 
b_single/b_count 0.68(±0.01) 0.67(±0.01) 0.66(±0.01) 0.66(±0.01) 
a_aro/HA 0.50(±0.02) 0.53(±0.02) 0.53(±0.02) 0.55(±0.02) 
b_rotN/HA 0.17(±0.01) 0.167(±0.003) 0.167(±0.003) 0.167(±0.003) 
b_ar/HA 0.53(±0.02) 0.55(±0.02) 0.545(±0.005) 0.548(±0.002) 









This study aims to elucidate common features of allosteric ligands compared to 
competitive ligands in order to understand their unique properties. The datasets were 
carefully curated to ensure the correct designation of their known mechanisms. 
Verifying the assays assures that we are only comparing allosteric ligands to competitive 
ligands. Lastly, this study also provides a larger dataset than previous studies performed 
on allosteric ligands.   
The chemical properties of allosteric and competitive ligands were compared. We took 
great care in normalizing the data so that frequently studied proteins did not overly bias 
the outcomes. The results indicate that allosteric compounds tend to be more 
hydrophobic, aromatic, and rigid. This is supported by an increase in SlogP and aromatic 
atoms per heavy atom.  It is also supported by a decrease in chemical saturation and 
rotatable single bonds. The allosteric ligands also have an increased population of 
ligands with ~3 aromatic rings.  The rigid nature of these ligands, combined with other 
studies that have shown protein allosteric hotspots are more flexible, suggest that the 
protein may adapt its conformation to the more rigid ligand and inducing an allosteric 
conformational change.  Lastly, “overlap” compounds are most like allosteric 
compounds, which means compounds with dual activity are found when the 
competitive ligands look allosteric, rather than allosteric compounds that resemble 
competitive ligands.  
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Chapter 4. Exploring the Effect of Mendelian Disease and Neutral: 
nsSNPs in Protein Structure - a Large Scale Analysis 
4.1 Abstract 
This paper focuses on genetic variations which cause amino acid changes and their 
effect on protein structure and function. Single nucleotide polymorphisms (SNPs) are 
the simplest and most frequent DNA variation in humans. Non-synonymous missense 
SNPs (nsSNP) have direct impact on the coding region, causing substitution of protein 
residues different from wild type. Many disease-causing SNPs have structural or 
functional impact on the protein depending on the nature of the substitution and where 
it occurs. We have integrated the nsSNP dataset (UniProt) of nsSNPs, Binding MOAD, 
and other annotation databases (like UniProtKB) into a single MySQL database. The 
location of nsSNPs in protein cores, protein surfaces, and ligand-binding sites based on 
protein-ligand structures and solvent accessible surface area were annotated. The result 
shows that disease nsSNPs occur more frequently in a protein core or binding site, 
rather than the rest of the protein surface. Neutral nsSNPs did not show this trend. The 
disruption of the protein-ligand interaction can be explained by a range structural 
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effects including the destabilization due to increasing of side chain size, a decrease in 
flexibility, and the loss of an electrostatic salt bridge. 
4.2 Introduction 
Over 4000 human Mendelian disorders, which are heritable diseases caused by a single-
gene defect[254]. The most common type of single-gene defect in humans takes the 
form of a single nucleotide polymorphism (SNPs), which is the replacement of a single 
nucleotide that may have observable impact on the phenotype. Among SNPs, most of 
the disease-associated gene defects are non-synonymous SNPs (nsSNPs), which are 
located in coding regions and results in a residue change in the translated protein. 
Deciphering the link between genetic mutations and a patient’s phenotype is still a 
major challenge in understanding when and how the variants cause disease. One 
possible link is that the mutation affects the protein structure which in turn influences 
biological functions. The location of the amino acid change caused by an SNP on the 
protein’s structure may be related to detrimental biological consequences. The amino 
acid residues which are changed may be in the core of the protein, on the surface, or in 
the ligand binding site. Given the data on both SNPs and protein structures, several 
questions can be asked and addressed. Are disease-associated missense mutations 
more likely to occur at certain structure locations? Secondly, are missense mutations at 
certain locations more likely to be disease-associated? Lastly, what are the residue 
changes and corresponding consequences of these mutations?  
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A vast amount of genome data generated by new sequencing methods and 
international research efforts such as the 1000 Genome Project[255] and HapMap 
projects[256] allows discovery of disease susceptible mutations genome wide. These 
methods facilitate massively parallel sequencing in a short time and at low cost[257]. 
The common SNPs are identified by comparative genome analysis of large-scale 
sequencing on thousands of individuals [258], [259]. Identification of disease associated 
mutations is based on statistical analyses of patients’ and control group’s sequences. 
Disease or neutral mutations are selected and reviewed in databases such as the Online 
Database of Mendelian Inheritance in Man (OMIM) [260], dbSNP[261], and the Human 
Gene Mutation Database (HGMD)[262] based on the published peer-reviewed 
biomedical literature. The Universal Protein Resource (UniProt) database provides high 
quality annotations of single amino acid polymorphisms (SAPs) by mapping nsSNP onto 
protein sequences[263]. These SAPs are selected by manual curation of peer-reviewed 
literature using strict inclusion criteria. The annotations of SAPs are used to recognize 
protein sequence locations of disease/neutral mutations.  
Meanwhile, structural genomics projects promoted the identification of 3-dimensional 
structures of proteins in living organisms[264]. The structures are experimentally solved 
from X-ray crystallography. In order to identify residue locations on proteins, biologically 
relevant protein-ligand complexes are needed. Careful curation of the Protein Databank 
has been undertaken recently to identify high-quality protein-ligand structures which 
can be used to identify where in the protein structure the amino acid mutation caused 
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by an SNP occurs.  Binding MOAD is one of the largest databases, which contain high 
quality protein-ligand complexes from the PDB with ligand annotation (biologically 
valid/invalid). This database can be used to extract interacting binding residues protein-
ligand complexes. 
The impact of disease-linked nsSNPs on various functional sites on protein structures is 
discussed in previous studies[34], [127], [134], [265]. Wang and Moult performed the 
first study with 262 monogenetic disease mutations from 26 proteins and found that 5% 
of mutations involve ligand binding and 80% are more likely to destabilize proteins[127]. 
More recently Dingerdissen et al examined enzyme active sites and showed that nsSNPs 
occurring at those sites make up <1% of all currently known nsSNPs[265]. In their study 
both nsSNPs and catalytic sites are mapped to residues of protein sequences from 
UniProtKB/Swiss-Prot. The result shows that 196 nsSNPs are located at 128 protein 
active sites[265]. Sun et al performed a molecular docking study with 69 therapeutic 
drug targets and 232 drugs. Then, distances from mutations to drug binding sites are 
calculated. They found that the majority (92.4%) of the SNPs are far from the binding 
sites of the docked drugs (>12 Å)[34]. Gao et al found that disease-associated mutations 
are much more likely to be found in the functionally relevant ligand-binding pockets 
created by protein-protein association. Alessia et al’s study indicated that protein-
protein interaction sites are hot spots for nsSNPs[134] with homology modeling of 537 
protein-protein interactions. However, the existing literatures are either limited by a 
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small data set[34], [127], [134], [265] or haven’t fully discussed the general impact of 
nsSNPs on protein-ligand interaction[266]. 
Given high quality data on both SAPs and biologically valid protein-ligand complexes, the 
impact of SNPs on protein ligand interactions can be revealed, which can deepen the 
understanding of molecular mechanisms of disease associations. The result has direct 
implications for the predictions of disease association and provides possible indication 
for drug resistance in the early stages of drug discovery. 
This study focuses on nsSNPs locations in the protein core, on the surface, and in 
biological relevant protein-ligand binding sites. In previous studies, for each protein 
binding site, one protein-ligand structure is used to annotate binding residues. In this 
study, the union binding site is used to fully capture all essential binding sites by joining 
binding site residues from multiple structures of the same protein. Many previous large 
scale studies include cancer mutations[34], [134], [266]. However, the mechanism 
behind cancer involves multiple mutations impairing proteins in cell cycle control or 
DNA repair, which is different from Mendelian disease mechanisms. This work focuses 
on only Mendelian diseases. 
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4.3 Results & Discussion 
4.3.1 Summary of the data set 
A large-scale analysis is performed on 3669 disease associated mutations in 242 proteins 
with experimental structures, as well as 1726 neutral mutations in 580 proteins for 
comparison. The dataset is much larger than previous studies with only 26, 69, or 128 
proteins[34], [265], [267].The mutation and corresponding amino acid change is 
gathered/compiled based on the August, 2015 release of the UniProt (Universal Protein 
Resource) database. The structural locations are the union of 5,167 biologically valid 
protein-ligand complexes downloaded from Binding MOAD 2014. Three locations are 
analyzed, including ligand binding site, core, and surface (that is not ligand binding site). 
The locations were identified by mapping the structural information to UniProt 
canonical sequence. Cancer associated mutations are removed to keep those with 
Mendelian disorder association. Every mutation collected has at least one high quality 
protein-ligand structure (has a resolution of 2.5 Å or better). The location preference of 
these mutations are analyzed in the following section. 
4.3.2 Disease-Associated Missense Mutations Have High Preference for Ligand Binding 
Sites and the Protein Core 
The result shows that disease-associated mutations are more likely to have impact on 
locations that affect protein stability and functionality. Neutral mutations are less likely 
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to happen on locations associated with protein stability. Disease associated mutations 
are less likely to occur on the protein surface outside of the binding site than within the 
binding site or protein core. A little more than half (52%) of disease mutations are 
located on the surface (not binding site) of protein, however surface residues make up 
~70% of the protein (Table 4-1). Therefore, the number of disease mutations on the 
surface is in fact lower than one would expect at random given the large number of 
surface residues. In contrast, neutral mutations on the protein surface residues occur 
slightly more than expected at random, since 74% is larger than 70% which one would 
expect given the number of surface residues. The result is also supported by the odds 
ratio test. The odds-ratio (OR) of mutations on the surface to other locations in the 
protein is less than one (OR: 0.461, p-value < 0.05, Table 4-2) further indicating a 
preference for disease mutations for the binding site. It is not surprising that disease 
mutations would occur less preferentially on the surface of the protein as surface 




Table 4-1. The total number of nsSNPs, the total number of residues in each of the 
locations, the probability of observing nsSNPs at one location, and odds for observing a 
nsSNPs at one location. 







(total # 3708) 
#in core 1193 (0.33) 47477 (0.22) 0.025 0.026 
#in binding site 564 (0.15) 16237 (0.08) 0.035 0.036 
#surface not binding 
site 
1912 (0.52) 148049 (0.70) 0.013 0.013 
total # nsSNPs 3669 211763 0.017 0.018 
Neutral 
(total # 1716) 
#in core 240 (0.14) 47477 (0.22) 0.005 0.005 
#in binding site 205 (0.12) 16237 (0.08) 0.013 0.013 
#surface not binding 
site 
1271 (0.74) 148049 (0.70) 0.009 0.009 





Table 4-2. The odds ratio (OR), 95% confidence interval (CI), and propensity for 
comparing the number of nsSNPs at two locations. 
Mutation 
Types 
Locations odds ratio 95% CI (OR) propensity 
Disease core vs non-core 1.68 1.57 - 1.81 1.67 
non-surface vs surface 2.17 2.03 - 2.31 2.14 
binding site vs non-
binding site 
2.23 2.04 - 2.44 2.19 
binding site vs surface 
non-binding-site 
2.75 2.50 - 3.03 2.69 
binding site vs core 1.40 1.26 - 1.55 1.38 
Neutral core vs non-core 0.56 0.49 - 0.64 0.56 
non-surface vs surface 0.81 0.73 - 0.91 0.81 
binding site vs non-
binding site 
1.64 1.42 - 1.9 1.63 
binding site vs surface 
non-binding-site 
1.48 1.27 - 1.71 1.47 





Table 4-3. The estimation of mixed effect model. 
 Fixed Effects Random 
Effects 
Location Slope estimate ± Std. 
Error 




Binding sites 1.6145 ± 0.2785 5.025  -7.2091 ± 
0.4721 
10.02 
Surface  -1.5848 ± 0.1607 0.205  -5.8768 ± 
0.5032 
9.867 







Table 4-4. The odds ratio (OR), 95% confidence interval (CI), and propensity for 




Locations odds ratio 95% CI (OR) propensity 
Disease core vs non-core 1.52 1.39 - 1.67 1.51 
non-surface vs surface 2.00 1.86 - 2.15 1.97 
binding site vs non-
binding site 
2.23 2.04 - 2.44 2.19 
binding site vs surface 
non-binding-site 
2.40 2.19 - 2.63 2.35 
binding site vs core 1.41 1.25 - 1.59 1.40 
Neutral core vs non-core 0.55 0.45 - 0.68 0.55 
non-surface vs surface 1.00 0.89 - 1.14 1.00 
binding site vs non-
binding site 
1.64 1.42 - 1.9 1.63 
binding site vs surface 
non-binding-site 
1.57 1.35 - 1.81 1.56 





To further support the result in the previous paragraph, a mixed model approach is used 
to evaluate the effect of nsSNPs located at different proteins. The distribution of nsSNPs 
on proteins are highly heterogeneous since a large number of mutations are located in a 
low percentage of proteins; 40% mutations are located on 22 (3%) proteins. This issue 
will be discussed further in “Check for Robustness” section. Mixed effect model is 
adopted in order to take the heterogeneity among proteins into account. The results 
using the mixed-effect model further support that disease nsSNPs have a decreased 
preference to the protein surface (OR: 0.205, p-value < 0.05, Table 4-3). The standard 
deviation of random effects in the model reveals the degree of variation that exists in 
the population of proteins. The standard deviation (9.867 for the model with protein 
surface residues, Table 4-3) indicates that the distribution of nsSNPs on proteins is 
highly skewed, thus a check for robustness is necessary to analyze how the skewed 
distributions affect the results. 
Disease mutations are more likely to happen in ligand binding site (OR: 1.40, p-value < 
0.05, Table 4-2), when comparing protein core and ligand binding site. The binding site 
residues only make up 8% of all residues, however, 15% of disease mutations are 
located in the binding site. The mixed effect model also indicates the importance of 
binding site. The binding site (vs non-binding site, OR: 5.025, p-value < 0.05, Table 4-3) is 
favored by disease mutations than protein core (vs non-core, OR: 3.207, p-value < 0.05, 
Table 4-3) after taking account the heterogeneity among proteins. Both protein core 
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and ligand binding sites are hotspots for disease mutations, but these mutations display 
an increased preference for ligand binding sites. 
Neutral mutations seem to have a decreased preference to be located in the protein 
core, while have higher preference on non-core and surface non-binding site residues. 
Neutral mutations have lower probability to locate on protein core (OR: 2.52, p-value < 
0.05, Table 4-2). One explanation is that core residues likely play a more important role 
in maintaining stability than binding site residues[269]. This result are in agreement with 
previous studies[127], [134], [266], [269]. 
The preference of neutral mutations in the ligand binding site is ambiguous. For the full 
data set, ligand binding sites are preferred by neutral mutations when compared to non-
binding site residues (OR: 1.64, p-value < 0.05, Table 4-2). One of the reasons might be 
some proteins are more resistant to mutations in the ligand binding site, especially for 
proteins with a large number of binding site residues. The preference for binding sites 
becomes insignificant (binding site versus non-binding site OR: 0.810, p-value > 0.05), if 
proteins with more than 60 binding site residues are removed (22 out of 671). This 
result is also valid for cutoffs of 45, 50, 55, 60, 65, and 70 binding site residues 
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4.3.3 Robustness check for location preference of disease mutation 
4.3.3.1 Varying the cutoff for surface residue. 
The solvent accessible surface area (SASA) cutoff adopted to identify surface residues 
may affect the result, since different cutoffs will generate a different distribution of 
amino acids. The common standard is 5 Å2 SASA [270], [271]. A cutoff of 0.5 Å2 SASA 
allows for more residues to be identified as surface residues. For this cutoff, the number 
of surface residues increases from 148,049 to 21,447. The preference odds ratios of 0.5 
Å2 cutoff shown in Table 4-4 is still consistent with those under 5 Å2 cutoff.  
4.3.3.2 Varying the cutoff for binding site residue. 
Binding site residues are identified by a distance cutoff, which indicates the energy 
between atoms. 4 Å is widely accepted as the cutoff for two contacted carbon atoms. 
Because the Van der Waal’s radius of carbon is 1.7, the contact distance cutoff should 
be 1.7 * 2 plus a tolerance [272]. Difference tolerance value 0.1 Å, 0.6 Å, 1.1 Å are used 
to check the robustness. The preference result (in Table 4-5) is still valid given these 
cutoffs. The change of cutoff does not dramatically alter the number of binding site 
residues. The number of binding site residues decreases by 25.5% after reducing the 
cutoff to 3.5 Å and increases by 12.7% after extending the cutoff to 4.5 Å.  
Binding site residues with shorter contact distances to ligands may have a higher 
interaction energy and an increased chance for protein-ligand interactions. The 
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mutations of these residues are more likely to disrupt ligand interaction, thus influence 
the functionality. A steady increase in the preference of disease mutations in binding 
site residues is observed as the cutoff for interactions is decreased. The odds ratios of 
binding site residues to non-binding site residues would be 2.14 (cutoff: 4.5 Å), 2.23 
(cutoff: 4.0 Å), 2.41 (cutoff: 3.5 Å), and 2.64 (cutoff: 3.0 Å). 
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Table 4-5. The odds ratio (OR), 95% confidence interval (CI), and propensity for comparing the number of nsSNPs at two locations for 
different distance cutoff (3.5 Å, 4.0 Å, and 4.5 Å) of ligand binding residues. 
 3.5 Å 4.0 Å 4.5 Å 
Mutation Types Locations odds 
ratio 









Disease core vs non-core 1.71 1.59 - 1.83 1.69 1.68 1.57 - 1.81 1.67 1.68 1.57 - 1.8 1.66 
non-surface vs 
surface 
2.15 2.02 - 2.3 2.12 2.17 2.03 - 2.31 2.14 2.17 2.03 - 2.32 2.14 
binding site vs non-
binding site 
2.41 2.19 - 2.67 2.36 2.23 2.04 - 2.44 2.19 2.15 1.96 - 2.34 2.11 
binding site vs 
surface non-binding-
site 
2.96 2.67 - 3.28 2.89 2.75 2.50 - 3.03 2.69 2.65 2.42 - 2.91 2.60 
binding site vs core 1.52 1.36 - 1.69 1.50 1.40 1.26 - 1.55 1.38 1.34 1.21 - 1.48 1.33 
Neutral core vs non-core 0.57 0.5 - 0.65 0.57 0.56 0.49 - 0.64 0.56 0.56 0.49 - 0.65 0.56 
non-surface vs 
surface 
0.79 0.71 - 0.89 0.79 0.81 0.73 - 0.91 0.81 0.81 0.73 - 0.91 0.81 
binding site vs non-
binding site 
1.75 1.49 - 2.06 1.74 1.64 1.42 - 1.9 1.63 1.55 1.35 - 1.79 1.55 
binding site vs 
surface non-binding-
site 
1.58 1.34 - 1.86 1.58 1.48 1.27 - 1.71 1.47 1.40 1.21 - 1.61 1.39 
binding site vs core 2.66 2.18 - 3.24 2.64 2.52 2.09 - 3.04 2.50 2.38 1.98 - 2.86 2.36 
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4.3.3.3 The impact of proteins with more than 50 mutations 
The distribution of mutations on different proteins is highly skewed to the right; 68% of 
proteins have less than 5 mutations. More than 40% of mutations are concentrated at 
22 (3%) proteins. Each has more than 50 mutations. Analysis of the subset with 
overrepresented proteins removed is necessary to understand whether the 
characteristics only belonged to these proteins would dominate the result. 
The associated diseases of the 22 proteins with a large number of mutations are mostly 
related to metabolic processes, for example Phenylketonuria (160 mutations), Fabry 
disease (155 mutations), Gaucher disease (131 mutations), Factor VII deficiency (101 
mutations), pyruvate kinase deficiency of red cells (99 mutations), Leukodystrophy 
metachromatic (96 mutations), Hemophilia B (85 mutations). A metabolic disease can 
be associated with a large number of genetic mutations because mutations can affect 
metabolic processes in various ways, including influencing enzyme structure and/or 
function, impeding transport and processing, or disrupting binding of cofactor.  
The disease mutation preference for the protein core and ligand binding sites is robust 
after removing proteins with high number (>50) of mutations. No significant change on 
the odds ratio are observed when comparing protein core to non-core residues (OR: 
0.56 to OR: 0.55) and binding site to non-binding site residues (OR: 2.23 to OR: 2.40). 
Also, neutral mutations still have high preference for binding sites compared to non-
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binding site residues (OR:1.64, p-value < 0.05) and non-core residues compared to core 
residues (OR: 0.56, p-value < 0.05). 
4.3.3.4 Why removing somatic mutations is necessary? 
Many previous studies[134], [266] and prediction methods[131], [273] include somatic 
mutations (mostly treated as neutral mutations), neutral mutations, and mutations from 
Mendelian diseases (germ line mutations). However, the somatic mutations may have 
different characteristics than other neutral mutations. There are two kinds of somatic 
mutations. The mutations that promote cancer development by providing a selective 
growth advantage are termed driver mutations, and those that do not are termed 
passenger mutations [274]. Most somatic mutation are passenger mutations [275]. The 
passenger mutations are treated as neutral mutations in previous studies[134], [265], 
because they don’t explicitly cause any disease. 
Neutral mutations do not show significant preference to binding site after removing 
proteins with a large number (> 45) of binding site residues. The somatic mutations tend 
to favor binding site residues, even after removing overrepresented proteins. This result 
is valid under cutoffs with different numbers of binding site residues. The odds ratio of 
nsSNPs located at ligand binding site comparing to those located at other places is 
greater than 1.44 and is significant (p-value < 0.05) for all cutoffs. These odds ratios are 
1.55 (45 residues), 1.50 (50 residues), 1.46 (55 residues), 1.44 (60 residues), 1.56 (65 
residues), and 1.58 (70 residues). 
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The preference of somatic mutations to ligand binding sites are also supported by a 
much larger set. The larger data set is created by joining by proteins used in this study 
with COSMIC, covering 1,099 unique proteins, 1,905 PDB files, and 315,861 unique 
mutations. The ligand binding sites are the most preferred locations compared to non-
binding site residues located on the surface (OR: 1.39, p-value < 0.05) and the protein’s 
core (OR: 1.58, p-value < 0.05). This result is also validated by removing proteins with 
large number of mutations under cutoffs with different numbers of mutations on 
proteins (45, 50, 55, 60, 65, and 70). 
The inclusion of somatic mutations in the neutral mutations diminishes the preference 
of disease mutation to ligand binding sites. This is supported by the odds ratio of disease 
nsSNPs on ligand binding sites to those on other locations in the mixed effect model. 
The odds ratio increases significantly from 1.85 to 5.025 after removing somatic 
mutations. Thus, somatic mutations are more likely to locate at ligand binding site than 





Figure 4-1. Side chain frequencies on entire protein with mutation (top). Side chain 
frequencies on protein structure (middle). Amino acid preference for all residues for 
disease/neutral nsSNPs (down). Frequency is divided by total number of residues and 





4.3.4 Amino acid preference 
In general, the tendency for disease nsSNPs is to mutate amino acids which play critical 
roles in protein stability and functionality. Disease nsSNPs have high preference to 
mutate tryptophan, cysteine, glycine, tyrosine, arginine, and leucine (one mutated 
amino acid type versus other mutated amino acid types OR > 1, p-value < 0.0016). 
Tryptophan and cysteine only make up 3.5% of all residues and 4.7% of binding site 
residues (Figure 4-1), so, the confidence interval for the odds ratio for these two amino 
acids is large. The mutations of these tryptophan and cysteine are more likely to be 
disease-associated. These amino acids perform critical function for a protein, and they 
are different than looking at the binding site as these structural functions would not 
occur at binding sites. For example, tryptophan-tryptophan pairs in β-hairpin peptides 
were shown to contribute significantly to the stability[276]. Additionally, two cysteine 
residues can bond to form a disulfide bond, which plays an important role in protein 
folding and stability. The importance of cysteine is also supported by a very low 
preference for being a neutral mutation. Glycine, tyrosine, and leucine are also 
preferred by disease mutation, and they are among top four of the most frequent amino 
acid in binding sites (Figure 4-1). This is consistent with the above result that ligand 
binding site are hotspots for disease mutations. 
Disease nsSNPs are less likely to mutate some hydrophilic amino acids, including lysine, 
glutamic acid, threonine, and asparagine. Hydrophilic amino acids are mostly located on 
the protein surface. Lysine is generally located on the protein surface with 92% of lysine 
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residues on the surface. The same is true for glutamic acid (90% on protein surface) and 
asparagine (81% on protein surface). Other than hydrophilic amino acids, valine and 
isoleucine are also less likely to be mutated by disease SNP. Valine is hydrophobic and 
42% of them are located in protein core.  
 
 
Figure 4-2. Amino acid preference on protein surface for disease/neutral nsSNPs. The 
data are sorted by estimated value of odds ratio of disease associated nsSNP. 
 
In order to understand the impact of property changes of amid acids, the investigation 
of amino acid changes by disease and neutral mutation is conducted for each protein 
location (i.e. protein surface, binding site, and protein core). For the protein surface in 
Figure 4-2, disease mutations have significant preference to occur with amino acids 
which are more likely to participate in hydrogen bonds (cysteine, tyrosine, tryptophan, 
glycine, and arginine). Leucine and valine do not appear significant in the chi-square test 
because they are hydrophobic and thus under represented on the protein’s surface. 
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In the protein core, disease nsSNPs are more likely to happen with amino acids that are 
used as a critical component in forming structure (Figure 4-3). Glutamic acid, 
asparagine, leucine, and glycine are significantly higher for disease nsSNPs. Glutamic 
acid and asparagine have low composition (<3% of all core residues) in protein core, but 
the mutation of glutamic acid can dramatically change the charges of local structure 
environment[277] and asparagine is used near the beginning of alpha-helices, which are 
essential to form the secondary structure[278]. Leucine and glycine have high 
composition (>20% of all core residues) in protein core. Leucine is one of the most 
prominent residues in β-strands, which play an essential role in the secondary 
structure[279]. Only glycine is allowed at certain turns of tight bends due to steric 
restrictions because of the small side chain size. The mutation of glycine can be 
deleterious, which are also supported by the low preference for neutral nsSNPs (OR: 






Figure 4-3. Amino acid preference on protein core for disease/neutral nsSNPs. The data 
are sorted by estimated value of odds ratio of disease associated nsSNP. 
 
For protein-ligand binding sites, disease mutations occur with amino acids more likely to 
affect the hydrogen bonding and flexibility (Figure 4-4). Binding sites have high 
preference for mutations of proline, glycine and arginine. The mutation of arginine may 
abolish a salt bridge between binding site and ligand. The mutation of glycine may have 
impact on protein flexibility or block protein ligand binding by increasing the size of the 
side chain. In the meantime, neutral nsSNPs have less preference for glycine (OR: 0.48, 





Figure 4-4  Amino acid preference on protein binding site for disease/neutral nsSNPs. The 
x-axis labels are sorted by estimated value of odds ratio of disease associated mutations. 




4.4.1 Preference calculation 
The preference of one type of nsSNP to a protein structural location i over location j is 
quantified by propensity and odds ratio. The protein structural location could be protein 
core, protein-ligand binding site, or protein surface. Propensity is widely used in many 
structural related studies, such as secondary structure propensity in model 
proteins[280], amino acid propensities for secondary structures[281], and amino acid 
propensities for protein-ligand binding sites[282]. Odds ratio is corresponding to the 









Where ni is the total number of residues in region i, and Ni is the number of residue with 
nsSNP in region i. With probability, the odds for nsSNP in region i is 
















If the odds ratio or propensity < 1, then nsSNP has higher preference to region i 
compared to location j. With the distribution of log odds ratio, a two-tailed p-value can 
be calculated by R package epitools[283]. A p-value less than 0.05 is considered 
significant. 
With a similar idea, for amino acid preference, the probability of observing an nsSNP 







where a is amino acid type, i.e. Ala, Arg, Cys...etc, Nk is the total number of amino acid 
with nsSNP k, and nak is the number of amino acid a with nsSNP k in certain structural 
region. The type of mutation, k, can be either disease, polymorphism, and unclassified. 
For the probability of amino acid in the same region, the probability of observing the 





where N is the total number of amino acid in the region, and na is the number of amino 








4.4.2 Mixed effects model 
The odds ratio or propensity may be biased for proteins with many mutations. To 
understand whether the preference is a general trend for most proteins, building a 
mixed effect model is necessary given a skewed SNP distribution among proteins. The 
skewed SNP distribution in proteins has not been discussed in much detail in previous 
studies, partially because previous data sets do not have a large number of nsSNPs[127], 
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[134] or they deal with this problem by randomly selecting 50 nsSNPs for proteins with 
more than 50 nsSNPs[266]. 
A mixed effects model is a statistical model which is particularly effective in 
accommodating data that are collected in groups. In mixed effects model, the 
coefficient can vary with respect to grouping variables (e.g. protein identity in this 
study). The model contains two parts: fixed effects and random effects. Fixed-effects 
(𝑋𝛽) terms represent individual specific effects (e.g. location, type of amino acid) that 
may be correlated with the response (e.g. disease/neutral). Random-effects (𝑍𝑏) 
estimates the variability of different groups (e.g. protein identity).  
𝑦 = 𝑋𝛽 + 𝑍𝑏 +  𝜀  
The significance of fixed effects in the model is evaluated by F tests via Kenward-Roger 
approximation[284]. The model takes heterogeneous nsSNPs distribution among 
proteins into account when evaluate the significance of association between nsSNP 
location and consequence (disease/neutral). 
4.4.3 Datasets 
The annotation of location for binding site residues and nsSNPs requires both high 
quality binding site data and SNP data. Binding MOAD [141], [285] is one of the largest 
collection of high resolution (2.5 Å or better) protein-ligand structures available from 
Protein Data Bank (PDB)[286]. Every ligand in Binding MOAD has annotation (biologically 
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valid vs crystallographic additive invalids). The annotation is hand curated by reading the 
peer-reviewed crystallography paper, which makes it unique among databases of this 
kind. The curation step is accelerated by guidance from natural language processing and 
text mining. Binding MOAD is updated once a year. 
UniProt is currently the largest collection of protein sequences and annotations for 
protein nomenclature, function, and important residues. UniProt provides 
comprehensive high-quality annotation based on labor-intensive literature-based expert 
curation. In terms of single amino acid polymorphism, a collection of information on 
human genetic diseases and variants are provided and manually reviewed by experts. All 
relevant biological knowledge for amino acid changes are linked, organized and made 
readily available to users. The relevant information includes gene-phenotype 
relationship characterized in Online Mendelian Inheritance in Man (OMIM) and 
identified genetic variation collected in Single Nucleotide Polymorphism Database 
(dbSNP). The manual annotation is based on statistical genetics considerations, 
computational methods predicting deleteriousness, and experimental evidence of 
variant effect on protein properties. 
The nsSNP annotation in UniProt’s human-variant data set has three categories: disease, 
polymorphisms, and unclassified8. “Disease” mutations are mutations associated to a 
known disease with statistical significance from peer-reviewed literatures. The 
experimental information for these nsSNPs are retrieved from the Single Nucleotide 
Polymorphism Database9 (dbSNP) database. nsSNPs with a minor allele frequency (MAF) 
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less than 0.1 will be further investigated to assess the disease-causing effect by more 
literature search. Most disease variant in the data set have a corresponding entry in the 
Online Mendelian Inheritance in Man Database10 (OMIM). “Polymorphisms” are nsSNPs 
for which there is not any evidence of association with a disease. OMIM, however, does 
not have a complete list of all possible disease-causing variants, therefore some 
polymorphism nsSNPs may in fact be disease-associated. More than 90% polymorphism 
nsSNPs with corresponding dbSNP entries show that they are not rare, disease-causing 
mutations4. “Unclassified” nsSNPs are identified in a pathological sample, but lack 
statistical or experimental evidence to prove the disease association. Both unclassified 
and disease nsSNPs are rare variants with MAF less than 0.1. 
UniProt human variant data includes a few thousands of somatic mutations. To obtain a 
better portrait of the location and mutated amino acids of somatically acquired 
mutations, the Catalogue Of Somatic Mutations In Cancer (COSMIC) database is utilized. 
The COSMIC database was specifically designed for collecting somatic mutations, 
curated from peer-reviewed papers and large scale experimental screen from The 
Cancer Genome Atlas[287] (TCGA; http://cancergenome.nih.gov) and International 
Cancer Genome Consortium[288] (ICGC; https://dcc.icgc.org) projects. The mutation 
information includes annotations of disease types and patient details. To retrieve the 
corresponding information for each experiment and mutation, COSMIC provides 
graphical Web system to help users navigate gene-centrically or tissue-centrically. The 
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data set (COSMIC v70; Aug 2014) used in this study includes information from over 2.0 
million coding mutations on 1.02 million samples. 
4.4.4 Definition of surface residues, ligand binding residues, and core residues 
Protein surface residues are recognized by solvent accessible surface area, quantified by 
DSSP12. DSSP rolls a water sphere (radius 1.4 Å) around the van der Waals surface of the 
protein to find all possible positions that are in contact with protein heavy atoms. For 
the protein-ligand complex, all known ligands are removed before calculating solvent 
accessible surface area (SASA). The default probe size is used, and waters and 
HETATOMS are ignored. Two definition of surface residue (≥ 5 Å2 and ≥ 0.5 Å2 SASA) are 
tested. For one protein with multiple biounit complexes, the maximum SASA is assigned 
to the residue so the flexibility of protein is also taken into account. The ligand binding 
residues are identified by a distance of 4.0 Å or less to the nearest biological valid ligand. 
Other cutoffs (3.5 Å, 4.5 Å) are also tested. An amino acid is considered a cored residue 




Chapter 5. Conclusions and Future Directions 
5.1 Significant contributions of this thesis 
Structure-Based Drug Discovery techniques reduce the time and cost for drug research 
and development (R&D) by providing efficient computational tools for the identification 
of potential hit molecules as starting points for drug discovery. Development of high 
quality ligand libraries and identifying binding sites of feasible target are critical for the 
success of SBDD. This thesis focuses on improving SBDD in two aspects, the construction 
of the ligand libraries and analysis of the target binding sites used. The visual exploration 
of compounds and differentiable physicochemical properties of allosteric ligands are 
discussed in Chapter 2 and 3, and the effect of genetic mutations on the target binding 
sites is studied in Chapter 4. 
To investigate the depth and breadth of ligand datasets, ChemTreeMap was developed 
in Chapter 2. ChemTreeMap is a tool used to explore chemical space and analyze the 
relationships between chemical structures and their physicochemical properties and/or 
biological activities. ChemTreeMap organizes chemical compounds in a hierarchical tree 
structure with branch length proportional to the value of molecular similarity. Molecular 
similarity is quantified by ECFP, which is able to capture substructures and global 
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similarity, but other similarity techniques can be incorporated. The hierarchical 
relationship and branch length is computed by the Neighbor-Joining algorithm, which 
has been widely used in building phylogenetic trees for large diverse sequences. Given 
the tree structure representation of molecular similarity, associated properties are 
shown by leaf color, size, and outline, which can be changed interactively by users.  
In order to illustrate the advantage and capability of ChemTreeMap, two possible 
applications were presented in comparison with other tools. The first application 
assessed overlap between datasets. ChemTreeMap was used to delineate newly 
covered chemical space between ChEMBL and ChemBank, as well as that between 
ChEMBL and BindingDB. Each data set is very large in terms of the number of molecules 
(ChEMBL: ~1.3 million chemicals, ChemBank: ~1.15 million, BindingDB: ~0.5 million). 
ChemTreeMap highlights a large region of chemical space which is unique to ChemBank 
and to ChEMBL. Combining ChEMBL and ChemBank can increase the breath of chemical 
structures. For adding BindingDB to ChEMBL, ChemTreeMap shows that no large 
branches are dominated by BindingDB. This argumentation would increase the number 
of molecules with small modifications to those which already exist in ChEMBL, which 
adds depth of coverage. 
The second application is for mining structure-activity relationships (SAR) in two protein-
specific datasets. SAR of FXa and CDK2 are analyzed by ChemTreeMap and four other 
similar tools. With ChemTreeMap, the chemical core responsible for activity was 
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successfully identified. “Activity cliffs” and SAR hot spots can be identified visually with 
ChemTreeMap by change of node color.  
For the analysis of SAR, other tools (e.g. SPT, Data Warrior) do not present global 
similarity of all molecules well, are overcrowded in areas with similar molecules (CheS-
Mapper), or they lose the relationship between molecules sharing a similar scaffold 
(Scaffold Hunter). The comparison demonstrates ChemTreeMap’s ability to deal with 
rather complex chemical analysis of diverse molecules since the pattern is clear from the 
visual representation. 
To build a molecular library biased towards allosteric compounds, the physicochemical 
differences between allosteric and orthosteric competitive compounds were discussed 
in Chapter 3. We showed that allosteric ligands tend to be more hydrophobic, aromatic, 
and rigid as compared to orthosteric, competitive compounds. The data set used in this 
chapter has an increased coverage of known allosteric compounds by combining both 
ASD and ChEMBL than those of previous works that mined for generic properties of 
allosteric ligands. The work is innovative in dealing with overrepresented molecules, 
which have not been carefully handled in previous studies. Two-level clustering is 
conducted in this chapter to ensure redundancy is removed at both the protein and 
ligand level. Similar ligands are then grouped into clusters. The representative for each 
cluster is investigated choosing only the cluster center or weighting each molecule’s 
properties by the number of molecules in its cluster. This study focused on properties 
that can be experimentally measured and can be predictively modified. To demonstrate 
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the robustness of the result, several statistical metrics were used to find the most 
persistent patterns. The statistical metrics include the Wilcoxon test if the cluster is 
represented by the center molecule, weighted Wilcoxon test if the representative is 
chosen by weighting the molecular properties, and overlap in the 95% confidence 
interval from a bootstrap based on weighted distribution. The overrepresented chain 
assemblies and ring structures and their impact on physicochemical properties were 
discussed. The data showed that allosteric ligands tend to be more hydrophobic, 
aromatic, and rigid. The differentiable physicochemical properties can be used as 
guidance for future design of allosteric molecules. 
To select target binding sites that may be less likely to be influenced by disease-linked 
mutations, Chapter 4 focuses on the effect of Mendelian disease-associated genetic 
variations on protein structure and function. In previous work, the impact of disease-
linked nsSNPs on various functional sites are discussed, including protein-protein 
interaction sites, the binding sites of docked drugs, and ligand binding pockets created 
by protein-protein association. This work is innovative on studying nsSNPs associated 
with Mendelian disease and using a “union ligand binding site” to identify interactive 
residues. The union binding site is a collection of residues from all experimentally 
determined protein-ligand complexes. The result shows that while mutations to protein 
cores are common among disease associated nsSNPs, mutations are actually statistically 
enriched at the observed ligand binding site. After taking the heterogeneous 
distribution of nsSNPs on different proteins into account, the result of the mixed effect 
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model showed that the ligand binding site is most preferred by disease associated 
nsSNPs. The robustness of the result has been tested by changing cutoffs for surface 
residues and binding site residues. The result is also valid after removing 
overrepresented proteins with more than 50 nsSNPs. After investigating mutated amino 
acid at ligand binding sites, the data suggests that the interruption of ligand binding is 
caused by destabilization of protein structures, a decrease in binding site flexibility, 
and/or the loss of electrostatic salt bridges. 
To improve ligand libraries and identifying feasible target binding sites, this thesis first 
provides a new visualization tool based on a phylogenetic tree to investigate structure 
property relationships, then discovers several guiding physicochemical properties for 
construction of ligand libraries biased to allosteric mechanism, and discusses possible 
impact of disease mutation on protein structure focusing on binding sites. 
5.2  Future Directions 
The potential extension for the thesis is listed as follows. 
5.2.1 Incorporating networks of similarity across binding sites of protein targets 
The chemical visualization tool, ChemTreeMap, is capable of displaying a molecular set 
with diverse structures. A proper way to display drug-target information has not yet 
been developed. Effective drugs may act on multiple targets rather than a single target. 
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A new approach, polypharmacology, is emerging with increasing understanding of the 
role of protein-protein and protein-ligand interaction networks in the robustness of 
biological systems. Polypharmacology is the concept that one compound specifically 
binds to two or more targets. Polypharmacology has shown promise for tackling the two 
major challenge in drug development - efficacy and toxicity [289]–[291]. However, the 
design of molecules based on polypharmacology faces considerable challenges, 
including exploring target combinations, and optimizing ligand efficiency while 
maintaining drug-like properties [290]. Visualization of both ligand and protein binding 
site similarity could provide intuitive understanding for this multi-objective optimization 
problem. In the future, a natural progression for ChemTreeMap would extend the 
current visualization tool to support exploration of possible binding targets for a 
molecule.  
5.2.2 Shared common substructure and SAR alerts on the ancestor nodes 
The parent nodes in ChemTreeMap can be used to represent the common features of all 
descendent molecules. Future enhancements for ChemTreeMap can display the 
common substructures and SAR alerts at parent nodes (i.e. where the tree branches). 
The common substructures can be generated by a general graph matching 
algorithms[292]–[294]. SAR alerts include measures, such as Structure Activity 
Landscape Index (SALI) [295], SAR Index (SARI) [296], and Pan-Assay Interference 
Compounds (PAINS)[297]. Incorporating and visualizing these scores in ChemTreeMap 
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would help to identify shared chemical scaffolds and regions where large changes in 
compound potency with small or even moderate changes in chemical structure. 
5.2.3 Analyzing allosteric binding sites 
In Chapter 3, the differentiable physicochemical properties are found for allosteric 
compounds. The next logical step would be to analyze the allosteric binding sites to 
reveal characteristics of allosteric proteins and allow for coupling the structure of 
allosteric sites and the structure of their modulators. The number of allosteric binding 
sites with crystal structures has grown rapidly in recent years because of the significant 
expansion of allosteric drug discovery[26]. The allosteric binding sites analysis would 
provide insight into the foundation of allosteric interactions and matching features to 
allosteric compounds. The properties of both allosteric modulators and binding sites 
could shed light into how the allosteric regulation is triggered. This extension would 
improve the understanding of the essential features for allosteric site prediction and the 
design of proteins with allosteric mechanisms. 
5.2.4 The effects and mechanism of the mutations around the allosteric site 
A major finding from Chapter 4 of this thesis is that disease mutations are more likely to 
mutate interacting residues for ligand binding. However, the general impact of 
mutations on or around protein allosteric sites has not been fully explored. With the 
recent growth in both allosteric binding site annotation and disease associated 
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mutations, the properties of mutations specifically in the allosteric sites will provide new 
insight into physiological abnormalities and the progression of genetic diseases. It is 
possible that disease-associated mutations are less likely to occur in allosteric binding 
sites than orthosteric competitive sites.  
5.2.5 Comparing with other control sets to analyze disease associated mutations 
For the analysis in Chapter 4, one could argue that mutations collected by UniProt may 
not represent a good control set to differentiate disease associated mutations. Two 
kinds of control sets could be used: 1. all possible single mutations for a genome and 2. 
the largest observed set of neutral mutations. For the first control set, the analysis of 
amino acid composition would be performed to get the most preferable amino acids by 
comparing disease associated mutations to mutations generated by random DNA single 
mutation. For the second control set, a large set of variants in about 1,000 healthy 
individuals could provide a neutral background. This would be collected from the 1000 
Genomes Project[259]. The results on location and amino acid type preference can be 
validated on these two control data sets by checking whether the mixed effect model 
still show statistical significance on binding sites and certain amino acids. We expect 
these results are still valid, because the functional impact of disease mutations will be 






Appendix A. ChemTreeMap Supplementary Information 
S1. Neighbor-joining algorithm pseudo code 
T is an empty tree structure 
D is a N x N distance matrix for all pairwise distance 
  
WHILE dimension of D > 2 
FOR i = 1 to num_mols 
   FOR j = 1 to num_mols 
    u[i] = D[i][j] / (n - 2) 
   END FOR 
END FOR 
  
FOR i = 1 to num_mols 
   FOR j = 1 to num_mols 
    Q[i][j] = D[i][j] - u[i] - u[j] 
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   END FOR 
END FOR 
   
min_i, min_j = find the index i, j with minimum Q 
vi = 0.5 * D[min_i][min_j] + 0.5 * (u[min_i] - u[min_j]) 
vj = 0.5 * D[min_i][min_j] + 0.5 * (u[min_j] - u[min_i]) 
add node ij, min_i, min_j to tree T 
add edge ij -- min_i, ij --min_j to tree T with length vi, vj 
  
FOR k = 1 to num_mols 
   D[num_mols + 1][k] = (D[min_i][k] + D[min_j][k] - D[min_i][min_j]) / 2 
END FOR 
  






S2. Radius of display 
ChemTreeMap’s display is dynamic, meaning that the leafs are mobile. This allows users 
to reposition branches if they desire. The positions for the leafs is maintained by 
branches holding nodes together, nodes repelling one another (to avoid overlap), and a 
central force that keeps all nodes within a radius.  
The “radius of display” slider actually increases/decreases the force from the center of 
the tree out to the leaves. A short, tight radius pulls the nodes closer to the center of 
the tree. A larger, loose radius allows the nodes to move farther away from one 
another. The branching can be easier to see with a large radius. The ability to zoom in 
and out allows users to still focus on a local region or pan out to see the whole dataset, 
as we have done below. The dataset for CYP3A4 is shown below.
 




S3. SAR in p38α data 
Activity switches are a slight variation on activity cliffs; switches involve groups of active 
compounds with large differences in potency, yet the structures are similar analogs. 
They are important for the detection of structural features that effect activity. In 
ChemTreeMap, we can find examples from adjacent branches with large activity 
changes. This can be shown using p38α as an example.  
The ChemTreeMap for 5139 inhibitors of p38α is given in Figure A-2(a). Sub-tree III 
contains three branches: high activity, low activity, and mixed activity. Six representative 
molecules are A-F that differ in the positions marked by the red and blue circles. Very 
little change in activity can be seen for molecules A-D, where a piperazine group in A is 
replaced by a wide variety of functional groups, see red circles in Figure A-2(b). By 
contrast, the difference between D-F shows the location of one chlorine atom causes 
significantly different activity (substitutions off of aromatic rings often cause large 
changes in bioactivity and chemical reactivity). ChemTreeMap’s layout places more 
similar molecules closer together which better identifies the specific structural features 
that lead to significant drops in affinity.  
Figure A-3(a) shows that SPT produces roughly the same organization of molecules 
compared to ChemTreeMap. In SPT, branches for A-F are flipped to read as F-A, which is 
trivial. Molecules D-F are separated from A-C, and the activity cliff appears to occur 
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between D and F. In Figure A-3 (b), Data Warrior does not show a clean activity 
transition. In Figure A-3 (c), the added rings on A and B cause Scaffold Hunter to 
organize them into different scaffolds than C-F. Adding the piperazine in compound A 
does increase the potency significantly, which is shown by all the methods, Scaffold 






Figure A-2 (a) ChemTreeMap of p38α shows an activity cliff in sub-tree III. (b) Molecules 
of sub-tree III. Red circles show large chemical modifications in the center from 1-methyl-











S4. SAR for local subsets 
Our analysis in the paper is based on global exploration of each dataset, but the 
discussions have focused on local sub-trees. For complete comparisons, the diagrams 
below show how all four methods perform when given just the compounds of each sub-
tree. Occasionally, there are very slight reorganizations, which are expected. Overall, the 
results are the same. 
For ChemTreeMap’s NJ algorithm, identifying the two nodes with the smallest Qij 
involves information from the entire dataset (step 3 in section 2.2 of the manuscript): 
𝑸𝒊𝒋 = 𝑫𝒊𝒋 − 𝒖𝒊 − 𝒖𝒋. 
Dij is simply the Tc between molecule i and j, but ui is the average distance between 
node i and all other nodes in the set (same for j).  In essence, it finds pairs that are most 
like one another and least like the rest of the set. By removing some of compounds in 
the dataset, we change the values of ui. 
For SPT, N trees are still created for N molecules, where each is used as the root. The 
same Tc values exist, so the tiers should be the same, but the scores for the trees can 
change. Meaning the optimal tree for the local data may have slightly different positions 
for some molecules vs the global dataset. 
For brevity, the discussions below compare ChemTreeMap and SPT. Scaffold Hunter is 
robust and produces the same classifications as it does with the full datasets. No 
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improvement is seen for Data Warrior; it produces similar graphs with limited 
connectivity of logical groups of compounds. 
 
FXa sub-tree I (47 molecules):  
In ChemTreeMap, the connectivity is the same, except compounds D and G have flipped 
their order. In the full dataset, ChemTreeMap places E/F/G closest together, grouping all 
aliphatic esters together which is more appropriate. Compound H is in the middle of 
subtree I in the full dataset, and as expected, it is the compound closest to the 
“common ancestor” once the root from the full dataset is removed. Compound L is still 
in a branch that is well separated from the other compounds. 
SPT levels remove some of the structural relationships between molecules but maintain 
relationships for others (e.g. compounds E and F). Compounds H, J, and K only differ by 
the location of one chlorine atom, yet they appear unrelated in Figure.2-8(a). 
Compound L has a unique substitution, but it is placed on the same level as A, B, E, G, I, 
and K. The colors of the nodes are different for the weaker compounds because the 




ChemTreeMap sub-tree I in full dataset 47 molecule subset 
 








Figure A-4 Figure for FXa subtree. 
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CDK2 sub-tree II (8 molecules):  
In ChemTreeMap, the connectivity is the same, except that compound H is closer to A/B 
instead of F/G being closer. In this instance, grouping H closer to A/B is more 
appropriate, given the large chemical differences of F and G from the rest of the set. For 
the full dataset, H is closest the root that connects the rest of the data, and once that 
restriction is removed, a small reposition of H is possible. 
Though drawn slightly differently, the resulting diagram from SPT is the same as the full 











SPT 2nd tree for full dataset 












Figure A-5 Figure for CDK2 subtree. 
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p38α sub-tree III (34 molecules) 
For ChemTreeMap, the connectivity across A-E is the same (A is closest to B, C is next, 
then D, etc.).  
For SPT, using F – the molecule with no chlorine (blue circles) – as a root to connect 
compounds is a reasonable alternative for organizing the data. This allows branches to 
be based on the different locations of the added chlorine in compounds E and D. Color 










SPT 15th tree for full dataset 
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 * @ngdoc function 
 * @name frontendApp.controller:InfoCtrl 
 * @description 
 * # InfoCtrl 
 * Controller of the frontendApp 
 */ 
angular.module('frontendApp') 
  .controller('InfoCtrl', function ($scope, $modalInstance) { 
 
    $scope.dismiss = function () { 
        $modalInstance.dismiss('cancel'); 
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    <h4>Activate the force directed graph.</h4> 
    <p>* Please note the dynamic graph can be slow for a data set with more 
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        Deactivate 
    </label> 
    <label> 
        <input type="radio" ng-model="forceAct.value" ng-value="true"> 
        Activate 










<div class="tooltip-close dismiss" ng-click="close()"><i class="fa fa-
close"></i></div> 
<h2 class="tooltip-title">{{data.object.orig_id}}</h2> 
<a target="_blank" ng-repeat="ext in data.external" ng-href="{{ext.link + 
data.object[ext.name]}}"> {{ext.name}} </a> 
 
<!-- compound specific properties --> 
<accordion ng-show="data.compound" close-others="oneAtATime"> 
    <accordion-group is-open="structureIsOpen" ng-init="structureIsOpen = 
true"> 
        <accordion-heading> 
            <span>structure</span> 
            <i class="tooltip-accordion-toggle" ng-class="{'fa fa-chevron-
down': structureIsOpen, 'fa fa-chevron-right': !structureIsOpen}"></i> 
        </accordion-heading> 
        <img class="tooltip-structure" ng-
src="images/{{data.object.orig_id}}.svg"> 
    </accordion-group> 
 
    <accordion-group is-open="activityIsOpen" ng-init="activityIsOpen = 
false"> 
        <accordion-heading> 
            <span>activities</span> 
            <i class="tooltip-accordion-toggle" ng-class="{'fa fa-chevron-
down': activityIsOpen, 'fa fa-chevron-
right': !activityIsOpen}"></i></accordion-heading> 
        <table class="tooltip-table"> 
            <tr ng-repeat="(activity, value) in data.object.activities"> 
                <td class="data-key">{{activity}}</td> 
                <td class="data-value">{{value | number:4}}</td> 
            </tr> 
        </table> 
    </accordion-group> 
 
    <accordion-group ng-show="true" is-open="propertiesIsOpen" ng-
init="propertiesIsOpen = false"> 
        <accordion-heading> 
            <span>properties</span> 
            <i class="tooltip-accordion-toggle" ng-class="{'fa fa-chevron-
down': propertiesIsOpen, 'fa fa-chevron-right': !propertiesIsOpen}"></i> 
        </accordion-heading> 
        <table class="tooltip-table"> 
           <tr ng-repeat="(property, value) in data.object.properties"> 
                <td class="data-key">{{property}}</td> 
                <td ng-show="angular.isNumber(value)" class="data-
value">{{value | number:4}}</td> 
                <td ng-hide="angular.isNumber(value)" class="data-
value">{{value}}</td> 
            </tr> 
        </table> 






<tree-slider    min="gravitySlider.min" 
                max="gravitySlider.max" 
                value="gravitySlider.value" 
                left-name="gravitySlider.leftName" 
                name = "gravitySlider.name" 
                id = "gravitySlider.id" 
                right-name="gravitySlider.rightName"></tree-slider> 
 
<tooltips       class="tooltip-detail" 
                visibility="tooltip.visibility" 
                data="tooltip.data" 
                click="select"></tooltips> 
 
<chem-tree      data="data" 
                data-selected="model.selected" 
                force-act="settings.forceAct" 
                tree-type="current.treeType" 
                circle-size-type="current.circleSizeType" 
                circle-border-type="current.circleBorderType" 
                activity-type="current.activityType" 
                gravity-value="gravitySlider.value" 








    position: absolute; 
    top: 45px; 
    width: 100%; 




    opacity: 1; 
    transition: fill 0.2s ease-in-out; 
    -webkit-transition: fill 0.2s ease-in-out; 
    -moz-transition: fill 0.2s ease-in-out; 
    -o-transition: fill 0.2s ease-in-out; 




    stroke: #999999; 




    stroke: #ca0a00; 




    display: none; 
    visibility: none; 




    stroke-opacity: 0.6; 
    stroke: #D3D3D3; 
    stroke-width: 5px; 
    transition: stroke-opacity 0.2s ease-in-out; 
    -webkit-transition: stroke-opacity 0.2s ease-in-out; 
    -moz-transition: stroke-opacity 0.2s ease-in-out; 
    -o-transition: stroke-opacity 0.2s ease-in-out; 







.colorbarA .axis text { 
    font-family: sans-serif; 
    font-size: 11px; 
} 
 
.colorbarB .axis text { 
    font-family: sans-serif; 
    font-size: 11px; 
} 
 
.colorbarA .axis line{ 
    fill: none; 
    /* 
    stroke: black; 
    */ 
    shape-rendering: crispEdges; 
} 
 
.colorbarA .axis .domain{ 
    fill: none; 
    stroke: black; 
    shape-rendering: crispEdges; 
} 
 
.colorbarB .axis line{ 
    fill: none; 
    /* 
    stroke: black; 
    */ 
    shape-rendering: crispEdges; 
} 
 
.colorbarB .axis .domain{ 
    fill: none; 
    stroke: black; 












  font-style: italic; 
  font-size: 18px; 
  background: #f9f9f9; 
  border-left: 10px solid #ccc; 
  margin: 1.5em 10px; 
  padding: 0.5em 10px; 












html, body, div, span, button, applet, object, iframe, 
h1, h2, h3, h4, h5, h6, p, blockquote, pre, 
a, abbr, acronym, address, big, cite, code, 
del, dfn, em, img, ins, kbd, q, s, samp, 
small, strike, strong, sub, sup, tt, var, 
b, u, i, center, 
dl, dt, dd, ol, ul, li, 
fieldset, form, label, legend, 
table, caption, tbody, tfoot, thead, tr, th, td, 
article, aside, canvas, details, embed,  
figure, figcaption, footer, header, hgroup,  
menu, nav, output, ruby, section, summary, 
time, mark, audio, video { 




.top-bar .name h1 { 
  font-size: 24px; 
} 
 
.top-bar-section ul li > a { 




    content:''; 
    float: left; 
    height: 100%; 
} 
#wrapper { 









    padding: 5px 0 5px 0; 
} 
 
.has-form ul li { 
  float: none; 
  color: black; 
  background: none; 
} 
 
/* nav bar */ 
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.top-bar, .top-bar-section li:not(.has-form) a:not(.button), .top-bar-
section .has-form, .top-bar-section .dropdown li:not(.has-
form):not(.active) > a:not(.button) { 
  background: #444; 
  } 
 
.top-bar-section .dropdown li:not(.has-form) a:not(.button):hover { 
  background: #363636; 
} 
 
.top-bar-section .dropdown li.active:not(.has-form) a:not(.button) { 
  background: #008CBA; 
} 
 
.top-bar-section .dropdown li.active:not(.has-form) a:not(.button):hover { 





  opacity: 0.75; 
  font-weight: lighter; 
  padding: .85em 0 0.5em 0; 
  line-height: 0.8125em; 




  position: absolute; 
  z-index: 5; 
  opacity: 0.6; 








  line-height: 1.0em; 
  padding-bottom: 0.75em; 
} 
 
/* typeahead list */ 
 
.has-form li:not(.has-form) a:not(.button), .has-form .dropdown { 
  color: black; 




  position:absolute; 
  left: 55px; 
  bottom: 0.75em; 
  line-height: 0.8123em; 
  font-weight: lighter; 
  font-size: 0.8123em; 






  position: absolute; 
  line-height: 1.0em; 
  font-size: 1.0em; 
  left: 55px; 









  width: 12em; 
} 
 




.has-form li.active:not(.has-form) a:not(.button), .has-form li:not(.has-
form):hover a:not(.button):hover, .has-form .dropdown { 
  color: white; 










    z-index: 100; 
} 
 
/* settings modal */ 
 
table.color-settings tbody tr { 




    opacity: 0.5; 
    transition: opacity 0.25s; 
    -webkit-transition: opacity 0.25s; 
    -moz-transition: opacity 0.25s; 










  position: absolute; 
  z-index:2; 
  margin-left: 5px; 
  margin-top: 15px; 




  width: 12em; 








@media only screen and (max-width: 40.063em) {  
 
    .magnifying-glass { 
 
      margin-top: 6px; 
 
    } 
 
    input[type="text"].dream-search { 
      width: 100%; 
 
    } 
 
    input[type="text"].dream-search:focus { 
      width: 100%; 
 








  opacity: 0; 
  -webkit-transition: opacity .15s linear; 
          transition: opacity .15s linear; 
} 
.fade.in { 




  -webkit-transition: -webkit-transform .3s ease-out; 
     -moz-transition:    -moz-transform .3s ease-out; 
       -o-transition:      -o-transform .3s ease-out; 
          transition:         transform .3s ease-out; 
  -webkit-transform: translate(0, -25%); 
      -ms-transform: translate(0, -25%); 





  -webkit-transform: translate(0, 0); 
      -ms-transform: translate(0, 0); 




  filter: alpha(opacity=0); 
  opacity: 0; 
} 
.reveal-modal-bg.in { 
  filter: alpha(opacity=50); 
  opacity: .5; 
} 
 
@media only screen and (min-width: 40.063em) and (max-width: 66em) {  
 
  .top-bar-section .has-dropdown > a { 
    padding-right: 15px !important;  
  } 
  .top-bar-section .has-dropdown > a::after { 
    display: none; 
  } 
} 
 
@media only screen and (min-width: 40.063em) and (max-width: 61em) { 
  .icon-label { 
    display: none; 
  } 
} 
 
@media only screen and (min-width: 40.063em) and (max-width: 56em) { 
  input[type="text"].dream-search { 
    width: 7em; 
  } 
} 
 
@media only screen and (min-width: 40.063em) and (max-width: 52em) { 
  .top-bar .name h1 a { 
    padding: 0 0 0 0; 
  } 
} 
 
@media only screen and (min-width: 40.063em) and (max-width: 50em) { 
  .top-bar .name { 
    display: none; 




.top-bar .toggle-topbar.menu-icon { 
  top: 22px; 
} 
 
.top-bar .toggle-topbar a { 
  -webkit-touch-callout: none; 
  -webkit-user-select: none; 
  -khtml-user-select: none; 
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  -moz-user-select: none; 
  -ms-user-select: none; 
  user-select: none; 
} 
 
.top-bar.expanded .toggle-topbar a { 
  color: #FFF; 
} 
.top-bar .name h1 a { 
  width: 100%; 
} 
nav.top-bar.expanded { 




  text-align: center; 
  padding-top: 60px; 
  width: 50%; 
  margin: auto; 
} 
 
@media only screen and (max-width: 600px) { 
  .main-section { 
    width: 300px; 
  } 
} 
 
@media only screen and (max-width: 40.063em) { 
  .main-section { 
    padding-top: 20px; 
  } 
} 
 
.main-section ul { 
  border-radius: 10px; 
  list-style-type: none; 
  margin: 20px 0 20px 0; 
  padding: 0; 
  background: #EEE; 
} 
 
.main-section li:first-child { 
  border-top-left-radius: 10px; 
  border-top-right-radius: 10px;  
} 
 
.main-section li:last-child { 
  border: none; 
  border-bottom-left-radius: 10px; 
  border-bottom-right-radius: 10px; 
} 
  
.main-section li { 
 
  cursor: default; 
  -webkit-user-select: none; /* Chrome/Safari */         
  -moz-user-select: none; /* Firefox */ 
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  -ms-user-select: none; /* IE10+ */ 
 
  /* Rules below not implemented in browsers yet */ 
  -o-user-select: none; 
  user-select: none; 
  text-decoration: none; 
  color: #000; 
  display: block; 
  text-align: center; 
  font: 200 20px/1.5 Helvetica, Verdana, sans-serif; 
  border-bottom: 1px solid #CCC; 
 
  -webkit-transition: font-size 0.3s ease, background-color 0.3s ease; 
  -moz-transition: font-size 0.3s ease, background-color 0.3s ease; 
  -o-transition: font-size 0.3s ease, background-color 0.3s ease; 
  -ms-transition: font-size 0.3s ease, background-color 0.3s ease; 
  transition: font-size 0.3s ease, background-color 0.3s ease; 
} 
 
.main-section li a { 
  color: black; 
  display:block; 
} 
 
.main-section li:hover { 
  background: #F6F6F6; 
} 
 
.main-section li.current { 









    display: none; 
    max-height: calc(100% - 110px); 
    overflow: auto; 
    position: absolute; 
    opacity: 0.9; 
    background: white; 
    user-select:none; 
    top: 80px; 
    right: 20px; 
    width: 280px; 
    z-index: 10; 
    -webkit-box-shadow: rgba(0, 0, 0, 0.188235) 0px 10px 30px 0px; 
    -webkit-font-smoothing: antialiased; 
    border-bottom-left-radius: 2px; 
    border-bottom-right-radius: 2px; 
    border-top-left-radius: 2px; 
    border-top-right-radius: 2px; 
    box-shadow: rgba(0, 0, 0, 0.188235) 0px 10px 30px 0px; 





    opacity: 0.4; 
    float:right; 
    vertical-align: middle; 




    padding: 0.25em 0.5em 0.0em 0.5em; 
    font-size: 20pt; 




    margin: 0 5% 0 5%; 
    width: 90%; 
    border: none; 
    border-spacing: 0; 
} 
 
.tooltip-table tr:nth-child(even) { 
    background-color: white; 
} 
 
.synergy-table tr td { 
    cursor: pointer; 
    color: #666666; 
    max-width: 120px; 
    transition: color 0.25s; 
    -webkit-transition: color 0.25s; 
    -moz-transition: color 0.25s; 
    -o-transition: color 0.25s; 
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    transition: background-color 0.1s; 
    -webkit-transition: background-color 0.1s; 
    -moz-transition: background-color 0.1s; 




    padding: 0.25em; 
} 
 
.accordion dd > .content { 
    padding: 0.4em; 
} 
 
.synergy-table tr:hover td { 
    color: #111111; 
    background-color: #F9F9F9; 
} 
 
.tooltip-table td.data-key { 
    text-align: left; 
    color: #333333; 
    font-weight: bold;  




.tooltip-table td.data-value { 
    text-align: right; 




.accordion dd a { 
    padding: 0.5em 1em 0.5em 1em; 
    font-weight: lighter; 
} 
 
.accordion dd div.content { 




    margin: -5px auto -5px auto; 
    display: block; 
    width: 10em; 








    color: #888888; 
    opacity: 0.6; 
    cursor: pointer; 
    display: inline-block; 
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    width: 120px; 
    transition: opacity 0.25s; 
    -webkit-transition: opacity 0.25s; 
    -moz-transition: opacity 0.25s; 




    color: #111111; 




    display: block; 
    margin-left: auto; 
    margin-right: auto; 
    width: 6em; 




    font-size: 14pt; 
    position: absolute; 
    top: 0.4em; 
    right: 0.8em; 








    position: relative; 
    z-index: 1; 
    width: 150px; 
    height: 17px; 
    top: 0px; 
    left: 20px; 
    opacity: 0.8; 
} 
 
.ui-slider .ui-slider-handle {  




    background: white; 
} 
 
.slider .section { 
    display: inline-block; 
    position: absolute; 
    height: 100%; 
    font-size: 10px; 
} 
 
.slider .left { 
    border-bottom-left-radius: 3px;  
    border-top-left-radius: 3px; 
    padding-left: 2.5%; 
    text-align: left; 
    float:left; 
} 
 
.slider .right { 
    border-bottom-right-radius: 3px;  
    border-top-right-radius: 3px; 
    padding-right: 2.5%; 
    text-align: right; 




    opacity: 0.0; 
    cursor: default; 
 
    user-select: none; 
    -o-user-select: none; 
    -webkit-user-select: none; /* Chrome/Safari */         
    -moz-user-select: none; /* Firefox */ 
    -ms-user-select: none; /* IE10+ */ 
 
    transition: all 0.2s ease-in-out; 
    -webkit-transition: all 0.2s ease-in-out; 
    -moz-transition: all 0.2s ease-in-out; 
    -o-transition: all 0.2s ease-in-out; 





.slider .section:hover .sm-label { 






    position: absolute; 
    left: 0px; 
    top: 17px; 
    width: 280px; 
    height: 20px; 
    margin: 0 auto; 
    margin-top: -1px; 
    opacity: 0.3; 
} 
 
svg.axis line { 
  stroke: #000; 
} 
 
svg.axis path { 
  display: none; 
} 
 
svg.axis .tick { 










 * @ngdoc overview 
 * @name frontendApp 
 * @description 
 * # frontendApp 
 * 




  .module('frontendApp', [ 
    'oitozero.ngSweetAlert', 
    'angular.filter', 
    'colorpicker.module', 
    'picardy.fontawesome', 
    'mm.foundation', 
    'angulartics', 
    'angulartics.google.analytics', 
    'ngAnimate', 
    'ngCookies', 
    'ngResource', 
    'ngRoute', 
    'ngSanitize', 
    'ngTouch' 
  ]) 
  .config(function ($routeProvider) { 
    $routeProvider 
      .when('/:dataset', { 
          templateUrl: 'views/tree.html', 
          controller: 'TreeController' 
      }) 
      .otherwise({ 
        redirectTo: '/aff' 
      }); 










 * @ngdoc overview 
 * @name frontendApp 
 * @description 
 * # frontendApp 
 * 




  .module('frontendApp', [ 
    'oitozero.ngSweetAlert', 
    'angular.filter', 
    'colorpicker.module', 
    'picardy.fontawesome', 
    'mm.foundation', 
    'angulartics', 
    'angulartics.google.analytics', 
    'ngAnimate', 
    'ngCookies', 
    'ngResource', 
    'ngRoute', 
    'ngSanitize', 
    'ngTouch' 
  ]) 
  .config(function ($routeProvider) { 
    $routeProvider 
      .when('/:dataset', { 
          templateUrl: 'views/tree.html', 
          controller: 'TreeController' 
      }) 
      .otherwise({ 
        redirectTo: '/aff' 
      }); 













 * @ngdoc function 
 * @name frontendApp.controller:NavController 
 * @description 
 * # NavController 
 * Controller of the frontendApp 
 */ 
angular.module('frontendApp') 
  .controller('NavController', function ($scope, $modal, dataService, 
SweetAlert) { 
 
    $scope.dataService = dataService; 
 
    $scope.currentSearch = ''; 
 
 
    $scope.getInfo = function(e, infoObject) { 
      e.stopPropagation(); 
      //console.log(dataService.metadata); 
      SweetAlert.swal({ 
        title: infoObject, 
        html: dataService.metadata[infoObject], 
        allowOutsideClick: true 
      }); 
    }; 
 
    $scope.select = function(a) { 
      dataService.model.selected = a; 
      console.log(dataService.model.selected); 
    }; 
 
    //open the settings modal 
    $scope.openSettings = function () { 
 
      $modal.open({ 
          templateUrl: 'views/settings.html', 
          controller: 'SettingsCtrl' 
        } 
      ); 
    }; 
 
    //open the info modal 
    $scope.openInfo = function () { 
 
      $modal.open({ 
          templateUrl: 'views/info.html', 
          controller: 'InfoCtrl' 
        } 
      ); 
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    }; 









 * @ngdoc function 
 * @name frontendApp.controller:SettingsCtrl 
 * @description 
 * # SettingsCtrl 
 * Controller of the frontendApp 




  .controller('SettingsCtrl', function ($scope, $modalInstance, settings) { 
 
 
    //dataService.current.forceAct = {value: false}; 
    $scope.forceAct = settings.forceAct; 
 
    $scope.reset = function () { 
      $scope.forceAct.value = settings.defaultForce.value; 
    }; 
 
    $scope.dismiss = function () { 
      $modalInstance.dismiss('cancel'); 
    }; 









 * @ngdoc function 
 * @name frontendApp.controller:TreeController 
 * @description 
 * # TreeController 
 * Controller of the frontendApp 
 */ 
angular.module('frontendApp') 
  .controller('TreeController', function ($scope, $routeParams, 
dataService, settings) { 
 
    //locate database from the route 
    $scope.datasetName = $routeParams.dataset; 
 
    //selected information is currently nothing 
    $scope.model = dataService.model; 
 
    $scope.current = dataService.current; 
 
    $scope.flatten = dataService.flatten; 
 
    $scope.tooltip = {visibility: false}; 
 
    $scope.settings = settings; 
 
    $scope.$watch('model.selected', function(selected) { 
 
      if (selected === null) { 
        $scope.tooltip.visibility = false; 
      } else { 
        //set up the tooltip for the specific selected item 
        $scope.tooltip.visibility = true; 
        $scope.tooltip.data = { 
          compound: true, 
          object: selected, 
          external: dataService.data.metadata.external 
        }; 
      } 
    }); 
 
    $scope.$watch('tooltip.visibility', function(newVis) { 
      if ( newVis === false ) { 
        $scope.model.selected = null; 
      } 
    }); 
 
    $scope.select = function(d) { 
      $scope.model.selected = d; 




    $scope.gravitySlider      = {min: 0, max: 0.2, value:0.1, id: 





    $scope.linkStrengthSlider = {min: 0, max: 10, value: 1, id: 
'linkstrength', name: 'Compactness', leftName: 'Looser', rightName: 
'Tight'}; 
 
    dataService.loadExample($routeParams.dataset, function() { 
        $scope.data = dataService.data; 
/*        // i deleted all slider parameters, but I need to add color bar 
parameters here. 
        $scope.$watch('dataService.current.circleBorderType', function() { 
            var extent = d3.extent($scope.data.nodes, function(d) { return 
d.strock; }); 
            $scope.borderColorbar.min = extent[0]; 
            $scope.borderColorbar.max = extent[1]; 
        });*/ 
 












 * @ngdoc directive 
 * @name frontendApp.directive:chem-tree 
 * @description 




  var orient = 'right', 
    lineWidth = 40, 
    size_ = 300, 
    tickFormat = d3.format('3e'), 
    color = d3.scale.linear().domain([0, 0.5, 1]).range(['blue', 'green', 
'red']), //v -> color 
    line = d3.svg.line().interpolate('basis'), 
    precision = 8, 
    points_, 
    tickSize_; 
 
  function component(selection){ 
    selection.each(function(){ 
      var container = d3.select(this), 
        tickSize = tickSize_ || lineWidth, 
        n, 
        points = points_ || (((orient === 'left') || (orient === 
'right'))?[[0,size_],[0,0]]:[[size_,0],[0,0]]), 
        quads = quad(sample(line(points),precision)), 
        size = (points)?n:size_, 
        aScale = 
color.copy().interpolate(d3.interpolate).domain(color.domain()).range([size
,0]), //v -> px 
        colorExtent = color.domain(), 
        normScale = 
color.copy().domain(color.domain().map(function(d){ return (d - 
colorExtent[0])/ (colorExtent[1] - colorExtent[0]);})), 
 
      //Save values for transitions 
        oldLineWidth = this.__lineWidth__ || lineWidth, 
        oldQuads = this.__quads__ || quads; 
      this.__quads__ = quads; 
      this.__lineWidth__ = lineWidth; 
 
      //Enters 
      var bar = container.selectAll('path.c').data(d3.range(quads.length), 
function(d){return d;}), 
        bEnter = bar.enter().insert('path','g.axis').classed('c',true), 
        bExit = d3.transition(bar.exit()).remove(), 
        bUpdate = d3.transition(bar), 
        bTransform = function(selection,f,lw){ 
          selection.style('fill', function(d) { return 
normScale(f(d).t); }) 
            .style('stroke', function(d) { return normScale(f(d).t); }) 
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            .attr('d', function(d) { var p = f(d); return lineJoin(p[0], 
p[1], p[2], p[3], lw); });}; 
 
      bEnter.call(bTransform,function(d){return oldQuads[oldQuads.length - 
1];},oldLineWidth); // enter from last of oldQuad 
      bExit.call(bTransform,function(d){return quads[quads.length - 
1];},lineWidth); //exit from last of quads 
      bUpdate.call(bTransform,function(d){return quads[d];},lineWidth); 
 
      var colorBarAxis = d3.svg.axis().scale(aScale).orient(orient) 
          .tickSize(tickSize).tickFormat(tickFormat), 
        a = container.selectAll('g.axis').data(function(d){return 
(aScale)?[1]:[];}), //axis container 
        aEnter = a.enter().append('g').classed('axis',true), 
        aExit = d3.transition(a.exit()).remove(), 
        aUpdate = d3.transition(a).call(colorBarAxis), 
        aTransform = function(selection,lw){ 
          selection.attr('transform', 'translate(' + (((orient === 'right') 
|| (orient === 'left'))?-lw/2:0) + ',' + (((orient === 'right') || (orient 
==='left'))?0:lw/2) + ')');}; 
 
      aEnter.call(aTransform,oldLineWidth); 
      aExit.call(aTransform,lineWidth); 
      aUpdate.call(aTransform,lineWidth); 
 
      // Compute stroke outline for segment p12. 
      function lineJoin(p0, p1, p2, p3, width) { 
        var u12 = perp(p1, p2), 
          r = width / 2, e, 
          a = [p1[0] + u12[0] * r, p1[1] + u12[1] * r], 
          b = [p2[0] + u12[0] * r, p2[1] + u12[1] * r], 
          c = [p2[0] - u12[0] * r, p2[1] - u12[1] * r], 
          d = [p1[0] - u12[0] * r, p1[1] - u12[1] * r]; 
 
        if (p0) { // clip ad and dc using average of u01 and u12 
          var u01 = perp(p0, p1); 
          e = [p1[0] + u01[0] + u12[0], p1[1] + u01[1] + u12[1]]; 
          a = lineIntersect(p1, e, a, b); 
          d = lineIntersect(p1, e, d, c); 
        } 
 
        if (p3) { // clip ab and dc using average of u12 and u23 
          var u23 = perp(p2, p3); 
          e = [p2[0] + u23[0] + u12[0], p2[1] + u23[1] + u12[1]]; 
          b = lineIntersect(p2, e, a, b); 
          c = lineIntersect(p2, e, d, c); 
        } 
 
        return 'M' + a + 'L' + b + ' ' + c + ' ' + d + 'Z'; 
      } 
 
      // Compute intersection of two infinite lines ab and cd. 
      function lineIntersect(a, b, c, d) { 
        var x1 = c[0], x3 = a[0], x21 = d[0] - x1, x43 = b[0] - x3, 
          y1 = c[1], y3 = a[1], y21 = d[1] - y1, y43 = b[1] - y3, 
          ua = (x43 * (y1 - y3) - y43 * (x1 - x3)) / (y43 * x21 - x43 * 
y21); 
        return [x1 + ua * x21, y1 + ua * y21]; 
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      } 
 
      // Compute unit vector perpendicular to p01. 
      function perp(p0, p1) { 
        var u01x = p0[1] - p1[1], u01y = p1[0] - p0[0], 
          u01d = Math.sqrt(u01x * u01x + u01y * u01y); 
        return [u01x / u01d, u01y / u01d]; 
      } 
 
 
      // Sample the SVG path string 'd' uniformly with the specified 
precision. 
      function sample(d,pre) { 
        var path = document.createElementNS(d3.ns.prefix.svg, 'path'); 
        path.setAttribute('d', d); 
 
        n = path.getTotalLength(); 
 
        var t = [0], i = 0; 
        while ((i += pre) < n) { 
          t.push(i); 
        } 
        t.push(n); 
 
        return t.map(function(t) { 
          var p = path.getPointAtLength(t), a = [p.x, p.y]; 
          a.t = t / n; 
          return a; 
        }); 
 
      } 
 
      // Compute quads of adjacent points [p0, p1, p2, p3]. 
      function quad(pts) { 
        return d3.range(pts.length - 1).map(function(i) { 
          var a = [pts[i - 1], pts[i], pts[i + 1], pts[i + 2]]; 
          a.t = (pts[i].t + pts[i + 1].t) / 2; 
          return a; 
        }); 
      } 
 
 
    });} 
 
  component.orient = function(_) { 
    if (!arguments.length) { 
      return orient; 
    } 
    orient = _; 
    return component; 
  }; 
 
  component.lineWidth = function(_) { 
    if (!arguments.length) { 
      return lineWidth; 
    } 
    lineWidth = _; 
    return component; 
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  }; 
 
  component.size = function(_) { 
    if (!arguments.length) { 
      return size_; 
    } 
    size_ = _; 
    return component; 
  }; 
 
  component.tickFormat = function(_) { 
    if (!arguments.length) { 
      return tickFormat; 
    } 
    tickFormat = _; 
    return component; 
  }; 
 
  component.tickSize = function(_) { 
    if (!arguments.length) { 
      return tickSize_; 
    } 
    tickSize_ = _; 
    return component; 
  }; 
 
  component.color = function(_) { 
    if (!arguments.length) { 
      return color; 
    } 
    color = _; 
    return component; 
  }; 
 
  component.precision = function(_) { 
    if (!arguments.length) { 
      return precision; 
    } 
    precision = _; 
    return component; 
  }; 
 
  component.points = function(_) { 
    if (!arguments.length) { 
      return points_; 
    } 
    points_ = _; 
    return component; 
  }; 
 
  component.line = function(_) { 
    if (!arguments.length) { 
      return line; 
    } 
    line = _; 
    return component; 








  .directive('chemTree', function () { 
    function link($scope, $elements) { 
      var xScale, yScale, activityScale, activityColor, slogpScale, 
ligeffScale, 
        borderScale, borderColor, sizeScale, force, nodes, linkDOM, 
nodeDOM; 
 
      //setup 
      var el = $elements[0]; 
 
      //append the svg element 
      var svg = d3.select(el) 
        .append('svg') 
        .attr({class: 'viz'}); 
 
      //clicking anywhere should set selected to none.  This should default 
away if clicking on an object 
      svg.on('click', function(){ 
        if (d3.event.defaultPrevented) { return; } 
        $scope.selected = null; 
        $scope.$apply(); 
      }); 
 
      var vis = svg.append('g'); // the zoom container 
 
      d3.selectAll('.viz').append('g').append('svg') 
        .attr('x', '80') 
        .attr('y', '100') 
        .append('g') 
        .attr('transform', 'translate(0, 10)').classed('colorbarA',true);// 
color bar Activyty 
 
      var barB = d3.selectAll('.viz').append('g').append('svg') 
        .attr('x', '20') 
        .attr('y', '100') 
        .append('g') 
        .attr('transform', 'translate(0, 10)').classed('barB', true); 
 
      barB.append('text').classed('barBtext', true); 
      barB.append('g') 
        .attr('transform', 'translate(0, 10)').classed('colorbarB',true);// 
color bar border 
 
      function flatten(root){ 
        var nodes = []; 
 
        function recurse(node) { 
          if (node.children) { node.size = node.children.reduce(function(p, 
v) { return p + recurse(v); }, 0); } 
          nodes.push(node); 
          return node.size; 
        } 
 
        root.size = recurse(root); 
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        return nodes; 
      } 
 
      function tick() { 
        linkDOM 
          .attr('x1', function(d) { return xScale(d.source.x); }) 
          .attr('y1', function(d) { return yScale(d.source.y); }) 
          .attr('x2', function(d) { return xScale(d.target.x); }) 
          .attr('y2', function(d) { return yScale(d.target.y); }); 
 
        nodeDOM 
          .attr('cx', function(d) { return xScale(d.x); }) 
          .attr('cy', function(d) { return yScale(d.y); }); 
      } 
 
      activityScale = d3.scale.linear() 
        .domain([4, 9]) 
        .clamp(true) 
        .range(['hsl(300,80%,50%)', 'hsl(0,80%,50%)']) 
        .interpolate(d3.interpolateString); 
 
      slogpScale = d3.scale.linear() 
        .domain([5, -5]) 
        .clamp(true) 
        .range(['hsl(300,80%,50%)', 'hsl(0,80%,50%)']) 
        .interpolate(d3.interpolateString); 
 
 
      ligeffScale = d3.scale.linear() 
        .domain([0, 0.5]) 
        .clamp(true) 
        .range(['hsl(300,80%,50%)', 'hsl(0,80%,50%)']) 
        .interpolate(d3.interpolateString); 
 
      // Activity colorbar 
      var colorbarA = colorBar() 
        .color(activityScale).size(350).lineWidth(20).precision(4).tickForm
at(d3.format('g')); 
 
      d3.select('.colorbarA') 
        .insert('text',':first-child') 
        .text('Activity'); 
 
      d3.select('.colorbarA') 
        .append('g') 
        .attr('transform', 'translate(0, 10)').call(colorbarA); 
 
 
      function changeBorderColorBar(nodes) { 
        var colorExtent, colorbarB; // for border color 
        if ($scope.circleBorderType === 'SLogP') { 
          borderScale = slogpScale; 
          colorbarB = colorBar() 
            .color(borderScale).size(350).lineWidth(20).precision(4).tickFo
rmat(d3.format('g')); 
        } else if ($scope.circleBorderType === 'Lig_Eff') { 
          borderScale = ligeffScale; 
          colorbarB = colorBar() 
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            .color(borderScale).size(350).lineWidth(20).precision(4).tickFo
rmat(d3.format('g')); 
        } else { 
          colorExtent = d3.extent(nodes, function(d) { if (d.name[0] === 
'B') { return d.stroke; } }); 
          borderScale = d3.scale.linear() 
            .domain([colorExtent[0], d3.mean(colorExtent), colorExtent[1]]) 
            .range(['#008000', '#FFFF00', '#FF0000']); 
        } 
 
 
        if ($scope.circleBorderType === 'None') { 
          d3.select('.barB').style('visibility','hidden'); 
          d3.select('.colorbarB').style('visibility','hidden'); 
        } else { 
          d3.select('.barB').style('visibility','visible'); 
          d3.select('.colorbarB').style('visibility','visible'); 
          d3.select('.barBtext') 
            .text($scope.circleBorderType); 
          d3.select('.colorbarB').call(colorbarB); 
        } 
      } 
 
      function addForce(nodes) { 
        var linkRange = d3.scale.linear() 
          .domain([0, 0.5]) 
          .range([5, 100]); 
 
        force = d3.layout.force() 
          .charge(function(d) { return d._children ? -d.size * 100 : -
50; }) 
          .linkDistance(function(d) {  return 
linkRange(Number(d.target.dist)); }) 
          .size([ 0.7 * window.innerWidth / 2, window.innerHeight / 2]); 
        var links = d3.layout.tree().links(nodes); 
 
        force.nodes(nodes).links(links); 
        force.on('tick', tick); 
        force.start(); 
      } 
 
      $scope.$watch('forceAct.value', function(newForce) { 
        console.log('new force act'); 
        console.log(newForce); 
        if (newForce === undefined){ return; } 
 
        if (newForce) { 
          addForce(nodes); 
        } else if (force) { 
          force.stop(); 
          force = null; 
        } 
      }); 
 
      //update data 
      $scope.$watch('treeType', function(newTreeType) { 





        if (newTreeType === undefined || $scope.data === undefined) { 
          return; 
        } 
 
        var root  = $scope.data.trees[newTreeType]; 
        nodes = flatten(root); 
        //  force = $scope.data.forces[$scope.treeType]; 
 
        //extract the scales 
        xScale = d3.scale.linear() 
          .domain(d3.extent(nodes, function(d) { return d.x; })) 
          .range([0.1 * window.innerWidth, 0.9 * window.innerWidth]); 
 
        yScale = d3.scale.linear() 
          .domain(d3.extent(nodes, function(d) { return d.y; })) 
          .range([0.1 * window.innerHeight, 0.9 * window.innerHeight]); 
 
        sizeScale = d3.scale.linear() 
          .domain(d3.extent(nodes, function(d) { return d.r; })) 
          .range([4, 10]); 
 
        changeBorderColorBar(nodes); 
 
        activityColor = function(d) { 
          return d._children ? '#3182bd' : d.children ? '#D3D3D3' : 
activityScale(d.fill); 
        }; 
 
        borderColor = function(d) { 
          return d._children ? '#CCC' : d.children ? '#D3D3D3' : 
borderScale(d.stroke); 
        }; 
 
        /** Drag behavior configuration **/ 
        // zoom and drag may interfere with each other, so here redefine 
drag function 
        function dragstarted(){ 
          d3.event.sourceEvent.stopPropagation(); 
          d3.select(this).classed('dragged', true); 
        } 
 
        function dragged(d){ 
          var mouselocation = d3.mouse(vis.node()); 
          d.x = xScale.invert(mouselocation[0]); 
          d.y = yScale.invert(mouselocation[1]); 
          tick(); // re-position this node and links connected to this node 
        } 
 
        function dragended(){ 
          d3.select(this).classed('dragging', false); 
          //force.resume(); 
        } 
 
        var drag = d3.behavior.drag() 
          .origin(function(d){ return d; }) // identify function 
          .on('dragstart', dragstarted) 
          .on('drag', dragged) 
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          .on('dragend', dragended); 
 
        function update() { 
          var links = d3.layout.tree().links(nodes); 
 
          //create the selections and bind them to the data 
          //console.log(links); 
          nodeDOM = vis.selectAll('circle').data(nodes, function(d) 
{ return d.name; }); 
 
          // Enter any new nodes. 
          nodeDOM.enter().append('svg:circle') 
            .attr('class', 'node') 
            .attr('cx', function(d) { return xScale(d.x); }) 
            .attr('cy', function(d) { return yScale(d.y); }) 
            .attr('r', function(d) { return d.children ? 2 : 
sizeScale(d.r); }) 
            .style('fill', activityColor) 
            .style('stroke', borderColor) 
            .style('stroke-width', function(d) { return d.strokeWidth; }) 
            //.on('click', click) 
            // .on('mouseover', mouseover) 
            .call(drag) // attach drag behavior to new circles 
            .append('svg:title') 
            .text( function(d){ return d.name; }); 




          // transition from old to new 
          nodeDOM.filter(function(d) { return d.name[0] === 'B' ? this : 
null; }) 
            //.transition().duration(750) 
            .attr('cx', function(d) { return xScale(d.x); }) 
            .attr('cy', function(d) { return yScale(d.y); }); 
          nodeDOM.filter(function(d) { return d.name[0] === 'B' ? null : 
this; }) 
            .attr('cx', function(d) { return xScale(d.x); }) 
            .attr('cy', function(d) { return yScale(d.y); }); 
 
          // Exit any old nodes. 
          nodeDOM.exit().remove(); 
 
          // 2. update new links 
          linkDOM = vis.selectAll('line') 
            .data(links, function(d) { return d.target.name; }); 
 
          // transition from old to new 
          linkDOM 
            //     .transition(0).duration(750) 
            .attr('x1', function(d) { return xScale(d.source.x); }) 
            .attr('y1', function(d) { return yScale(d.source.y); }) 
            .attr('x2', function(d) { return xScale(d.target.x); }) 
            .attr('y2', function(d) { return yScale(d.target.y); }); 
 
          // Enter any new links. 
          linkDOM.enter().insert('svg:line', '.node') 
            .attr('class', 'link') 
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            .attr('x1', function(d) { return xScale(d.source.x); }) 
            .attr('y1', function(d) { return yScale(d.source.y); }) 
            .attr('x2', function(d) { return xScale(d.target.x); }) 
            .attr('y2', function(d) { return yScale(d.target.y); }) 
            .style('stroke', '#D3D3D3') 
            .style('stroke-width', '5px'); 
 
          // 2. Exit previous links 
          linkDOM.exit().remove(); 
 
          // 3. transition 
          //linkDOM.transition().duration(750) 
          //  .style('stroke-opacity', 0.5); 
 
        } 
 
        update(); 
 
        //click - select the element that was clicked 
        nodeDOM.on('click', function (compound) { 
          //  if (compound.name[0] !== 'B') { return click(compound); } 
          if (d3.event.defaultPrevented) { return; } 
          d3.event.preventDefault(); 
          if (compound === $scope.selected) { 
            $scope.selected = null; 
          } else { 
            $scope.selected = 
$scope.data.compounds[parseInt(compound.name.substring(1))]; 
          } 
          $scope.$apply(); 




        //zoomer 
        /** Zoom behavior configuration **/ 
 
        function zoom() { 
          tick(); // update position by tick, so the actual d.x, d.y won't 
change 
        } 
 
        var zoomer = d3.behavior.zoom() 
          // allow only 10 times zoom in or out 
          .scaleExtent([0.1, 10]) 
          // attach zoom function for variable modification 
          .on('zoom', zoom); 
 
        // let zoomer ajust coordinates by xScale and yScale 
        zoomer.x(xScale).y(yScale); 
 
        svg.call(zoomer); 
 
        if ($scope.forceAct.value) { 
          addForce(nodes); 
        } else if (force) { 
          force.stop(); 
          force = null; 
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        } 
      }); 
 
      $scope.$watch('circleSizeType', function(newCircleSizeType) { 
 
        if (newCircleSizeType === undefined || $scope.data === undefined) { 
          return; 
        } 
 
        var extent = d3.extent(nodes, function(d) { if (d.name[0] === 'B') 
{ return d.r; } }); 
 
        var sizeLowerbound = 4; 
        var sizeScale = d3.scale.linear() 
          .domain(extent) 
          .range([sizeLowerbound, 10]); 
 
        // transition from old to new 
        if (nodeDOM) { 
          nodeDOM.filter(function(d) { return d.name[0] === 'B' ? this : 
null; }) 
            .transition().delay(100).duration(750) 
            .attr('r', function(d) { if (extent[0] === extent[1]) { return 
sizeLowerbound; } else { return sizeScale(d.r);}}); 
        } 
      }); 
 
      $scope.$watch('circleBorderType', function(newCircleBorderType) { 
 
        if (newCircleBorderType === undefined || $scope.data === undefined) 
{ 
          return; 
        } 
 
        //nodeDOM = vis.selectAll('circle').data(nodes, function(d) 
{ return d.name; }); 
        changeBorderColorBar(nodes); 
 
        // transition from old to new 
        if (nodeDOM) { 
          nodeDOM.filter(function(d) { return d.name[0] === 'B' ? this : 
null; }) 
            .transition().delay(100).duration(750) 
            .style('stroke', function(d) { return borderScale(d.stroke); }) 
            .style('stroke-width', function(d) { return d.strokeWidth; }); 
        } 
      }); 
 
      $scope.$watch('activityType', function(newActivityType) { 
 
        if (newActivityType === undefined || $scope.data === undefined) { 
          return; 
        } 
 
        // transition from old to new 
        if (nodeDOM) { 




            .transition().delay(100).duration(750) 
            .style('fill', function(d) { return activityScale(d.fill); }); 
        } 
      }); 
 
      $scope.$watch('gravityValue', function(newGravity) { 
 
        if (newGravity === undefined || $scope.data === undefined) { 
          return; 
        } 
 
        //console.log('new gravity:' + newGravity); 
 
        force.resume(); 
        force.gravity( newGravity ); 
 
      }); 
 
      $scope.$watch('linkStrengthValue', function(newLinkStrength) { 
 
        if (newLinkStrength === undefined || $scope.data === undefined) { 
          return; 
        } 
 
        console.log('new linkStrength:' + newLinkStrength); 
 
        force.linkStrength( newLinkStrength ); 
        force.resume(); 
        $scope.$apply(); 
 
        console.log('tree type is: ', $scope.treeType); 
        console.log('setted linkStrength:' + force.linkStrength()); 
      }); 
 
 
      ////watch the selected scope variable - this can be controlled from 
outside the directive or inside the directive 
      $scope.$watch('selected', function (selected) { 
 
          if (selected === undefined || $scope.data === undefined) { 
            return; 
          } 
 
          //if nothing is selected set the $elements to not be selected 
          if (selected === null) { 
            nodeDOM 
              .filter(function(d) { return d.name[0] === 'B' ? this : 
null; }) 
              .style('fill', function (d) { 
                return activityScale(d.fill); 
              }); 
          } else { 
            nodeDOM 
              .filter(function(d) { return d.name[0] === 'B' ? this : 
null; }) 
              .style('fill', function (d) { 




              }); 
          } 
        } 
      ); 
 
    } 
    return { 
      restrict: 'E', 
      link: link, 
      scope: { 
        data: '=', 
        current: '=', 
        gravityValue: '=', 
        linkStrengthValue: '=', 
        treeType: '=', 
        circleSizeType: '=', 
        circleBorderType: '=', 
        activityType: '=', 
        selected: '=', 
        forceAct: '=' 
      } 
    }; 









 * @ngdoc directive 
 * @name frontendApp.directive:tooltip 
 * @description 
 * # tooltip 
 */ 
angular.module('frontendApp') 
  .directive('tooltips', function (dataService) { 
 
    return { 
        scope: {visibility: '=', data: '=', height: '@', click: '='}, 
        templateUrl: 'views/tooltip.html', 
        restrict: 'E', 
        link: function (scope, elements) { 
 
            var parent = $(elements[0]); 
 
            scope.dataService = dataService; 
 
            scope.close = function() { 
                scope.visibility = false; 
            }; 
 
 
            scope.$watch('visibility', function(newVisibility) { 
                if (newVisibility) { 
                    parent.show(400); 
                } else { 
                    parent.hide(400); 
                } 
            }); 
 
 
        } 
    }; 









 * @ngdoc directive 
 * @name frontendApp.directive:treeSlider 
 * @description 




  .directive('treeSlider', function () { 
    return { 
      scope: { 
        min: '=', 
        max: '=', 
        value: '=', 
        leftName: '=', 
        rightName: '=', 
        name: '=', 
        id: '=' 
      }, 
      templateUrl: 'views/tree-slider.html', 
      restrict: 'E', 
      link: function postLink(scope, elements) { 
 
        var nameTag = $('<div class="name section"></div>'), 
          leftSection = $('<div class="left section"></div>'), 
          leftLabel = $('<span class="sm-label">left</span>'), 
          rightSection = $('<div class="right section"></div>'), 
          rightLabel = $('<span class="sm-label">right</span>'), 
          slider= $('<div class="slider"  title="Please activate the force 
directed graph first."></div>'); 
 
        //console.log('#' + scope.id); 
        //console.log(slider); 
        var el = elements.find('div'); 
 
        $(el).append([nameTag, slider]); 
 
        slider.append([leftSection, rightSection]); 
        rightLabel.appendTo(rightSection); 
        leftLabel.appendTo(leftSection); 
 
        nameTag.text(scope.name); 
        rightLabel.text(scope.rightName); 
        leftLabel.text(scope.leftName); 
 
        slider.slider({ 
          //range: true, 
          min: scope.min, 
          max: scope.max, 
          step: 0.01, 
          value: scope.value, 
          //animate: 'fast', 
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          slide: function(evt, ui) { 
              scope.value = ui.value; 
              scope.$apply(); 
          } 
        }); 
 
      } 










 * @ngdoc service 
 * @name frontendApp.dataService 
 * @description 
 * # dataService 
 * Factory in the frontendApp. 
 */ 
angular.module('frontendApp') 
  .factory('dataService', function ($http, $q) { 
    // Service logic 
    // ... 
 
    // create the service to be returned by the factory 
    var dataService = {}; 
 
    //selected molecules 
    // also a variable dataService.model.selected 
    dataService.model = {selected: null}; 
 
    //initially, there is no data 
    dataService.data = null; 
 
    //initially, there are no representations in data 
    dataService.available = { 
      treeTypes: [], 
      circleSizeTypes: ['None'], 
      circleBorderTypes: ['None'], 
      activityTypes: [] 
    }; 
 
    //initially, there is no active spaces 
    dataService.current = { 
      treeType: null, 
      circleSizeType: null, 
      circleBorderType: null, 
      activityType: null 
    }; 
 
    dataService.flatten = function (root) { 
      var nodes = []; 
 
      function recurse(node) { 
        if (node.children) { node.r = node.children.reduce(function(p, v) 
{ return p + recurse(v); }, 0);} 
        nodes.push(node); 
        return node.size; 
      } 
 
      root.size = recurse(root); 
      return nodes; 
    }; 
 
    // 
    // api for changing the data 
211 
 
    // 
 
    // doesn't touch the data directly, calls 
setDimensionalityReductionType to actually change the data 
    dataService.setTreeType = function (newTreeType) { 
 
      console.log('Set Tree to ' + newTreeType); 
      dataService.current.treeType = newTreeType; 
 
      this.setActivityType(this.current.activityType); 
 
    }; 
 
    // 
    dataService.setCircleSizeType = function (newCircleSize) { 
 
      console.log('Set circle size:' + newCircleSize); 
 
      // should check if is a member of available 
      this.current.circleSizeType = newCircleSize; 
 
      var root  = this.data.trees[this.current.treeType]; 
      var nodes = dataService.flatten(root); 
 
      if (newCircleSize === 'None') { 
        nodes.forEach(function(d) { 
          d.r = 2; 
        }); 
      } else { 
        nodes.forEach(function(d) { 
          if (d.name.startsWith('B')) { 
            d.r = 
dataService.data.compounds[parseInt(d.name.substring(1))].properties[newCir
cleSize]; 
          } 
        }); 
      } 
 
    }; 
 
    // use to change the border type 
    dataService.setCircleBorderType = function (newCircleBorderType) { 
 
      console.log('Set circleBorderType:', newCircleBorderType); 
 
      // should check if is a member of available 
      dataService.current.circleBorderType = newCircleBorderType; 
 
      var root  = this.data.trees[this.current.treeType]; 
      var nodes = dataService.flatten(root); 
 
      if (newCircleBorderType === 'None') { 
        nodes.forEach(function(d) { 
          d.stroke = 0; 
          d.strokeWidth = 0; 
        }); 
      } else { 
        nodes.forEach(function(d) { 
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          if (d.name.startsWith('B')) { 
            d.stroke = 
dataService.data.compounds[parseInt(d.name.substring(1))].properties[newCir
cleBorderType]; 
            d.strokeWidth = 3; 
          } 
        }); 
      } 
 
    }; 
 
    // use to change the activity type 
    dataService.setActivityType = function (newActivityType) { 
 
      console.log('Set activity type:', newActivityType); 
 
      // should check if is a member of available 
      dataService.current.activityType = newActivityType; 
 
      var root  = this.data.trees[this.current.treeType]; 
      var nodes = dataService.flatten(root); 
 
      nodes.forEach(function(d) { 
        if (d.name.startsWith('B')) { 
          d.fill = 
dataService.data.compounds[parseInt(d.name.substring(1))].activities[newAct
ivityType]; 
        } 
      }); 
 
    }; 
 
    //remove all the data 
    dataService.empty = function () { 
      this.available.treeTypes.length = 0; 
      this.available.circleSizeTypes = ['None']; 
      this.available.circleBorderTypes = ['None']; 
      this.available.activityTypes.length = 0; 
      this.current.treeType = null; 
      this.current.circleSizeType = null; 
      this.current.circleBorderType = null; 
      this.current.activityType = null; 
      return this; 
    }; 
 
    dataService.initializeData = function () { 
 
      // remove old representation types if any previously existed 
      this.empty(); 
 
      // add metadata for each option 
      this.metadata = {}; 
 
      // add tree types 
      this.data.metadata.treeTypes.forEach(function(d) { 
        dataService.metadata[d.name] = d.metadata; 




      this.setTreeType(this.available.treeTypes[0]); 
 
      // add circle size 
      this.data.metadata.circleSizeTypes.forEach(function(d) { 
        dataService.metadata[d.name] = d.metadata; 
        dataService.available.circleSizeTypes.push(d.name); }); 
 
      this.setCircleSizeType(this.available.circleSizeTypes[0]); 
 
      // add tree types 
      this.data.metadata.circleBorderTypes.forEach(function(d) { 
        dataService.metadata[d.name] = d.metadata; 
        dataService.available.circleBorderTypes.push(d.name); }); 
 
      this.setCircleBorderType(this.available.circleBorderTypes[0]); 
 
      // add activity types 
      this.data.metadata.activityTypes.forEach(function(d) { 
        dataService.metadata[d.name] = d.metadata; 
        dataService.available.activityTypes.push(d.name); }); 
 
      this.setActivityType(this.available.activityTypes[0]); 
 
      // set first in list to be active 
 
      return this; 
    }; 
 
    // load up an example dataset 
    dataService.loadExample = function(name, callback) { 
 
      var delay = $q.defer(); 
 
      $http.get('data/' + name + '.json') 
        .then(function(response) { 
          //retrieve the data as a property 
          dataService.datasetName = name; 
          dataService.data = response.data; 
 
          //process the data 
          dataService.initializeData(); 
 
          return delay.resolve(response); 
        }) 
        .then(callback); 
 
      return delay.promise; 
    }; 
 
    return dataService; 











 * @ngdoc service 
 * @name frontendApp.settings 
 * @description 
 * # settings 
 * Service in the frontendApp. 
 */ 
angular.module('frontendApp') 
  .service('settings', function () { 
 
    this.defaultForce = {value: false}; 
 
    this.forceAct = {value: false}; 
 





Appendix C. ChemTreeMap Back End Code 
setup.py 
 
#! /usr/bin/env python 
# 
# Copyright (C) 2016 Jing Lu <ajingnk@gmail.com> 
# License: Apache 
 
# -*- coding: utf-8 -*- 
 
# pylint: disable=too-few-public-methods 
 
from distutils.core import setup, Extension 
 
from setuptools.command.install import install 







    def run(self): 
        uid, gid = 0, 0 
        mode = 0700 
        install.run(self) # calling install.run(self) insures that 
everything that happened previously still happens, so the installation does 
not break! 
        # here we start with doing our overriding and private magic .. 
        print self.install_scripts 
        for filepath in self.get_outputs(): 
            if filepath.endswith("rapidnj-linux-64"): 
                log.info("Overriding setuptools mode of scripts ...") 
                log.info("Changing ownership of %s to uid:%s gid %s" % 
                         (filepath, uid, gid)) 
                os.chown(filepath, uid, gid) 
                log.info("Changing permissions of %s to %s" % 
                         (filepath, oct(mode))) 
                os.chmod(filepath, mode) 
 
setup( 
    name='treebuild', 
    version='0.1.0', 
    packages=['treebuild'], 
    url='https://github.com/ajing/ChemTreeMap', 
    license='Apache 2.0', 
    author='ajing', 
    author_email='ajingnk@gmail.com', 
    description='Generate Tree Structures for Biochemical Similarity in 
Molecular Datasets. Please install rdkit and graphviz first, because they 
are not pip installable.', 
    install_requires=[ 
        #'rdkit',  ## currently rdkit is not pip installable 
        #               ## so this dependency must be met by the installer 
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        'ete2' 
    ], 
    package_data={'treebuild': ['data/*.txt', 'data/*.py', 'lib/rapidnj-
linux-64']}, 












from csv import DictReader 
from rdkit import Chem, DataStructs 
 
from ete2 import Tree 
 




    """ 
    Guess the number of columns with floats by the first line of the file 
 
    :param firstline: 
    :return: 
    """ 
    num_colnam = [] 
    for key in firstline: 
        try: 
            float(firstline[key]) 
            num_colnam.append(key) 
        except: 
            continue 
    return num_colnam 
 
def ConvertToFloat(line, colnam_list): 
    """ 
    Convert some columns (in colnam_list) to float, and round by 3 decimal. 
 
    :param line: a dictionary from DictReader. 
    :param colnam_list: float columns 
    :return: a new dictionary 
    """ 
    for name in colnam_list: 
        line[name] = round(float(line[name]), 3) 
    return line 
 
def ParseLigandFile(infile, identifier): 
    """ 
    Parse ligand file to an dictionary, key is ligand id and valud is a 
dictionary with properties and property values. 
    This program will guess the type for each column based on the first 
row. The program will assume there is only two types of data: number and 
string. 
 
    :param infile: input filename 
    :param identifier: the identifier column name 
    :return: a dictionray 
    """ 
    ''' 
 
    ''' 
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    mol_dict = dict() 
    flag = 1 # first line flag 
    id_count = 0 
    for line in DictReader(open(infile), delimiter = "\t"): 
        if flag: 
            num_colnam = GuessByFirstLine({k:v for k,v in line.items() }) 
        new_id = "B" + str(id_count) 
        id_count += 1 
        mol_dict[new_id] = ConvertToFloat({k:v for k,v in line.items()}, 
num_colnam) 
        mol_dict[new_id]["orig_id"] = line[identifier] 
    return mol_dict 
 
 
def WriteJSON(dict_obj, outfile, write_type): 
    """ 
    Dump json object to a file. 
 
    :param dict_obj: dictionary object 
    :param outfile: output file name 
    :param write_type: append or rewrite ('a' or 'w') 
    :return: void 
    """ 
    fileobj = open(outfile, write_type) 
    fileobj.write(json.dumps(dict_obj)) 
 
 
def SelectColumn(lig_dict, colname): 
    """ 
    Prune the dictionary, only attribute in colname will be left. 
 
    :param lig_dict: a tree like dictionary 
    :param colname: what attribute you want to keep. 
    :return: a new dictionary 
    """ 
    lig_new = dict() 
    for k in lig_dict: 
        lig_new[k] = {sk:v for sk, v in lig_dict[k].items() if sk in 
colname} 
    return lig_new 
 
 
def WriteAsPHYLIPFormat(smile_list, fp_func): 
    """ 
    Prepare the input for RapidNJ. 
 
    :param smile_list: a list of smiles string 
    :param fp_func: the fingerprint function 
    :return: tje filename with PHYLIP format (input for rapidnj) 
    """ 
    fp_list = ToFPObj(smile_list, fp_func) 
    print "finish parsing smile list" 
    list_len = len(fp_list) 
 
    newfilename = datetime.datetime.now().strftime(FILE_FORMAT) + ".dist" 
    fileobj  = open(newfilename, "w") 




    for i in range(list_len): 
        lig1 = fp_list[i] 
        lig1list = [] 
        for j in range(list_len): 
            lig2 = fp_list[j] 
            sim  = getSimilarity(lig1[1], lig2[1]) 
            lig1list.append([lig2[0], 1 - sim]) 
 
        sim_values = [ "%.4f" % x[1] for x in lig1list] 
        line = "\t".join([lig1[0], "\t".join(sim_values)]) + "\n" 
        fileobj.write(line) 
 
    fileobj.close() 
 
    return newfilename 
 
 
def ToFPObj(alist, fp_func): 
    """ 
    A list of SMILE string object with (id, smiles) to a list of 
fingerprint object with (id, fp_obj) 
 
    :param alist: a list of two element list, the first item is ligand 
name, the second is smile 
    :param fp_func: the fingerprint function 
    :return: a new list of two element list, with first item as ligand 
name, second item as a fingerprint object. 
    """ 
    newlist = [] 
    for each in alist: 
        smile = each[1] 
        m = Chem.MolFromSmiles(smile) 
        if m is None: 
            continue 
        fp = fp_func(m) 
        newlist.append([each[0], fp]) 




    """ 
    Write newick string to a DOT file 
 
    :param newick: a string with newick tree structure 
    :return: DOT file name 
    """ 
    tree = Tree(newick) 
 
    dot_file_name = datetime.datetime.now().strftime(FILE_FORMAT) + ".gv" 
    fileobj = open(dot_file_name, "w") 
 
    # rename internal tree name 
    i = 0 
    for n in tree.traverse(): 
        if not n.name: 
            n.name = "F" + str(i) 
            i = i + 1 
        else: 
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            n.name = n.name.replace("\'", "") 
 
    aline = "graph G{\nnode [shape=circle, style=filled];" 
    fileobj.write(aline + "\n") 
    filecontent = [] 
    for n in tree.traverse(): 
        if n.up: 
            filecontent.append(n.name + "--" + n.up.name + "[len=" + 
"{:f}".format(n.dist).rstrip("0") + "]") 
        else: 
            filecontent.append(n.name) 
 
    fileobj.write("\n".join(filecontent) + "}") 




    """ 
    Rewrite dot file, with removing back slash of dot file. 
 
    :param dotfile: DOT file name 
    :return: void 
    """ 
    # remove backslash and replace all " quote sign 
    f = open(dotfile, 'r+') 
    content = f.readlines() 
    newcontent = [] 
    for line in content: 
        line = line.replace("\"", "") 
        if line.endswith("\\\n"): 
            newcontent.append(line[:-2]) 
        elif line.endswith("\n") and line[-2] != ";": 
            newcontent.append(line[:-1]) 
        else: 
            newcontent.append(line) 
    f.seek(0) 
    f.write("".join(newcontent)) 
    f.truncate() 
    f.close() 
 
 
def Dot2Dict(dotfile, moldict): 
    """ 
    Read a DOT file to generate a tree and save it to a dictionary. 
 
    :param dotfile: DOT file name 
    :param moldict: a dictionary with ligand information 
    :return: a dictionary with the tree 
    """ 
    rootname = "F0" 
    # dotfile is a dot file 
    contents = open(dotfile).readlines() 
    # get the root of the network 
    root = GetRoot(dotfile, rootname) 
    curr_nodes = [root] 
    curr_name_list = [root.name] 
    next_nodes     = 1 
    while next_nodes: 
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        next_nodes = [] 
        for each_node in curr_nodes: 
            next_nodes += extendChildren(each_node, contents, 
curr_name_list) 
        curr_nodes = next_nodes 
    rootdict = RecursiveNode2Dict(root, moldict) 
    return rootdict 
 
 
def getSimilarity(fp1, fp2): 
    """ 
    Generate similarity score for two smiles strings. 
 
    :param fp1: fingerprint object (rdkit) 
    :param fp2: fingerprint object (rdkit) 
    :return: Tanimoto similarity 
    """ 
    if (fp1 is None or fp2 is None): 
        return 
    return DataStructs.TanimotoSimilarity(fp1, fp2) 
 
 
def GetRoot(dotfile, rootname): 
    """ 
    Return root name with rootname. 
 
    :param dotfile: DOT file 
    :param rootname: the name of the root 
    :return: the object of the root 
    """ 
    for eachline in open(dotfile): 
        if NodeNameExist(eachline) and not IsEdge(eachline): 
            name, attr = NameAndAttribute(eachline) 
            name = name.strip() 
            if name == rootname: 
                name, size, position = GetNodeProperty(eachline) 
                return Node(name, size = size, position = position) 
 
 
def extendChildren(a_node, contents, cur_list): 
    """ 
    Find all children of a node in a tree. 
 
    :param a_node: a node in a tree 
    :param contents: contents from DOT file 
    :param cur_list: current children 
    :return: a list of node objects (children) 
    """ 
    children_list = [] 
    for eachline in contents: 
        if IsEdge(eachline): 
            name, attr = NameAndAttribute(eachline) 
            fnode, snode = ProcessName(name, True) 
            eachline = CleanAttribute(eachline) 
            if fnode == a_node.name and not snode in cur_list: 
                edge_len  = GetAttributeValue("len", eachline) 




            if snode == a_node.name and not fnode in cur_list: 
                edge_len  = GetAttributeValue("len", eachline) 
                AddNewChild(contents, a_node, fnode, edge_len, 
children_list, cur_list) 




    """ 
    Whether this line in DOT file is an edge. 
 
    :param line: a string line in DOT file 
    :return: True or False 
    """ 
    if "--" in line: 
        return True 
    else: 
        return False 
 
 
def RecursiveNode2Dict(node, info_dict): 
    ''' 
    Recursively populate information to the tree object with info_dict. 
 
    :param node: tree object with all info 
    :param info_dict: information for each ligand. 
    :return: a tree dictionary 
    ''' 
    if not node.children: 
        x, y   = map(float, node["position"].split("-")) 
        result = {"name": node.name, "size": 1, "x": x, "y": y, "dist": 
abs(float(node.dist))} 
        if info_dict: 
            result.update(info_dict[node.name]) 
    else: 
        x, y   = map(float, node["position"].split("-")) 
        result = {"name": node.name, "x": x, "y": y, "dist": 
abs(float(node.dist))} 
        if info_dict and node.name in info_dict: 
            result.update(info_dict[node.name]) 
    children = [RecursiveNode2Dict(c, info_dict) for c in node.children] 
    if children: 
        result["children"] = children 




    """ 
    Functions for parsing DOT file. 
 
    :param line: a line from DOT file 
    :return: whether there is a node name in this line 
    """ 
    if "CHEMBL" in line or "ASD" in line or "Chk1" in line or "B" in line 
or "F" in line: 
        return True 
    else: 






    """ 
    Split name and attribute. 
 
    :param line: DOT file name 
    :return: name string and attribute string 
    """ 
    split_index = line.index("[") 
    name   = line[:split_index] 
    attr   = line[split_index:] 
    return name, attr 
 
 
def AddNewChild(contents, a_node, new_node_name, edge_length, children, 
currentlist): 
    """ 
    Add a new child to a node. 
 
    :param contents: a string, a line from DOT 
    :param a_node: a node object 
    :param new_node_name: new node name 
    :param edge_length: the length of edge 
    :param children: existing children 
    :param currentlist: current list of node name 
    :return: void 
    """ 
    # return a node object 
    newnode = NodeByName(new_node_name, contents) 
    newnode.set_dist(edge_length) 
    a_node.add_child(newnode) 
    children.append(newnode) 




    """ 
    Get node property from a string. 
 
    :param line: a string 
    :return: name, size, and position of the node 
    """ 
    name, attr = NameAndAttribute(line) 
    name = ProcessName(name, False) 
    position = GetAttributeValue("pos", attr)[:-1].replace(",", "-") 
    attr = CleanAttribute(attr) 
    width = GetAttributeValue("width", attr) 
    #group = GetAttributeValue("color", attr) 
    size = SizeScale(GetSize(width)) 
    return name, size, position 
 
 
def ProcessName(name, isedge): 
    """ 
    Process the name of the node. 
 
    :param name: name of the node 
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    :param isedge: whether this is a edge 
    :return: new name 
    """ 
    if isedge: 
        firstnode, secondnode = name.split("--") 
        firstnode = firstnode.strip() 
        secondnode = secondnode.strip() 
        return firstnode, secondnode 
    else: 
        return name.strip() 
 
 
def GetAttributeValue(attrname, attr): 
    """ 
    Get node attribute. 
 
    :param attrname: name of the attribute 
    :param attr: the attribute string 
    :return: the value for the attribute 
    """ 
    left = attr.index("[") + 1 
    right = attr.index("]") 
    attr  = attr[left:right] 
    attrlist = attr.split() 
    for each in attrlist: 
        if attrname in each: 
            value = each.split("=")[1] 
            if value.endswith("!"): 
                return value[:-1] 
            else: 




    """ 
    Clean attribute, remove ','. 
 
    :param attr: old attribute string 
    :return: new string 
    """ 
    new_attr = attr.replace(",", "") 
    return new_attr 
 
 
def NodeByName(name, contents): 
    """ 
    Create node with name name. 
 
    :param name: a string with node name 
    :param contents: a list of string from DOT file 
    :return: node object 
    """ 
    for eachline in contents: 
        if not IsEdge(eachline) and NodeNameExist(eachline): 
            nodename, attr = NameAndAttribute(eachline) 
            if name == nodename.strip(): 
                name, size, position = GetNodeProperty(eachline) 






    """ 
    Rescale the size (currently only convert to float). 
 
    :param size: a string 
    :return: a float 
    """ 




    """ 
    Get the size. 
 
    :param width: 
    :return: 
    """ 
    if isinstance(width, str): 
        width = float(width) 




    """ 
    class for node of tree, each node can only have one parent 
    """ 
    def __init__(self, name, **attr): 
        self.name = name 
        self.parent = None 
        self.children = [] 
        self.dist   = 0 
        self.update(attr) 
 
    def __str__(self): 
        return "a node with name:" + self.name 
 
    def get_dist(self, a_node): 
        """ 
        get the node as a dictionary. 
 
        :param a_node: Node object 
        :return: a dictionary 
        """ 
        if not isinstance(a_node, Node): 
            raise TypeError("argument should be Node class") 
        if a_node == self.parent: 
            return self.dist 
        if a_node in self.children: 
            return a_node.dist 
        else: 
            return None 
 
    def add_child(self, a_node): 
        """ 




        :param a_node: Node object 
        :return: void 
        """ 
        if not isinstance(a_node, Node): 
            raise TypeError("argument should be Node class") 
        self.children.append(a_node) 
        a_node.set_parent(self) 
 
    def set_parent(self, a_node): 
        """ 
        Set the parent for a node. 
 
        :param a_node: Node object 
        :return: void 
        """ 
        if not isinstance(a_node, Node): 
            raise TypeError("argument should be Node class") 
        self.parent = a_node 
 
    def set_dist(self, dist): 
        """ 
        set the dictionary attribute for the Node object. 
 
        :param dist: 
        :return: 
        """ 
        self.dist = dist 
 
 
if __name__ == "__main__": 







#! /usr/bin/env python 
# 
# Copyright (C) 2016 Jing Lu <ajingnk@gmail.com> 
# License: Apache 
 
# -*- coding: utf-8 -*- 
 
# pylint: disable=too-few-public-methods 
import math 
from rdkit import Chem 
from rdkit.Chem import AllChem 
from rdkit.Chem.AtomPairs import Pairs 
 




    """ 
    representing fingerprint types 
    """ 
    def __init__(self, name, fp_func, metadata): 
        """ 
        Initialize the fingerprint type 
 
        :param name: name of fingerprint 
        :param fp_func: the function to generate a fingerprint 
        :param meta: string for fingerprint document 
        :return: 
        """ 
        self.name = name 
        self.fp_func = fp_func 
        self.metadata = metadata 
 
    def to_dict(self): 
        """ 
        Show the information for this fingerprint 
 
        :return: dictionary with basic info 
        """ 




    """ 
    representing biological or chemical properties 
    """ 
    def __init__(self, name, metadata, transfunc=None, colname=None): 
        """ 
        :param name: a string name of property 
        :param metadata: a string with property meaning 
        :param transfunc: a function to generate the property 
        :return: 
        """ 
        self.name = name 
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        self.metadata = metadata 
        self.transfunc = transfunc  # the signiture for transfunc is 
transfunc(a_value, a_mol_dict) 
        self.colname = colname 
 
    def set_col_name(self, col_name): 
        """ 
        Set the property name from the input file 
 
        :param col_name: original column name in the input file 
        :return: 
        """ 
        self.colname = col_name 
 
    def gen_property(self, mol_dict = None): 
        """ 
        generate value for this property type 
 
        :param prop_name: the name of the property 
        :param mol_dict: other information about the molecule 
        :return: a generated value for this property 
        """ 
        # if self.colname is None: 
        #     raise Exception("Please set the column name for this 
property") 
 
        if self.colname in mol_dict: 
            return mol_dict[self.colname] 
 
        if self.name in mol_dict: 
            return mol_dict[self.name] 
 
        if not self.transfunc is None and not mol_dict is None: 
            return self.transfunc(mol_dict) 
        else: 
            raise Exception("please provide the transformation function and 
molecule information for " + str(self)) 
 
 
    def to_dict(self): 
        """ 
        Show the information 
 
        :return: dictionary with basic info 
        """ 
        return {"name": self.name, "metadata": self.metadata} 
 
    def __str__(self): 
        return self.name 
 
# property functions 
def _lig_eff(mol_dict): 
    smile = mol_dict[SMILE_COLUMNNAME] 
    m = Chem.MolFromSmiles(smile) 
    num_heavy = m.GetNumHeavyAtoms() 
    if POTENCY in mol_dict: 
        ic50  = mol_dict[POTENCY] 
        return round(1.37 * (9 - math.log10(ic50)) / num_heavy, 5) 
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    elif "pIC50" in mol_dict: 
        pic50 = mol_dict["pIC50"] 
        return round(1.37 * pic50 / num_heavy, 5) 
    else: 
        raise Exception("Cannot calculate ligand efficiency, please change 




    smile = mol_dict[SMILE_COLUMNNAME] 
    m = Chem.MolFromSmiles(smile) 
    return round(Chem.rdMolDescriptors.CalcCrippenDescriptors(m)[0], 5) 
 
def _pic50(mol_dict): 
    ic50 = mol_dict[POTENCY] 
    return round(9 - math.log10(float(ic50)), 5) 
 
ecfp6 = FingerPrintType(name = "ECFP6", fp_func= lambda mol: 
AllChem.GetMorganFingerprint(mol, 3), metadata = "Extended Connectivity 
fingerprint, implemented in <a href=\"http://www.rdkit.org\">RDKit</a>. 
<br/>Parameters used: Radius = 3") 
 
atom_pair = FingerPrintType(name = "AtomPair", fp_func= 
Pairs.GetAtomPairFingerprint, metadata = "Atom Pairs as Molecular Features, 
describe in  R.E. Carhart, D.H. Smith, R. Venkataraghavan; \"Atom Pairs as 
Molecular Features in Structure-Activity Studies: Definition and 
Applications\" JCICS 25, 64-73 (1985).implemented in <a 
href=\"http://www.rdkit.org\">RDKit</a>. <br/>") 
 
lig_eff = PropertyType(name = "Lig_Eff", metadata = "Ligand efficiency. The 
value is calculated by the function 1.37 * pIC50 / a_heavy", transfunc = 
_lig_eff) 
 
slogp   = PropertyType(name = "SLogP", metadata = "SLogP, the coefficients 
are a measure of the difference in solubility of the compound in water and 
octanol. describe in    S. A. Wildman and G. M. Crippen JCICS 39 868-873 
(1999) R.E. Carhart, D.H. Smith, R. Venkataraghavan; \"Atom Pairs as 
Molecular Features in Structure-Activity Studies:", transfunc = _slogp) 
 
ic50   = PropertyType(name = "IC50", colname = "IC50", metadata = "The half 
maximal inhibitory concentration (IC50) is a measure of the effectiveness 
of a substance in inhibiting a specific biological or biochemical 
function.") 
 
pic50 = PropertyType(name = "pIC50", metadata = "This number assumes IC50 
in nM unit, so it is calculated by 9 - log(IC50). Please change your data 
or the code to make it appropriate.", transfunc = _pic50) 
 
bindingdb = {"name": "BindingDB", "link": 
"https://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomeri
d="} 
chebi = {"name": "CHEBI", "link": 
"https://www.ebi.ac.uk/chebi/searchId.do?chebiId="} 
pubchem = {"name": "PubChem", "link": 
"https://pubchem.ncbi.nlm.nih.gov/compound/"} 
 
DEFAULT_FINGERPRINT_TYPES = [ecfp6, atom_pair] 
DEFAULT_ACTIVITY_TYPES = [ic50, pic50] 
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DEFAULT_PROPERTY_TYPES = [lig_eff, slogp] 







#! /usr/bin/env python 
# 
# Copyright (C) 2016 Jing Lu <ajingnk@gmail.com> 
# License: Apache 
 
# -*- coding: utf-8 -*- 
 






from rdkit import Chem 
from rdkit.Chem.Draw import MolToFile 
 
from .types import FingerPrintType 
from .util import ParseLigandFile, WriteJSON, WriteAsPHYLIPFormat, 
Dot2Dict, \ 
    WriteDotFile, RemoveBackSlash 




    """ 
    There are a few assumptions for the input file: 
        1. potency unit is nM 
        2. the file must have a id column, you can set the column name with 
id_column 
        3. the file must have a SMILES column, with 'Canonical_Smiles' as 
column name 
        4. the file must have at least one activity column. 
    To build the tree 
        1. the identity column needs to be specified with id_column 
        2. a list of fingerprints and a list of properties need to be 
specified 
        3. the directories for input and output file are also needed to be 
specified 
    """ 
    def __init__(self, input_file, output_file, id_column, fps, 
properties): 
        """Setting parameters to build the tree. 
 
        :param input_file: input file is a tab delimited text file. 
        :param output_file: output file is a json file 
        :param id_column: the id for each column, which will shown as the 
identifier in the visualization. 
        :param fps: a list of FingperPrintType 
        :param properties: a list of PropertyType 
        :return: void, the program will generate input file for the 
visualization. 
        """ 
        # initial setting 
        self._RAPIDNJ_COMMAND = RAPIDNJ_COMMAND 
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        self._FILE_FORMAT = FILE_FORMAT 
 
        # creating folders 
        if not os.path.exists(TMP_FOLDER): 
            os.makedirs(TMP_FOLDER) 
        if not os.path.exists(IMG_DIR): 
            os.makedirs(IMG_DIR) 
 
        activities = properties["activities"] 
        other_properties = properties["properties"] 
        ext_links = properties["ext_links"] 
        lig_dict = self.parse_lig_file(input_file, id_column) 
        trees = dict() 
        for fp in fps: 
            assert isinstance(fp, FingerPrintType) 
            trees[fp.name] = self.build_single_tree(lig_dict, fp) 
        metadata = dict() 
        metadata["activityTypes"] = [act.to_dict() for act in activities] 
        metadata["treeTypes"] = [fp.to_dict() for fp in fps] 
        metadata["circleSizeTypes"] = [prop.to_dict() for prop in 
other_properties] 
        metadata["circleBorderTypes"] = [prop.to_dict() for prop in 
other_properties] 
        metadata["external"] = ext_links 
 
        ext_names = [ext["name"] for ext in ext_links] 
 
        comp_info = self.gen_properties(lig_dict, activities, 
other_properties, ext_names) 
        final_dict = {"metadata": metadata, "trees": trees, "compounds": 
comp_info} 
 
        WriteJSON(final_dict, outfile=output_file, write_type="w") 
         # make image file 
        self.make_structures_for_smiles(lig_dict) 
 
        # delete tmp folder 
        shutil.rmtree(TMP_FOLDER) 
 
 
    def build_single_tree(self, lig_dict, fp): 
        """ 
        Build a single tree with fingerprint function 
 
        :param lig_dict: all ligand information 
        :param fp: fingerprint object 
        :return: dot filename 
        """ 
        distfile = self.gen_dist_file(lig_dict, fp.fp_func) 
        newick_o = self.run_rapidnj(distfile) 
        dot_inf = self.write_dotfile(newick_o) 
        dot_out = self.sfdp_dot(dot_inf, 10) 
        dot_dict = self.dot2dict(dot_out) 
        return dot_dict 
 
    @staticmethod 
    def parse_lig_file(in_file, identifier): 
        """ 
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        parse ligand file and return a dictionary with identifier as IDs 
 
        :param in_file: input file directory 
        :param identifier: name for the identifier 
        :return: a dictionray with ligand information 
        """ 
        return ParseLigandFile(in_file, identifier) 
 
    @staticmethod 
    def gen_dist_file(liganddict, fp_func): 
        """ 
        generate distance file which is the input of rapidnj program. 
 
        :param liganddict: ligand information 
        :param fp_func: fingerprint function 
        :return: filename for distance file 
        """ 
        smile_list = [ [lig_name, liganddict[lig_name][SMILE_COLUMNNAME]] 
for lig_name in liganddict.keys()] 
        print "finish smile list" 
        filename   = WriteAsPHYLIPFormat(smile_list, fp_func) 
        print "finish writing phyli file" 
        return filename 
 
    def run_rapidnj(self, distance_file): 
        """ 
        run rapidnj program on distance_file 
 
        :param distance_file: directory of distance file 
        :return: newick string 
        """ 
        proc = subprocess.Popen([self._RAPIDNJ_COMMAND, distance_file, "-
i", "pd"], stdout=subprocess.PIPE) 
        newick = proc.stdout.read() 
        return newick 
 
    @staticmethod 
    def write_dotfile(newick): 
        """ 
        write newick string as dot file 
 
        :param newick: newick string 
        :return: dot file 
        """ 
        return WriteDotFile(newick) 
 
    def sfdp_dot(self, dot_infile, size): 
        """ 
        run sdfp on dot file 
 
        :param dot_infile: directory for dot file 
        :param size: parameter for the sfdp 
        :return: new filename 
        """ 
        fmt= self._FILE_FORMAT + '_sfdp.gv' 
        newfilename = datetime.datetime.now().strftime(fmt) 
        if os.path.isfile(newfilename): 
            os.remove(newfilename) 
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        command = "sfdp -Gsmoothing=triangle -Gsize={size} {infile} > 
{outfile}".format(size=size, infile=dot_infile, outfile=newfilename) 
        subprocess.Popen( command, shell = True, stdout = 
subprocess.PIPE ).communicate() 
        RemoveBackSlash(newfilename) 
        return newfilename 
 
    @staticmethod 
    def dot2dict(dot_outfile): 
        return Dot2Dict(dot_outfile, None) 
 
    @staticmethod 
    def gen_properties(ligand_dict, activities, properties, ext_cols): 
        """ 
        Generate properties for each molecule. 
 
        :param ligand_dict: ligand dictionary which keep all ligand 
information 
        :param activities: a list of PropertyType objects 
        :param properties: a list of PropertyType objects 
        :param ext_cols: the column name for external links 
        :return: 
        """ 
        compounds = [] 
        for idx in range(len(ligand_dict)): 
            lid = "B" + str(idx) 
            comp = dict() 
            comp["id"] = lid 
            comp["orig_id"] = ligand_dict[lid]["orig_id"] 
            comp["activities"] = dict() 
            comp["properties"] = dict() 
            comp["external"] = dict() 
            for act in activities: 
                comp["activities"][act.name] = 
act.gen_property(ligand_dict[lid]) 
            for prop in properties: 
                comp["properties"][prop.name] = 
prop.gen_property(ligand_dict[lid]) 
            for col in ext_cols: 
                ext_val = ligand_dict[lid][col] 
                if isinstance(ext_val, float): 
                    comp[col] = str(int(ext_val)) 
                else: 
                    comp[col] = str(ext_val) 
            compounds.append(comp) 
 
        return compounds 
 
    @staticmethod 
    def make_structures_for_smiles( ligand_dict ): 
        """ 
        Make structure figures from smile strings. All image files will be 
in the IMG_DIR 
 
        :param ligand_dict: ligand dictionary which keep all ligand 
information 
        :return: 
        """ 
235 
 
        relative_dir = IMG_DIR 
        for key in ligand_dict: 
            smile = ligand_dict[key][ SMILE_COLUMNNAME ] 
            filename = ligand_dict[ key ][ "orig_id" ] 
            mol = Chem.MolFromSmiles(smile) 
            try: 
                MolToFile( mol, os.path.join(relative_dir, 
'{}.svg'.format(filename)) ) 
            except: 








#! /usr/bin/env python 
# 
# Copyright (C) 2016 Jing Lu <ajingnk@gmail.com> 
# License: Apache 
 
# -*- coding: utf-8 -*- 
 
# pylint: disable=too-few-public-methods 
 
""" 





SMILE_COLUMNNAME = "Canonical_Smiles" 
 
RAPIDNJ_COMMAND = os.path.join(os.path.dirname(__file__), "lib/rapidnj-
linux-64") 
 
# temperary files 
TMP_FOLDER  = "./.tmp" 
FILE_FORMAT = './.tmp/%Y-%m-%d-%Hh-%Mm-%Ss' 
## image directory 
IMG_DIR = "./images/" 
 
# Potency 








#! /usr/bin/env python 
# 
# Copyright (C) 2016 Jing Lu <ajingnk@gmail.com> 
# License: Apache 
 
# -*- coding: utf-8 -*- 
 
# pylint: disable=too-few-public-methods 
 
class GenerateIDs: 
    """ 
    Retrieve other external ids for BindingDB IDs. 
    """ 
    def __init__(self, infile, outfile): 
        """ 
        Initialize the object with a spreadsheet input file, and output a 
file with 
        CHEBI ID and PubChem ID. 
 
        :param infile: 
        :param outfile: 
        :return: 
        """ 
        self.infile = infile 
        self.outfile = outfile 
 
        self.pubchem_dict = 
self.parse_dict_file("./data/BindingDB_CID.txt") 
        self.chebi_dict = 
self.parse_dict_file("./data/BindingDB_CHEBI_ID.txt") 
 
        self.cannot_find_pubchem = 0 
        self.cannot_find_chebi   = 0 
        self.run_for_file() 
 
        print("# PubChem ID cannot find " + str(self.cannot_find_pubchem)) 
        print("# CHEBI ID cannot find " + str(self.cannot_find_chebi)) 
 
 
    @staticmethod 
    def parse_dict_file(filename): 
        """ 
        Parse BindingDB_CID and BindingDB_CHEBI_ID 
 
        :param filename: ID mapping between BindingDB and other databases 
        :return: dictionray with BindingDB ID as the key. 
        """ 
        id_dict = dict() 
        with open(filename) as fobj: 
            for line in fobj: 
                cont = line.split() 
                id_dict[cont[0]] = cont[1] 




    def get_pubchemid_from_bdid(self, bdid): 
        """ 
        Get PubCHEM ID with BindingDB ID 
 
        :param bdid: bindingdb id 
        :return: pubchem id 
        """ 
        try: 
            return self.pubchem_dict[bdid] 
        except: 
            self.cannot_find_pubchem += 1 
            return None 
 
    def get_chebiid_from_bdid(self, bdid): 
        """ 
        Get CHEBI ID with BindingDB ID 
 
        :param bdid: CHEBI ID 
        :return: pubchem id 
        """ 
        try: 
            return self.chebi_dict[bdid] 
        except: 
            self.cannot_find_chebi += 1 
            return None 
 
    def run_for_file(self): 
        """ 
        Create a new file based on the input file 
 
        :return: 
        """ 
        import csv 
        out_obj = open(self.outfile, "w") 
        with open(self.infile) as in_obj: 
            reader = csv.DictReader(in_obj, delimiter = '\t') 
            writer = csv.DictWriter(out_obj, reader.fieldnames + 
["PubChem"], delimiter = '\t') 
            writer.writeheader() 
            for line in reader: 
                line["PubChem"] = 
self.get_pubchemid_from_bdid(line["BindingDB"]) 
                #line["CHEBI"] = 
self.get_chebiid_from_bdid(line["BindingDB"]) 
                writer.writerow(line) 
 
if __name__ == "__main__": 
    import sys 







#! /usr/bin/env python 
# 
# Copyright (C) 2016 Jing Lu <ajingnk@gmail.com> 
# License: Apache 
 
# -*- coding: utf-8 -*- 
 
# pylint: disable=too-few-public-methods 
 
from .tree_build import TreeBuild 
from .types import ( 
    FingerPrintType, 
    PropertyType, 
    DEFAULT_ACTIVITY_TYPES, 
    DEFAULT_FINGERPRINT_TYPES, 
    DEFAULT_PROPERTY_TYPES, 








Appendix D. Allosteric versus Competitive Compound Supplementary 
Information 
Table D-1 Protein Targets for Allosteric and Competitive Compounds 
Allosteric compound targets ligand 
count 
Competitive compound targets ligand 
count 
Metabotropic glutamate receptor 1 1947 Acyl-CoA synthase 309 
Metabotropic glutamate receptor 2 1195 Metabotropic glutamate receptor 5 204 
Muscarinic acetylcholine receptor M1 969 Menin/Histone-lysine N-
methyltransferase MLL 
202 
Alpha-7 nicotinic receptor 722 Estrogen receptor beta 184 
Metabotropic glutamate receptor 6 502 Dopamine D2 receptor 170 
Glutamate receptor ionotropic, AMPA 465 Adenosine A2b receptor 156 
NMD-R1 402 Muscarinic acetylcholine receptor 
M1 
118 
ABPP 356 Thrombin 82 
GABA receptor alpha-2 subunit 351 Androgen Receptor 75 
GABA(A) receptor subunit gamma-2 349 Monoamine oxidase A 75 
GABABR1 347 Histamine H3 receptor 74 
GABA-B-R2 345 HERG 69 
GABA-A receptor beta-3 subunit 340 Dopamine transporter 66 
Adenosine receptor A2b 330 Progesterone receptor 63 
Alpha-3 beta-4 nicotinic acetylcholine 
receptor 
324 Acetylcholinesterase 56 
Neuronal nicotinic acetylcholine 
receptor alpha-4 subunit 
300 Dopamine D4 receptor 54 
MAPK/ERK kinase 1 291 Inhibitor of apoptosis protein 3 54 
Presenilin-1 CTF subunit 283 Thromboxane A2 receptor 52 
RNA-directed RNA polymerase 275 Nociceptin receptor 51 
PK 275 Mineralocorticoid receptor 49 
PK-1 275 Alpha-1b adrenergic receptor 46 
PtdIns-3-kinase subunit p110-gamma 270 Endothelin receptor ET-A 44 
Cannabinoid CB1 receptor 247 Glutamate (NMDA) receptor 
subunit zeta 1 
42 
Avian erythroblastic leukemia viral (v-
erb-b) oncogene homolog 
239 Cytochrome P450 19A1 41 
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Drosophila relative of ERBB 232 Carbonic anhydrase II 41 
G-protein coupled receptor 71 229 Receptor-type tyrosine-protein 
phosphatase beta 
41 
Sweet taste receptor T1R3 229 Glucocorticoid receptor 38 
AMPK subunit alpha-2 228 MAP kinase p38 alpha 38 
AMPK subunit beta-1 228 Glandular kallikrein 38 
Protein kinase AMP-activated gamma 228 Integrin alpha-5/beta-1 38 
Uncharacterized protein MJ1225 
Protein-Kinase 
228 Aldo-keto-reductase family 1 
member C3 
37 
RT 219 Beta-glucocerebrosidase 36 
Cell division protein kinase 2 217 Translocator protein 35 
GLP-1 receptor 202 Histamine H2 receptor 33 
CAMP-specific phosphodiesterase 
PDE4D6 
201 Serine/threonine-protein kinase 
Chk1  
33 








Kinesin-like spindle protein HKSP 181 Adenosine A2a receptor 30 
GL-R 178 Melatonin receptor 30 
Interleukin-1 receptor type I 177 Muscarinic acetylcholine receptor 
M2 
29 
PN3 175 PI3-kinase p110-beta subunit 29 
L-glutamine amidohydrolase 166 Histamine H4 receptor 27 
HPDK1 162 Rap guanine nucleotide exchange 
factor 4 
27 
p21-activated kinase 1 157 Histamine H1 receptor 26 
Muscarinic acetylcholine receptor M2 152 Muscarinic acetylcholine receptor 
M5 
26 
Sodium channel, voltage-gated, type I, 
alpha polypeptide 
149 Dopamine D1 receptor 25 
Protein kinase B 138 Prostanoid EP2 receptor 25 
FBPase 1 136 Retinoid X receptor beta 24 
D-fructose-1,6-bisphosphate 1-
phosphohydrolase 
136 Neuronal acetylcholine receptor 
protein alpha-7 subunit 
23 
FBPase class 1 136 Subtilisin 23 
Non-structural protein 5 136 Cannabinoid CB1 receptor 22 
MMP-13 124 3-phosphoinositide dependent 
protein kinase-1 
22 
S1P receptor Edg-3 124 Beta-2 adrenergic receptor 21 
GluN2B 120 Trypanothione reductase 21 
Integrase 120 Cannabinoid receptor 21 
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CAMP-dependent protein kinase type 
II-beta regulatory chain 
119 Polymerase acidic protein 21 
PKA C-beta 119 Serotonin 2a (5-HT2a) receptor 21 
Tissue-specific extinguisher 1 119 FK506 binding protein 4 20 
Follicle stimulating hormone receptor 118 Fatty acid-binding protein, liver 20 
Biotin carboxylase 117 Glutamate receptor ionotropic, 
AMPA 2 
20 
Prealbumin 114 Plasminogen 20 
DNA polymerase beta 103 Renin 19 
GRO/MGSA receptor 100 Serotonin 1a (5-HT1a) receptor 19 
Hsp90 99 Complement C1s 19 
Bruton tyrosine kinase 96 PI3-kinase p110-alpha subunit 19 
Serotonin receptor 2A 92 GABA-A receptor; anion channel 18 
Rapamycin and FKBP12 target 1 86 Gamma-amino-N-butyrate 
transaminase 
18 
EK4 81 Acrosin 18 
DA transporter 78 Aminopeptidase N 18 
5-hydroxytryptamine receptor 3 74 Cholecystokinin B receptor 18 
ALADH 72 Hepatocyte growth factor receptor 18 
hSIRT1 69 Peptidyl-glycine alpha-amidating 
monooxygenase  
18 
Exoribonuclease H 63 Transthyretin 18 
SDH 63 Apoptosis regulator Bcl-X 17 
MAP kinase 14 58 Galectin-3 17 
Short transient receptor potential 
channel 4 
57 Galectin-9 17 
Tyrosine kinase non-receptor protein 2 57 Melanin-concentrating hormone 
receptor 1 
17 
Heat shock 70 kDa protein 1/2 55 Neurokinin 2 receptor 17 
5-HT1A 54 Platelet activating factor receptor 17 
Cytochrome P450 NF-25 54 RAC-alpha serine/threonine-
protein kinase 
17 
Farnesyl diphosphate synthase 54 CpG DNA methylase 17 
B2R 53 Rho-associated protein kinase 1  17 
Dopamine D3 receptor 53 Ryanodine receptor 1 17 
Serotonin receptor 1A 53 Beta-1 adrenergic receptor 16 
Parathyroid cell calcium-sensing 
receptor 
52 Galectin-7 16 
GR 52 Cyclooxygenase-2 16 
ATP receptor 50 Ras-related C3 botulinum toxin 
substrate 1 
16 
Hemoglobin alpha-1 chain 50 T-cell protein-tyrosine phosphatase 16 
243 
 
US28 50 Choline acetylase 15 
Beta globin chain 50 Matrix metalloproteinase 13 15 
Muscarinic acetylcholine receptor M3 49 Dihydrofolate reductase 14 
Ribonucleotide reductase small chain 49 Galectin-8 14 
Adenosylcobalamin-dependent 
ribonucleoside-triphosphate reductase 
49 Serotonin 7 (5-HT7) receptor 14 
P2X4 49 Vitamin D receptor 14 
Putative uncharacterized protein TRT1 49 3-dehydroquinate dehydratase  14 
Ribonucleoside-diphosphate reductase 
1 subunit alpha 
49 Melanocortin receptor 5 14 
Ribonucleoside-diphosphate reductase 
2 subunit alpha 
49 Peptide deformylase mitochondrial 14 





49 Serotonin (5-HT) receptor 14 
TP2 49 Sialidase 14 
Phosphatidylinositol 3-kinase p100 
subunit 
45 Thymidine kinase, cytosolic 14 
c-Jun N-terminal kinase 1 45 Integrin alpha-4 13 
NKR 44 Cytochrome P450 2D6 13 
Janus kinase 1 44 Heat shock protein HSP 90-alpha 13 
HIV-1 PR 41 Lipoxygenase 13 
GPR-CY6 41 Sigma opioid receptor 13 
Protein-tyrosine phosphatase 1B 40 Apoptosis regulator Bcl-2 12 
Protein toll 40 Anandamide amidohydrolase 12 
Free fatty acid activated receptor 2 38 Glycogen phosphorylase, muscle 
form 
12 
Integrin beta-1 38 Monoglyceride lipase 12 
Abelson murine leukemia viral 
oncogene homolog 1 
37 Autotaxin 12 
RGS4 37 Casein kinase II alpha 12 
Apoptosis regulator Bcl-2 36 Cathepsin B  12 
SAMDC 36 Cathepsin L 12 
Serpin C1 36 Gonadotropin-releasing hormone 
receptor 
12 
nPKC-epsilon 36 Kallikrein 5 12 
Apoptosis inhibitor survivin 35 G protein-coupled receptor 44 11 
CGS-PDE 35 Luciferin 4-monooxygenase 11 
30S ribosomal protein S2 34 Alpha-chymotrypsin 11 
A2 A adenosine receptor 33 Beta-lactamase 11 
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Cell surface glycoprotein MAC-1 
subunit alpha 
33 Botulinum neurotoxin type A 11 
Neurotrophic tyrosine kinase receptor 
type 1 
33 Calcitonin gene-related peptide 1 11 
TER ATPase 33 Fibroblast activation protein alpha 11 
CD11 antigen-like family member A 32 Nuclear receptor ROR-alpha 11 
Nuclear receptor subfamily 3 group C 
member 4 
32 Peptide deformylase 11 
Ubiquitin carrier protein D3 31 Retinoic acid receptor beta 11 
Thrombin light chain 30 Serine/threonine-protein kinase 
PIM1  
11 
GluK1 30 Tyrosinase 11 
SR31747-binding protein 30 Alpha-L-fucosidase I 10 
ET-A 28 Disks large homolog 4 10 
Epoxide hydratase 28 Leukocyte elastase 10 
Glucagon-like peptide 2 receptor 28 P-selectin 10 
Toll-like receptor 9 28 Purine nucleoside phosphorylase 10 
CD49 antigen-like family member E 26 Thymidine kinase 10 
SMO 26 Tyrosine-protein kinase receptor 
FLT3 
10 
Thrombin receptor 26 Xanthine dehydrogenase 10 
Flavin-containing amine oxidase 
domain-containing protein 2 
24 Adenylate kinase 3 alpha like 1 10 
Porphobilinogen synthase 24 Angiotensin II receptor 10 
SL3/AKV core-binding factor alpha B 
subunit 
24 CD209 antigen 10 
UDP/CysLT receptor 24 Coagulation factor X 10 
AChE 23 Glutathione reductase 10 
Voltage-gated calcium channel subunit 
alpha Cav3.2 
23 Histone-lysine N-





22 Tyrosine-protein kinase Lyn  10 
GSase 22 FK506-binding protein 1A 9 
MC5-R 22 Thymidylate synthase 9 
gp68 22 Growth factor receptor-bound 
protein 2 
9 
Plasmin 21 Histone deacetylase 3/Nuclear 





D-OR-1 21 Induced myeloid leukemia cell 
differentiation protein Mcl-1 
homolog 
9 
GDH 2 21 Penicillin-binding protein 2a 9 
PGE2 receptor EP2 subtype 20 Phosphodiesterase 4B 9 
Ha-Ras 19 S-adenosylmethionine synthetase 
(MAT 1 and MAT 2) 
9 
Cannabinoid CB2 receptor 18 Thymidylate kinase 9 
DNA-binding factor KBF1 18 Asialoglycoprotein receptor 1 8 
Myosin II heavy chain 18 Baculoviral IAP repeat-containing 
protein 3 
8 
Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3 
18 Catechol O-methyltransferase 8 
RNase P protein subunit 18 Cytochrome P450 3A4 8 
TGase-2 18 Inositol 1,4,5-trisphosphate 
receptor type 1 
8 
Isocitric dehydrogenase subunit gamma 17 Phenylalanine-4-hydroxylase 8 
P60-Src 17 Testis-specific androgen-binding 
protein 
8 
P94 17 Vesicular glutamate transporter 3 8 
Beta-Ketoacyl-acyl carrier protein 
reductase 
17 3-dehydroquinate dehydratase 8 
Chloride channel Ka 17 Cytochrome P450 2C9 8 
GABA-A receptor; anion channel 17 D-amino-acid oxidase 8 
Glucose-1-phosphate 
thymidylyltransferase 
17 Glycogen synthase kinase-3 alpha 8 
Helicase with RNase motif 17 Histone deacetylase 10 8 
IDH 17 Histone deacetylase 6 8 
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial 
17 Histone deacetylase 8 8 
Isocitrate dehydrogenase subunits 3/4 17 Integrin alpha-V/beta-5 8 
Leukotriene A(4) hydrolase 17 Mitogen-activated protein kinase 
kinase kinase 5 
8 
NAD(+)-specific ICDH subunit beta 17 Serine/threonine-protein kinase 
Aurora-A 
8 
Tumor necrosis factor-alpha receptor 16 Serine/threonine-protein kinase 
Aurora-C 
8 
AtMEPCT 16 Cyclophilin A 7 
CBF-beta 16 Adenylate kinase 2 7 
Focal adhesion kinase 1 16 Leukotriene B4 receptor 1 7 
NR2C 16 Mu opioid receptor 7 
hsAC 16 Serotonin 2b (5-HT2b) receptor 7 
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Cu-NIR 15 Serotonin 6 (5-HT6) receptor 7 
E-NPP 2 15 Acidic alpha-glucosidase 7 
Glycine receptor 48 kDa subunit 15 Adrenergic receptor alpha-2 7 
Glycine receptor 58 kDa subunit 15 Cruzipain 7 
Hydroxylamine reductase 15 Cytosol aminopeptidase 7 
MurI 15 Dual-specificity tyrosine-
phosphorylation regulated kinase 
1A 
7 
PEPCase 1 15 Histone deacetylase 11 7 
Rd 15 Histone deacetylase 4 7 
Scatter factor 15 Kallikrein 7 7 
Estradiol receptor 14 Macrophage colony stimulating 
factor  receptor  
7 
IKK-B 14 Neuronal acetylcholine receptor; 
alpha4/beta2 
7 
PEPCase 14 Protein tyrosine kinase 2 beta 7 
Gelatinase B 14 Ribonuclease pancreatic 7 
Malate dehydrogenase 14 Trypsin I 7 
Malate dehydrogenase, 
decarboxylating 
14 Vascular endothelial growth factor 
receptor 2 
7 
NADP-malic enzyme 2 14 Coagulation factor XI 6 
SCFR 14 Adenylate kinase 1 6 
Tryptophan synthase beta chain 14 Gamma-glutamyltranspeptidase 1 6 
Voltage-gated potassium channel 
subunit Kv11.1 
14 Glutamate [NMDA] receptor 
subunit epsilon 3 
6 
Calcium pump 1 13 Human immunodeficiency virus 
type 1 protease 
6 
Integrin alpha-4 13 Leukocyte adhesion molecule-1 6 
SA 13 Prostanoid EP4 receptor 6 
Tryptophan synthase alpha chain 13 Thermolysin 6 
SPAAT 13 Adrenergic receptor alpha-1 6 
CD49b 12 Cystine/glutamate transporter 6 
GCS-beta-3 12 Furin 6 
Huff 12 G-protein coupled bile acid 
receptor 1 
6 
Seed lipoxygenase-1 12 HLA class II histocompatibility 
antigen DRB3-1 
6 
CUL-5 12 Histone deacetylase 7 6 
GC-C 12 Insulin receptor 6 
GCS-alpha-2 12 L-lactate dehydrogenase A chain 6 
Hemocyanin A chain 12 Leukotriene A4 hydrolase 6 
LIMK-2 12 Ornithine decarboxylase 6 
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Threonine aspartase subunit alpha 12 Pyruvate kinase isozymes R/L 6 
GPDH 11 Sphingosine kinase 1 6 
Protein Yama 11 Tubulin 6 
Aspartate carbamoyltransferase 
catalytic chain 
11 Tyrosine-protein kinase JAK2 6 
DNA deoxyribophosphodiesterase 11 p53-binding protein Mdm-2 6 
Exonuclease I 11 Beta-galactosidase 5 
Glyceraldehyde-3-phosphate 
dehydrogenase (NADP+) 
11 Ghrelin receptor 5 
Glyceraldehyde-3-phosphate 
dehydrogenase (Phosphorylating) 
11 Neutral alpha-glucosidase AB 5 
Monoamine oxidase type B 11 Prostanoid EP3 receptor 5 
Nuclear receptor subfamily 2 group B 
member 1 
11 Prostanoid IP receptor 5 
ODC 11 Vanilloid receptor 5 
Alpha-glucosidase I 10 WD repeat-containing protein 5 5 
PLD 10 1-deoxy-D-xylulose-5-phosphate 
synthase 
5 
Coagulation factor XI 10 Adhesin protein fimH 5 
PDC 10 Arachidonate 12-lipoxygenase 5 
Phosphofructokinase-M 10 Beta amyloid A4 protein 5 
OTCase 9 Beta-secretase 1 5 
SSAO 9 C5a anaphylatoxin chemotactic 
receptor 
5 
TP 9 Cystinyl aminopeptidase 5 
AK 9 Cytochrome P450 1A2 5 
Beta-1 metal-binding globulin 9 Ephrin type-B receptor 2 5 
Breast tumor-amplified kinase 9 Eukaryotic translation initation 
factor 
5 
CPT1-M 9 Glucagon receptor 5 
CaMK-II subunit gamma 9 Glyoxalase I 5 
Cathepsin O 9 Heat shock protein HSP 60 5 
Cytochrome b-562 9 Indoleamine 2,3-dioxygenase 5 
IP-10 receptor 9 Phosphodiesterase 10A 5 
P2U purinoceptor 1 9 Phosphotyrosine-protein 
phosphatase PTPB 
5 
Serine/threonine protein kinase 9 Platelet-derived growth factor 
receptor beta 
5 
ATP-sulfurylase 8 Serine/threonine-protein kinase 
PLK1 
5 
CRF-R1 8 Tryptophan 2,3-dioxygenase 5 
Deoxycytidylate aminohydrolase 8 Tyrosine-protein kinase ABL 5 
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UDP-GlcNAc-2-epimerase 8 Vitamin K-dependent protein C 5 
VEGF Receptor 2 8 c-Jun N-terminal kinase 2 5 
5-HT4 8 Seed lipoxygenase-1 4 
ATP-PRT 8 Adenosine deaminase 4 
Arachidonate 15-lipoxygenase B 8 DNA polymerase alpha subunit 4 
Endoribonuclease 8 Diamine oxidase 4 
GnRH-R 8 Dihydroorotate dehydrogenase 4 
Phosphohexokinase 8 Kynureninase 4 
cAMP-GEFII 8 Kynurenine 3-monooxygenase 4 
CHK1 7 Neurotensin receptor 1 4 
ICE-LAP3 7 Nitric oxide synthase, inducible 4 
Na(+)/K(+) ATPase alpha-1 subunit 7 Prostanoid EP1 receptor 4 
TS 7 Vascular endothelial growth factor 
receptor 1 
4 





7 ALK tyrosine kinase receptor 4 
ATP-dependent helicase E1 7 Aminopeptidase B 4 
Caspase-6 subunit p11 7 Casein kinase I isoform alpha-like 4 
G-protein coupled receptor 40 7 DNA-dependent protein kinase 4 
GC-A 7 Discoidin domain-containing 
receptor 2 
4 
Inducible NOS 7 Dual specificity phosphatase 
Cdc25B 
4 
MOP-5 7 Glutamate receptor ionotropic, 
kainate 
4 
Na(+)/K(+) ATPase subunit gamma 7 Matrix metalloproteinase 14 4 
Nuclear receptor subfamily 3 group C 
member 3 
7 Max-like protein X 4 






7 Neurotrophic tyrosine kinase 
receptor type 2 
4 
AMP deaminase isoform M 6 Nicotinamide 
phosphoribosyltransferase 
4 
ATP citrate synthase 6 Pantothenate synthetase 4 
Insulin-like growth factor I receptor 6 Phosphodiesterase 7A 4 
Lactose Repressor 6 Prolyl endopeptidase 4 
Oxytocin-neurophysin 1 6 Protein kinase C epsilon 4 
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RNase P protein subunit DRpp40 6 Receptor protein-tyrosine kinase 
erbB-2 
4 
UGT1.1 6 Serine/threonine-protein kinase B-
raf 
4 
Alpha-1C adrenergic receptor 6 Serotonin 1d (5-HT1d) receptor 4 
Cyclic nucleotide-binding protein 6 Stem cell growth factor receptor 4 
Dihydropteroate synthase 6 Subtilisin/kexin type 6 4 
Estrogen synthase 6 Tyrosine-protein phosphatase 
yopH 
4 





like protein 3 
6 HMG-CoA reductase 3 
Homoserine dehydrogenase 6 Adenosylhomocysteinase  3 
Mitogen-activated protein kinase 
phosphatase 3 
6 Angiotensin II type 2 (AT-2) 
receptor 
3 
Nicotinic acid receptor 6 Asparagine synthetase 3 
Probable ribonuclease P/MRP protein 
subunit POP5 
6 Bradykinin B2 receptor 3 
RNase MRP protein subunit 6 Cyclin A2 3 
Sensory neuron-specific G-protein 
coupled receptor 1 
6 DNA topoisomerase I 3 
Transformation-related protein 53 6 Folylpoly-gamma-glutamate 
synthetase 
3 
AE 1 5 Glutathione S-transferase A1  3 
Beta-Carbonic Anhydrase 5 Hexokinase 3 




Glutamate [NMDA] receptor subunit 
epsilon 4 
5 Selectin E 3 
Phosphoglycerate dehydrogenase 5 Succinyl-diaminopimelate 
desuccinylase 
3 
Pur regulon repressor 5 Tubulin alpha chain  3 
Pyruvate dehydrogenase, lipoamide, 
kinase isozyme 2, mitochondrial 
5 UDP-glucuronosyltransferase 2B7 3 
TEM-5 5 Vitamin D-binding protein 3 
Threonine dehydratase 5 Activin receptor type-1B 3 
1,25-dihydroxyvitamin D3 receptor 5 Apoptosis regulator Bcl-W 3 
Exchange protein directly activated by 
cAMP 1 
5 B-cell receptor CD22 3 
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G protein-coupled receptor kinase 
GRK6 
5 Bcl-2-related protein A1 3 
GABA(C) receptor 5 Bifunctional protein glmU 3 
GLIC 5 Carbepenem-hydrolyzing beta-
lactamase KPC 
3 
ICE-like apoptotic protease 6 5 Casein kinase I gamma 2 3 
IMP dehydrogenase 1 5 Chymotrypsin C 3 
PDT 5 Coagulation factor VII 3 
PGDH 5 DNA topoisomerase II alpha 3 




nPKC-zeta 5 Enoyl-[acyl-carrier-protein] 
reductase [NADH] 
3 
p75 5 Inosine-5'-monophosphate 
dehydrogenase, probable 
3 
6-DEB hydroxylase 4 MAP kinase-activated protein 
kinase 2 
3 
ADP-glucose synthase 4 Macrophage migration inhibitory 
factor 
3 
Biotin--acetyl-CoA-carboxylase ligase 4 Mannosidase 2 alpha 1 3 
CGMP-binding cGMP-specific 
phosphodiesterase 
4 Monoacylglycerol lipase ABHD6 3 
Carbamoyl-phosphate synthetase 
ammonia chain 









4 Prostaglandin E synthase 3 








UPRTase 4 Pyridoxal kinase 3 
cGMP-dependent protein kinase I 4 Quinone reductase 2 3 
1.3.1.20</ecNumber 4 Riboflavin-binding protein 3 
235aa long hypothetical biotin--[acetyl-
CoA-carboxylase] ligase 
4 SHC-transforming protein 1 3 





ATP-PRTase 4 Signal transducer and activator of 
transcription 3 
3 
Acute-phase response factor 4 Sn1-specific diacylglycerol lipase 
beta 
3 
Adenylyl cyclase 4 Sphingosine kinase 2 3 
Alpha-2AAR subtype C10 4 Sucrase-isomaltase 3 
Bacteriophage N4 adsorption protein C 4 TRAIL receptor-1 3 
Beta-thionase 4 Terminal 
deoxynucleotidyltransferase 
3 
Biotin repressor 4 Trace amine-associated receptor 1 3 
Burkitt lymphoma receptor 1 4 Tyrosine-protein kinase ITK/TSK  3 
CXXC-type zinc finger protein 9 4 Urease 3 
Carbamoyl-phosphate synthetase 
glutamine chain 
4 Uridine phosphorylase 1 3 
Cytochrome P450-J 4 Vasopressin V2 receptor 3 
DAHP synthase 4 Voltage-gated L-type calcium 
channel 
3 
FADD-like ICE 4 Epoxide hydratase 2 
KDC 4 Alpha-1d adrenergic receptor 2 
Lysis protein 4 Beta-3 adrenergic receptor 2 





4 Glyoxalase II 2 
N-end-recognizing protein 4 Myelin-associated glycoprotein 2 
PAS domain-containing protein 2 4 Neuropilin-1 2 
PTH/PTHrP type I receptor 4 Orotidine 5'-phosphate 
decarboxylase 
2 
Prohormone convertase 4 Orotidine phosphate decarboxylase 2 
Putative deoxycytidylate deaminase 4 Penicillin-binding protein 1A 2 
Regulatory protein SIR2 homolog 3 4 Penicillin-binding protein 2B 2 
Ribose-phosphate pyrophosphokinase 1 4 Penicillin-binding protein 2x 2 
Stuart factor 4 Serotonin 5a (5-HT5a) receptor 2 
TIS10 protein 4 Vasoactive intestinal peptide 
receptor  
2 
Trypanothione synthetase, putative 4 Vasopressin V1a receptor 2 
Tyrosine 3-hydroxylase 4 1-aminocyclopropane-1-
carboxylate synthase 5 
2 
UDP-glucose 6-dehydrogenase 4 5-enolpyruvylshikimate-3-
phosphate synthase 
2 
UDPGDH 4 6-phospho-1-fructokinase 2 
CAP 3 ATP-citrate synthase 2 
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CK II beta 3 Acetylcholine receptor protein 
delta chain 
2 
CaM 3 Aldehyde dehydrogenase 2 
Cytochrome c oxidase subunit 2 3 Alpha-glucosidase 2 
Cytosine aminohydrolase 3 Anthrax lethal factor 2 
D-alanyl-D-alanine carboxypeptidase 3 Beta-hexosaminidase 2 
ICE 3 Beta-hexosaminidase subunit beta 2 
Kinesin-related protein CENPE 3 Beta-lactamase type II 2 
Orphan nuclear receptor PXR 3 Bone morphogenetic protein 
receptor type-2 
2 
PGF receptor 3 Bradykinin B1 receptor 2 
RNA polymerase subunit beta 3 Breast cancer type 1 susceptibility 
protein 
2 
Serotonin receptor 7 3 C-C motif chemokine 2 2 
Tryptamin 2,3-dioxygenase 3 Catenin beta-1 2 
4,5-PCD 3 Chitinase 2 
AKIII 3 Cyclin-dependent kinase 5 2 
Aspartate kinase 3 D-alanine--D-alanine ligase 2 
Aspartate kinase 1 3 D-alanylalanine synthetase 2 
CASP-2 3 Dipeptidyl peptidase VIII 2 
CCK2-R 3 Dual specificity mitogen-activated 
protein kinase kinase 1 
2 
CK II alpha 3 Dual specificity protein kinase 
CLK2 
2 
Cytochrome c oxidase subunit 1 3 Dual specificty protein kinase 
CLK1 
2 
Cytochrome c oxidase subunit 3 3 Fibroblast growth factor receptor 2 2 
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial 
3 FkbO 2 
DHEA-ST 3 Hematopoietic cell protein-tyrosine 
phosphatase 70Z-PEP 
2 
DNA-directed RNA polymerase 
subunit alpha 
3 Histone-lysine N-
methyltransferase, H3 lysine-9 
specific 3 
2 
Diguanylate kinase 3 Inhibitor of nuclear factor kappa B 
kinase alpha subunit 
2 
EK 3 Isoprenylcysteine carboxyl 
methyltransferase 
2 
Fructose-bisphosphate aldolase A 3 Lysine-specific demethylase 2A 2 





HD2 3 MAP/microtubule affinity-
regulating kinase 2 
2 
IMP--aspartate ligase 3 Matrix metalloproteinase 7 2 
Inflammation-related G-protein 
coupled receptor EX33 
3 Matrix metalloproteinase 9 2 
Insulysin 3 Mitogen-activated protein kinase 
kinase kinase 1 
2 
M-calpain 3 Myosin light chain kinase family 
member 4 
2 
MIF 3 N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 
2 
Mevalonate kinase 3 Neuropeptide FF receptor 1 2 
NS3 protein 3 Neurotensin receptor 2 
PCB 3 PI3-kinase p110-gamma subunit 2 
PP-1A 3 Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 
2 
PPAR-gamma 3 Phosphodiesterase 11A 2 
PelD 3 Phosphodiesterase 1A 2 
RNAP subunit alpha 3 Phosphodiesterase 2A 2 
RNAP subunit beta 3 Phosphodiesterase 3A 2 
Receptor-interacting protein 1 3 Phosphodiesterase 5A 2 
SK 1 3 Phosphodiesterase 8A 2 
SPCA 3 Phosphodiesterase 9A 2 
Serpin E1 3 Prostanoid FP receptor 2 
Sodium-dependent glutamate/aspartate 
transporter 1 
3 Proteasome component C5 2 
Steroid Delta-isomerase 3 Protein kinase C theta 2 
TRPO 3 Ribosomal protein S6 kinase alpha 
6 
2 
Transmembrane protein 142A 3 RocR 2 
Tryptase II 3 S-ribosylhomocysteine lyase 2 
Tryptophan oxygenase 3 Serine/threonine-protein kinase 
DCLK2 
2 
U-PAR 3 Serine/threonine-protein kinase 
GAK 
2 
Uridylate kinase 3 Serine/threonine-protein kinase 
PAK 1 
2 
Voltage-gated calcium channel subunit 
alpha Cav1.2 
3 Serine/threonine-protein kinase 
PLK4 
2 
hGPCR33 3 Somatostatin receptor 2 
2-oxoglutarate dehydrogenase, 
mitochondrial 
2 Squalene synthetase 2 
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6-phosphofructokinase II 2 Tumour suppressor 
p53/oncoprotein Mdm2 
2 
AAA+ ClpX hexamers 2 Tyrosine-protein kinase receptor 
RET 
2 
ATP-binding cassette sub-family B 
member 1 
2 Tyrosine-protein kinase receptor 
Tie-1 
2 
Alpha-glucan phosphorylase 2 Tyrosine-protein kinase receptor 
UFO 
2 
Aspartate beta-decarboxylase 2 Urokinase-type plasminogen 
activator 
2 
Beta2-adrenoceptor 2 DNA polymerase beta 1 
CFTR 2 4-hydroxyphenylpyruvate 
dioxygenase 
1 
CM 2 Atrial natriuretic peptide receptor 
C 
1 
Chitin synthase 2 2 Beta-xylosidase  1 
Chloroplastic 2 Excitatory amino acid transporter 2 1 
DegS 2 Fucosyltransferase 5 1 




2 Galanin receptor 2 1 
GroEL 2 Glutamate dehydrogenase 1 
Guanase 2 Glycerol kinase 1 
Hexokinase I 2 Heparanase 1 
Hydroxymethylbilane synthase 2 Inosine-5'-monophosphate 
dehydrogenase 2 
1 
Influenza A M2 channel 2 Lactase-glycosylceramidase 1 
L-LDH 2 Lanosterol synthase 1 
N(1),N(8)-bis(glutathionyl)spermidine 
reductase 
2 Nitric-oxide synthase, brain 1 
N-WASP 2 Papain 1 
NAGS 2 Phenylethanolamine N-
methyltransferase 
1 
Oligomycin sensitivity conferral 
protein 
2 Solute carrier family 22 member 
12 
1 











Phosphopentokinase 1 2 3-oxoacyl-acyl-carrier protein 
reductase  
1 
Phosphorylase kinase subunit gamma 1 2 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase 3 
1 
Prephenate dehydratase 2 ATP-dependent RNA helicase 
DDX3X 
1 
PriA helicase 2 Adaptor-associated kinase 1 
RNA Polymerase 2 Aldehyde dehydrogenase dimeric 
NADP-preferring 
1 
RTX 2 Alpha-galactosidase 1 
RecA 2 Alpha-galactosidase A 1 
Srr 2 Alpha-glucosidase MAL62 1 
Type II IPP 2 Aminoacyl-tRNA synthetase 1 
hPanK1 2 Aryl hydrocarbon receptor 1 
11R-lipoxygenase 2 BMP-2-inducible protein kinase 1 
ATP-binding cassette, sub-family B, 
member 1 
2 Baculoviral IAP repeat-containing 
protein 7 
1 
Abelson murine leukemia viral 
oncogene homolog 2 
2 Beta-lactamase OXA-10 1 
Allantoate deiminase 2 Bifunctional protein NCOAT 1 
Amino acid biosynthesis regulatory 
protein 
2 Bile salt export pump 1 
AtCM1 2 Bombesin receptor subtype-3 1 
Beta-galactoside-binding lectin L-14-I 2 Bromodomain adjacent to zinc 




2 Bromodomain-containing protein 2 1 
CXC-R4 2 Bromodomain-containing protein 4 1 
Chitin synthase 1 2 C-terminal processing protease of 




2 C-type lectin domain family 7 
member A 
1 
Cholesterol acyltransferase 1 2 CaM-kinase kinase beta 1 
DHDPS 2 Carboxylesterase 1D 1 
DHOase 2 Carnitine palmitoyltransferase 2 1 
DNA double-strand break repair Rad50 
ATPase 
2 Casein kinase II beta  1 




succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 





Dihydroorotase 2 Citron Rho-interacting kinase 1 
Ecto-5'-nucleotidase 2 Cyclin-dependent kinase 7 1 
Env polyprotein 2 Cyclin-dependent kinase 9 1 
FimX 2 Cyclin-dependent kinase-like 1 1 
GMD 2 Cytochrome P450 11A1 1 
GPATase 2 D-alanyl-D-alanine dipeptidase 1 
Glycine hydroxymethyltransferase 2 DNA polymerase kappa 1 
HD domain protein 2 Dual specificity protein kinase 
CLK3 
1 
Hexosephosphate aminotransferase 2 Dual-specificity tyrosine-








MGS 2 Endoplasmin 1 





2 Eukaryotic translation initiation 
factor 2-alpha kinase 4 
1 
N-acetylglutamate kinase / N-
acetylglutamate synthase 
2 FK506 binding protein 12 1 
Oleoyl-[acyl-carrier-protein] hydrolase 2 Fatty acid synthase 1 
Oxoglutarate dehydrogenase (Succinyl-
transferring), E1 component 
2 Fe(3+)-Zn(2+) purple acid 
phosphatase 
1 





PNPase 2 Glucose-6-phosphate translocase 1 
Phosphorylase b kinase regulatory 
subunit alpha, skeletal muscle isoform 
2 Glutamine synthetase 1 
Phosphorylase kinase beta-subunit 2 Glutathione S-transferase Mu 1 1 
Polyprotein 2 Glyceraldehyde-3-phosphate 
dehydrogenase, glycosomal 
1 
Prephenate dehydrogenase 2 Guanine deaminase 1 
Protein IPGM-1, isoform a 2 Heat shock protein 75 kDa, 
mitochondrial 
1 
Protein phosphatase type 1A (formely 
2C) Mg-dependent alpha isoform 
2 Hepatitis C virus serine protease, 
NS3/NS4A 
1 
Putative uncharacterized protein 
PH0207 
2 Histidase 1 
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RAR-epsilon 2 Histo-blood group ABO system 
transferase 
1 
RXR-interacting protein 14 2 Histone acetyltransferase KAT5 1 
Recessive suppressor of secretory 
defect 
2 Histone acetyltransferase PCAF 1 
Regulatory protein SIR2 2 Histone acetyltransferase p300 1 
Rhodobacter sphaeroides 2.4.1 
chromosome 1, complete sequence 
2 Histone deacetylase-like 
amidohydrolase 
1 
Rts protein 2 Histone-lysine N-
methyltransferase, H3 lysine-9 
specific 5 
1 
SH2 domain-containing inositol 5'-
phosphatase 1 
2 Homeodomain-interacting protein 
kinase 1 
1 
Ste2p 2 Homeodomain-interacting protein 
kinase 3 
1 
Sulfonylurea receptor 2 2 Homeodomain-interacting protein 
kinase 4 
1 
Toxin B 2 Hormonally up-regulated neu 
tumor-associated kinase 
1 
UPRT 2 Human immunodeficiency virus 
type 1 reverse transcriptase 
1 
Uncharacterized protein 2 IGF-like family receptor 1 1 
Voltage-gated calcium channel subunit 
alpha Cav3.3 
2 IgG receptor FcRn large subunit 
p51 
1 
WASp 2 Interferon-induced, double-
stranded RNA-activated protein 
kinase 
1 
eIF-4E 2 Interleukin-1 receptor-associated 
kinase 3 
1 
nPKC-delta 2 Interleukin-2 receptor alpha chain 1 




1 Kelch-like ECH-associated protein 
1 
1 
2'-5'-oligoisoadenylate synthetase 1 1 Low affinity neurotrophin receptor 
p75NTR 
1 
3-hydroxybutyrate dehydrogenase 1 Lymphocyte differentiation antigen 
CD38 
1 
ALS-III 1 Lysine-specific histone 
demethylase 1 
1 





Adenylate nucleosidase 1 Mandelate racemase 1 









1 Mitogen-activated protein kinase 
15 
1 
CTP synthetase 1 Mitogen-activated protein kinase 7 1 
Complex III subunit III 1 Mitogen-activated protein kinase 
kinase kinase 10 
1 
Cyclophilin A 1 Mitogen-activated protein kinase 
kinase kinase 4 
1 
D-alanine:D-alanine ligase 1 Mitogen-activated protein kinase 
kinase kinase 7 
1 
DNA helicase Rep and single-stranded 
DNA-dependent ATPase 
1 Mixed lineage kinase 7 1 
Deadenylating nuclease 1 Myosin light chain kinase 1 
G6PD 1 N-arachidonyl glycine receptor 1 
GNPDA 1 1 N-lysine methyltransferase 
SMYD2 
1 
GPD-C 1 NAD-dependent deacetylase 
sirtuin 1 
1 
Gamma-glutamate kinase 1 NUAK family SNF1-like kinase 1 1 
Glutamate carboxypeptidase-like 
protein 2 
1 Neutral cholesterol ester hydrolase 
1 
1 
Glutamine amido-transferase 1 O-acetylserine sulfhydrylase 1 
Glutamine amidotransferase:cyclase 1 Oxytocin receptor 1 
Glycerokinase 1 P-hydroxybenzoate hydroxylase  1 
HMG-CoA reductase 1 P2X purinoceptor 4 1 
HSCARG 1 Peptide N-myristoyltransferase 1 1 
Iron(III) dicitrate transport protein fecA 1 Peptidyl-prolyl cis-trans isomerase 
D 
1 
L-asparaginase I 1 Phosphatidylinositol-4-phosphate 
3-kinase C2 domain-containing 
beta polypeptide 
1 
LivG 1 Phosphatidylinositol-4-phosphate 
5-kinase type-1 alpha 
1 
M.EcoDam 1 Phosphatidylinositol-5-phosphate 







Mitochondrial uncoupling protein 1 Plasmepsin 2 1 





1 Pregnane X receptor 1 
NADH:nitrate reductase 1 Proline racemase 1 
OAS-TL A 1 Proteasome Macropain subunit 1 
PTE 1 Protein VAC14 homolog 1 
Parkingson disease protein 7 1 Protein farnesyltransferase 1 
Protein Dhm1 1 Protein kinase C alpha  1 
Pyrophosphate-dependent 6-
phosphofructose-1-kinase 
1 Protein-tyrosine phosphatase 2C 1 
RBP 1 Protein-tyrosine phosphatase LC-
PTP 
1 




RecA, E. coli, homolog of 1 Serine hydroxymethyltransferase, 
cytosolic 
1 
RuvB Protein 1 Serine-protein kinase ATR 1 
S-Rnase 1 Serine/threonine-protein kinase 10 1 
Teichoic acid biosynthesis protein D 1 Serine/threonine-protein kinase 11 1 
Troponin I, cardiac muscle 1 Serine/threonine-protein kinase 
17A 
1 
TrpRS 1 Serine/threonine-protein kinase 2 1 
Tryptophan RNA-binding attenuator 
protein 
1 Serine/threonine-protein kinase 
32B 
1 
(p)ppGpp synthase 1 Serine/threonine-protein kinase 
LATS1 
1 





1 Serine/threonine-protein kinase 
MST2 
1 
5-HT-1B 1 Serine/threonine-protein kinase 
NEK2 
1 
6-HDNO 1 Serine/threonine-protein kinase 
PAK 4 
1 
67 kDa protein 1 Serine/threonine-protein kinase 
PCTAIRE-3 
1 





ACAT-2 1 Serine/threonine-protein kinase 
RIO1 
1 
ACR-20, isoform a 1 Serine/threonine-protein kinase 
RIO2 
1 
ADP-ribosylation factors guanine 
nucleotide-exchange protein 100 
1 Serine/threonine-protein kinase 
RIO3 
1 
AGK 1 Serine/threonine-protein kinase 
SRPK3 
1 
AHAS-I 1 Sphingosine 1-phosphate receptor 
Edg-1  
1 
AHAS-II 1 Squalene synthase 1 
ALDH class 2 1 Steryl-sulfatase  1 
ARF1-directed GTPase-activating 
protein 
1 Sulfate anion transporter 1 1 
ATP-dependent protease La 1 TRAF2- and NCK-interacting 
kinase 
1 
Acetohydroxy-acid synthase II small 
subunit 
1 Telomerase reverse transcriptase 1 
Acetokinase 1 Testis-specific serine/threonine-
protein kinase 1 
1 
Alpha-NaCH 1 Thymidine kinase, mitochondrial 1 
Amplified in liver cancer protein 1 1 Thymidine phosphorylase 1 
Annexin V 1 Transient receptor potential cation 
channel subfamily M member 8 
1 
Anthranilate phosphoribosyltransferase 1 Tyrosine- and threonine-specific 
cdc2-inhibitory kinase 
1 
Anthranilate synthase component I 1 Tyrosine-protein kinase ABL2 1 
Aurone synthase 1 Tyrosine-protein kinase FER 1 
AvrA 1 Tyrosine-protein kinase SYK 1 
Beta-chimerin 1 Tyrosine-protein phosphatase non-




1 Tyrosyl-DNA phosphodiesterase 1 1 
Brain-liver-intestine amiloride-




C5a-R 1 Ubiquitin carboxyl-terminal 
hydrolase 5 
1 
CKI-alpha 1 Vascular endothelial growth factor 
receptor 3 
1 
CPSase I 1 Vasopressin V1b receptor 1 
CXCR-7 1 Vesicular acetylcholine transporter 1 
Carbon catabolite protein A 1   
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Caspase-5 subunit p10 1   
Catechol oxidase 1   
Cav3.1c 1   
Chaperone protein MSI3 1   
Chymotrypsin-C 1   
Chymotrypsinogen B2 1   
Coagulation factor IXa light chain 1   
Complement C3b alpha' chain 1   
CooA protein 1   
Copper-sensitive operon repressor 1   
Cytosolic IMP-GMP specific 5'-
nucleotidase 
1   
D-methionine transport system 
permease protein metI 
1   
DNA topoisomerase II 1   
Dimeric hemoglobin 1   
Dipeptidyl peptidase-like protein 9 1   
E3 ubiquitin ligase complex SCF 
subunit CDC4 
1   
EF-G 1   
ELIC 1   
Ecto-NAD+ glycohydrolase 1   
GALR-2 1   
GMP-PDE gamma 1   
GSH-S 1   
GST class-pi 1   
Galactose operon repressor 1   
Galectin 1   
Gamma-ENaC 1   
Gibberellin-insensitive dwarf protein 1 1   
Glycerol dehydrase beta subunit 1   
Glycerol dehydrase gamma subunit 1   
Glycerol dehydratase large subunit 1   
Guanine nucleotide-binding protein 
alpha-q 
1   
HBP23 1   
HD 1   
HD4 1   
HDC 1   
HGF activator 1   
HL-60 PAD 1   
HM63 1   
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HPr kinase/phosphatase 1   
HPrK/P 1   
Heat shock protein HslU 1   
Hypothetical phosphoserine 
phosphatase 
1   
ICD1 1   
IDH kinase/phosphatase 1   
IL-2 1   
IRK-1 1   
ImGP synthase subunit hisF 1   
Intracellular protease I 1   
Isopropylmalate/homocitrate/citramalat
e synthase 
1   
Kinesin-related protein HSET 1   
L-serine dehydratase (Iron, sulfur-
dependent) 
1   
Lasalocid biosynthesis protein Lsd19 1   
MALT lymphoma-associated 
translocation 
1   
MHC class II antigen DRA 1   
MHCK-A 1   
Metacaspase MCA2 1   
MutT/nudix family protein 1   
Mutated in multiple advanced cancers 
1 
1   
Myeloproliferative leukemia protein 1   
Myosin heavy chain 7 1   
N-acetyl-L-glutamate 5-
phosphotransferase 
1   
NAGSA dehydrogenase 1   
Na(+)/Ca(2+)-exchange protein 1 1   
Na(+)/PI cotransporter 1 1   
Nuclear matrix protein 265 1   
Nuclear receptor subfamily 1 group A 
member 1 
1   
OTRPC1 1   
Oligosaccharyltransferase 1   
P-element transposase 1   
PGE2 receptor EP4 subtype 1   
PI3Kalpha 1   
PLC-delta-1 1   
PPIase FKBP1A 1   
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Phospholipase A2 1   
PilZ domain protein 1   
Platelet membrane glycoprotein IIb 1   
Psi-conotoxin P3.8 1   
Pyrophosphate--fructose 6-phosphate 
1-phosphotransferase subunit beta 
1   
QAPRTase 1   
Rab geranylgeranyl transferase 
componenet, subunit beta 
1   
Regulatory protein SIR2 homolog 2 1   
SAPKK1 1   
SK2 1   
STE20-like kinase MST 1   
Selenocysteine lyase 1   
Shaw2 1   
Spermidine n1-acetyltransferase 1   
StyR 1   
T4-binding globulin 1   
Transcortin 1   
Transcriptional regulator, MarR family 1   
Ubiquitin-conjugating enzyme E2-
CDC34 
1   
VAChT 1   
cAMP and cGMP phosphodiesterase 
11A 
1   
cGMP phosphodiesterase 6C 1   
hMSH2 1   
hPanK2 1   
hPanK3 1   





Table D-2. Medians (95%ci) of the 37 physicochemical properties for the original 2012 dataset. Numbers in bold are statistically significant differences between allosteric and 
competitive compounds. The list is ordered by largest differences. Red properties do not repeat in 2015 data. The analysis is done with center of clusters. 
 Clustering level 60%/0.6 75%/0.75 90%/0.9 100%/1.0 
Descriptors Allosteric Competitive   Allosteric Competitive   Allosteric Competitive   Allosteric Competitive 
chiral 0(±0) 1(±0)   0(±0) 1(±0)   0(±0) 1(±0)   0(±0) 1(±0) 
chiral/HA 0(±0) 0.0476(±0.005)   0(±0) 0.0400(±0.0035)   0(±0) 0.0400(±0.0035)   0(±0) 0.0435(±0.002) 
SlogP 3.26(±0.09) 1.92(±0.23)   3.58(±0.05) 2.14(±0.16)   3.70(±0.04) 2.24(±0.1)   3.69(±0.04) 2.07(±0.13) 
b_ar/b_count 0.30(±0.01) 0.21(±0.01)   0.310(±0.004) 0.222(±0.004)   0.309(±0.003) 0.214(±0.004)   0.309(±0.001) 0.214(±0.007) 
b_single/HA 1.17(±0.01) 1.50(±0.04)   1.17(±0.01) 1.50(±0.02)   1.17(±0.01) 1.52(±0.01)   1.18(±0.01) 1.53(±0.01) 
b_single 29(±1) 36(±2)   30(±0) 38(±1)   32(±0) 41(±1)   32(±1) 41(±1) 
b_ar/HA 0.52(±0.01) 0.41(±0.01)   0.548(±0.003) 0.444(±0.016)   0.545(±0.003) 0.429(±0.003)   0.5484(±0.0029) 0.4286(±0) 
a_aro/HA 0.51(±0.01) 0.41(±0.01)   0.54(±0.01) 0.43(±0.01)   0.55(±0.01) 0.43(±0.01)   0.55(±0.01) 0.42(±0.01) 
b_1rotN/HA 0.174(±0.003) 0.200(±0.008)   0.172(±0.001) 0.192(±0.008)   0.172(±0.001) 0.200(±0.006)   0.172(±0.001) 0.211(±0.004) 
b_single/b_count 0.67(±0.01) 0.76(±0.01)   0.654(±0.003) 0.758(±0.004)   0.655(±0.002) 0.763(±0.003)   0.655(±0.002) 0.764(±0.004) 
logS -4.63(±0.1) -4.14(±0.14)   -4.99(±0.05) -4.40(±0.08)   -5.25(±0.05) -4.61(±0.07)   -5.32(±0.04) -4.67(±0.06) 
b_count/HA 1.80(±0.02) 1.98(±0.03)   1.80(±0.01) 1.97(±0.03)   1.81(±0.01) 2.00(±0.03)   1.81(±0.01) 1.98(±0.02) 
a_acc/HA 0.107(±0.004) 0.097(±0.003)   0.107(±0.002) 0.091(±0.004)   0.107(±0.004) 0.095(±0.002)   0.107(±0.004) 0.097(±0.003) 
b_count 43(±1) 47(±2)   46(±1) 50(±1)   49(±1) 54(±1)   49(±0) 55(±1) 
a_nC/HA 0.739(±0.002) 0.762(±0.011)   0.75(±0.01) 0.77(±0.01)   0.750(±0.004) 0.767(±0.006)   0.7500(±0) 0.7561(±0.0061) 
b_1rotN 4(±0) 5(±0)   4(±0) 5(±0)   5(±0) 5(±0)   5(±0) 5(±0) 
a_base 0(±0) 1(±1)   0(±0) 1(±0)   0(±0) 1(±0)   0(±0) 1(±0) 
a_base/HA 0.0000(±0) 0.0208(±0.0208)   0.0000(±0) 0.0244(±0.004)   0.0000(±0) 0.0222(±0.0094)   0.0000(±0) 0.0250(±0.002) 
a_aro 12(±0) 11(±1)   12(±0) 12(±0)   14(±1) 12(±0)   15(±1) 12(±0) 
b_ar 12(±0) 11(±1)   12(±0) 12(±0)   15(±1) 12(±0)   16(±1) 12(±0) 
a_don/HA 0.037(±0.001) 0.040(±0.004)   0.036(±0.001) 0.034(±0.003)   0.0345(±0) 0.0345(±0.0012)   0.034(±0.001) 0.034(±0.003) 
b_rotN/HA 0.20(±0.01) 0.21(±0.01)   0.2(±0.0) 0.2083(±0.0083)   0.2(±0.0) 0.2174(±0.0031)   0.2(±0.0) 0.2258(±0.0036) 
a_nC 18(±1) 19(±1)   19(±0) 20(±1)   20(±0) 21(±0)   20(±0) 21(±0) 
b_1rotN/b_count 0.098(±0.002) 0.103(±0.003)   0.097(±0.001) 0.100(±0.002)   0.098(±0.001) 0.103(±0.002)   0.097(±0.001) 0.106(±0.003) 
b_rotN/b_count 0.113(±0.003) 0.109(±0.006)   0.111(±0.003) 0.105(±0.002)   0.111(±0.002) 0.111(±0.003)   0.111(±0.002) 0.118(±0.003) 
a_acc 2(±1) 2(±0)   3(±0) 2(±0)   3(±0) 3(±0)   3(±0) 3(±0) 
a_acid 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
a_acid/HA 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
a_don 1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0) 
a_heavy 24(±0) 24(±1)   26(±0) 26(±0)   27(±0) 27(±1)   27(±0) 28(±1) 
b_rotN 5(±0) 5(±0)   5(±0) 5(±0)   6(±1) 5(±1)   6(±1) 6(±1) 
FCharge 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
FCharge/HA 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
lip_druglike 1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0) 
lip_violation 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
opr_leadlike 1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0) 
opr_violation 0(±0) 0(±1)   0(±0) 0(±0)   0(±0) 1(±0)   0(±0) 1(±0) 
rings 3(±0) 3(±0)   3(±0) 3(±0)   3(±0) 3(±0)   3(±0) 3(±0) 
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Table D-3. Medians (95%ci) of the 37 physicochemical properties for the original 2015 dataset. Numbers in bold are statistically significant differences between allosteric and 
competitive compounds. The list is ordered by largest differences. Red properties do not repeat in 2012 data. The analysis is done with center of clusters. 
 Clustering level 60%/0.6 75%/0.75 90%/0.9 100%/1.0 
Descriptors Allosteric Competitive   Allosteric Competitive   Allosteric Competitive   Allosteric Competitive 
a_don/HA 0.037(±0.001) 0.045(±0.002)   0.0345(±0) 0.0435(±0.0018)   0.0323(±0) 0.0417(±0.0018)   0.031(±0.001) 0.042(±0.002) 
b_single 29(±1) 34(±1)   31(±0) 36(±1)   34(±0) 39(±1)   34(±1) 39(±0) 
SlogP 3.19(±0.03) 2.67(±0.07)   3.40(±0.01) 2.88(±0.04)   3.53(±0.01) 2.95(±0.04)   3.56(±0.01) 2.90(±0.04) 
b_single/HA 1.22(±0.01) 1.38(±0.02)   1.20(±0.01) 1.38(±0.01)   1.20(±0.01) 1.40(±0.01)   1.212(±0.002) 1.421(±0.008) 
b_ar/b_count 0.283(±0.004) 0.250(±0.006)   0.293(±0.001) 0.254(±0.004)   0.294(±0.001) 0.245(±0.005)   0.2927(±0.0004) 0.2391(±0.0038) 
b_count 44(±0) 48(±1)   47(±1) 50(±1)   50(±1) 53(±1)   51(±0) 54(±0) 
b_1rotN/HA 0.1667(±0) 0.1786(±0.0032)   0.1667(±0) 0.1795(±0.0023)   0.172(±0.001) 0.188(±0.002)   0.1739(±0) 0.1892(±0.0017) 
b_ar/HA 0.51(±0.01) 0.48(±0.01)   0.524(±0.003) 0.486(±0.014)   0.526(±0.003) 0.474(±0.012)   0.5217(±0.0021) 0.4615(±0) 
b_count/HA 1.810(±0.003) 1.915(±0.011)   1.800(±0.004) 1.923(±0.007)   1.806(±0.001) 1.933(±0.006)   1.815(±0.001) 1.944(±0.006) 
b_single/b_count 0.681(±0.002) 0.720(±0.006)   0.667(±0.006) 0.720(±0.004)   0.671(±0.005) 0.727(±0.002)   0.673(±0.001) 0.732(±0.003) 
a_acc/HA 0.118(±0.002) 0.111(±0.004)   0.120(±0.001) 0.107(±0.002)   0.121(±0.001) 0.107(±0.001)   0.120(±0.001) 0.107(±0.001) 
a_aro/HA 0.5000(±0) 0.4737(±0.0121)   0.5217(±0) 0.4800(±0.0017)   0.5217(±0) 0.4615(±0.0072)   0.522(±0.004) 0.458(±0.006) 
b_rotN/HA 0.1905(±0.003) 0.2(±0.0)   0.1905(±0.0018) 0.2(±0.0)   0.2(±0.0) 0.2105(±0.0038)   0.2(±0.0) 0.2143(±0.0038) 
b_1rotN/b_count 0.093(±0.002) 0.097(±0.002)   0.094(±0.001) 0.096(±0.001)   0.0972(±0.0004) 0.1000(±0.002)   0.0978(±0.0003) 0.1000(±0.0013) 
a_nC/HA 0.7333(±0.0026) 0.7500(±0)   0.733(±0.003) 0.750(±0.007)   0.7308(±0) 0.7500(±0)   0.7308(±0) 0.7500(±0) 
logS -4.48(±0.02) -4.62(±0.07)   -4.79(±0.02) -4.85(±0.05)   -5.16(±0.01) -5.12(±0.04)   -5.17(±0.01) -5.14(±0.03) 
a_nC 18(±0) 19(±0)   19(±0) 20(±0)   20(±0) 21(±0)   20(±1) 21(±0) 
a_heavy 24(±0) 25(±0)   26(±0) 26(±0)   28(±0) 28(±0)   28(±0) 28(±0) 
b_1rotN 4(±0) 5(±1)   4(±0) 5(±0)   5(±0) 5(±0)   5(±0) 5(±0) 
b_rotN/b_count 0.106(±0.001) 0.105(±0.002)   0.106(±0.001) 0.106(±0.001)   0.110(±0.002) 0.111(±0.002)   0.1111(±0) 0.1111(±0.0021) 
a_acc 3(±0) 3(±0)   3(±0) 3(±0)   3(±0) 3(±0)   3(±0) 3(±0) 
a_acid 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
a_acid/HA 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
a_aro 12(±0) 12(±0)   12(±0) 12(±0)   15(±0) 12(±0)   15(±0) 12(±0) 
a_base 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
a_base/HA 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
a_don 1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0) 
b_ar 12(±0) 12(±0)   12(±0) 12(±0)   16(±0) 12(±0)   16(±0) 12(±0) 
b_rotN 5(±0) 5(±0)   5(±0) 5(±0)   5(±0) 6(±0)   6(±0) 6(±0) 
chiral 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 1(±0)   0(±0) 1(±0) 
chiral/HA 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0.0256(±0.0039)   0(±0) 0.0278(±0.0016) 
FCharge 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
FCharge/HA 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
lip_druglike 1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0) 
lip_violation 0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0)   0(±0) 0(±0) 
opr_leadlike 1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0)   1(±0) 1(±0) 
opr_violation 0(±0) 0(±0)   0(±0) 1(±1)   1(±0) 1(±0)   1(±0) 1(±0) 
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